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SAMENVATTING 
Onze huidige samenleving wordt uitgedaagd door een steeds toenemende prevalentie van obesitas. Dit 
wordt veroorzaakt door een overvloed aan voeding en een toenemende sedentaire levenstijl en is 
geassocieerd met belangrijke metabole complicaties zoals type 2 diabetes, non-alcoholic fatty liver 
disease (NAFLD) en hart- en vaatlijden. Hoewel obesitas gedefinieerd wordt als een abnormale en 
overmatige opstapeling van vetweefsel doorheen het lichaam met negatieve impact op de gezondheid, 
blijft de exacte pathofysiologie die leidt tot de gevolgen ervan nog steeds onvolledig gekend. Op heden 
wordt het steeds duidelijker dat een aantal signaalwegen kunnen interageren en resulteren in de 
ontwikkeling van metabole ziekten. Als gevolg van de overmaat aan energie die opgenomen wordt 
zullen de vetweefsel depots zich gaan uitzetten, wat leidt tot ontwikkeling van grotere vetcellen. 
Uiteindelijk zal dit resulteren in disfunctie van het vetweefsel, dat gekarakteriseerd wordt door een 
aangetast lipide metabolisme met verhoogde vrijstelling van vetzuren, lokale inflammatie en een 
verstoorde vrijstelling van adipokines (signaalstoffen afkomstig uit de vetcellen). Deze lekkage van 
lipiden vanuit de klassieke vetweefsel depots geeft aanleiding tot ectopische vetaccumulatie in organen 
en weefsels zoals de lever, pancreas, spier en hart, wat bijdraagt tot de ontwikkeling van metabole 
complicaties. Bovendien vermoedt men dat inflammatoire factoren en het verstoord adipokine 
secretieprofiel ook bijdraagt tot deze gevolgen. 
NAFLD wordt vaak aangeduid als de hepatische manifestatie van obesitas en omvat een breed spectrum 
aan leverziekten, gaande van eenvoudige leververvetting (simple fatty liver disease of steatose) tot non-
alcoholic steatohepatitis (NASH) en zelfs eindstadium levercarcinoom. Hoewel het nog steeds onvolledig 
gekend is hoe obesitas leidt tot NAFLD, wordt verondersteld dat insulineresistentie (IR) en 
disfunctioneel vetweefsel centrale componenten vormen in de pathogenese van NAFLD. Het wordt 
steeds meer erkend dat een verstoord secretiepatroon van adipokines een centrale rol zou kunnen 
spelen bij de ontwikkeling van metabole ziekten, inclusief NAFLD en de progressie naar NASH. Ter 
illustratie, serumspiegels van adiponectine , één van de bekendste adipokines, zijn verlaagd bij obesitas 
en worden geassocieerd met zowel IR als de ernst van NAFLD. Echter, recent werden nog veel meer 
adipokines beschreven (> 700), waarvan hun rol in de ontwikkeling van obesitas-gerelateerde 
aandoeningen zoals NAFLD nog onthuld moet worden. 
Nog een gekende bijwerking van obesitas is een verstoord metabolisme van de geslachtshormonen. Bij 
obese mannen is het voornaamste geslachtshormoon testosteron (T) vaak verlaagd. Hepatische IR die 
leidt tot een laag sex hormone binding globulin (SHBG) gehalte vormt een belangrijke oorzaak voor dit 
 
 
 
 
laag T gehalte. Echter, bij ernstige obesitas ziet men eveneens een onderdrukking van de hypothalame-
hypofysaire-gonadale as. Ook hiervan is de pathofysiologie nog steeds onduidelijk en er bestaan 
verschillende hypothesen. Een verstoorde hypothalame signalering van leptine bijvoorbeeld, werd 
verondersteld hierin een mogelijk mechanisme te zijn. Een andere verklaring zou een verhoogde 
enzymatische aromatase activiteit in de vergrote adipocyten kunnen zijn, welke leiden tot een grotere 
omzetting van T naar estradiol. Dit zou dan op zich kunnen leiden tot een grotere suppressie ter hoogte 
van de hypothalame-hypofysaire-gonadale as. Gezien T normaal belangrijke anabole acties vertoont en 
de lichaamssamenstelling gunstig zou kunnen beïnvloeden, is meer inzicht in de pathofysiologie van 
deze lage androgeen gehaltes van  groot belang alsook in de gevolgen ervan bij obese mannen. 
Om meer inzicht te krijgen in deze obesitas-gerelateerde complicaties, was het doel van dit proefschrift 
om het disfunctioneel vetweefsel bij obese patiënten te onderzoeken alsook het verband met biopsie-
geverifieerd NAFLD en het verstoord gehalte in geslachtshormonen bij mannen te bestuderen. In het 
bijzonder werd getracht om de mogelijke rol van adipokines in NAFLD te analyseren en een beter zicht 
te krijgen op de complexe relatie tussen de lichaamssamenstelling, geslachtshormonen en metabole 
parameters bij obese mannen. 
Hoofdstuk I bevat een algemene achtergrond omtrent de pathofysiologie van obesitas en de 
gerelateerde metabole complicaties op basis van de huidig beschikbare literatuur. Daarnaast worden de 
onderzoeksdoeleinden in dit hoofdstuk beschreven. De studiepopulaties en methodologie die doorheen 
dit proefschrift gebruikt werden worden vermeld in hoofdstuk II. 
In hoofdstuk III werden associaties bestudeerd tussen niet-klassieke adiopokines en de 
histopathologische ernst in patiënten met biopsie-geverifieerd NAFLD. Vooreerst werd een 
systematische review uitgevoerd omtrent de huidige kennis over recent beschreven adipokines en hun 
relatie met lever histologie in patiënten met NAFLD (hoofdstuk 3.1.). Hoewel chemerine, adipocyte-
fatty-acid-binding protein (AFABP) en resistine onafhankelijk geassocieerd werden met leverschade en 
steatose in verschillende studies, vertoonden deze onderzoeken vaak te veel verschillen om hun 
mogelijke bijdrage in NAFLD voldoende te bewijzen. In het algemeen blijft de beschikbare data over de 
impact van deze recente adipokines op de progressie van NAFLD beperkt, met een grote heterogeniteit 
tussen de studieresultaten en deze werden vaak gebaseerd op kleine patiëntengroepen. Deze review 
benadrukt de dringende noodzaak aan longitudinale studies met grotere en meer homogene 
patiëntengroepen en met het gebruik van gestandaardiseerde meetmethoden om de concentraties van 
adipokines te bepalen.  
 
 
In hoofdstuk 3.2. werd een selectie gemaakt van nieuwere adipokines, waarvan een bijdrage in NAFLD 
verwacht werd op basis van in vitro data. De histologische parameters in leverbiopten en zowel het 
serumgehalte als de expressie in visceraal vetweefsel van deze adipokines werden onderzocht in een 
cross-sectionele studie met obese patiënten van middelbare leeftijd met NAFLD. Het doel van deze 
studie was te onderzoeken of deze adipokines onafhankelijke associaties vertoonden met de graad van 
steatose, inflammatie, ballooning in de levercellen en/of fibrose in leverbiopten, om zo hun mogelijke 
bijdrage in de ontwikkeling van NAFLD en/of de progressie ervan te verduidelijken. Gezien van de 
adipokines afkomstig van visceraal vetweefsel verondersteld wordt dat zij direct aan de lever geleverd 
worden via de portale vene, werd zowel het serumgehalte als de viscerale expressie gemeten van 
adiponectine, omentine, chemerine, monocyte chemoattractant protein-1 (MCP-1) en secreted frizzled-
related protein 4 (SFRP4). Hierbij werd bevestigd dat de serumspiegels van adiponectine een negatieve 
associatie vertonen met de NAFLD activity score (NAS), hoewel deze associatie verdween na correctie 
met IR. Deze bevinding suggereert dat lage circulerende adiponectinespiegels kunnen bijdragen tot IR, 
wat op zijn beurt NAFLD kan beïnvloeden. Vervolgens was de chemerine expressie in visceraal 
vetweefsel verlaagd en negatief geassocieerd met NAS en hepatische steatose, onafhankelijk van de 
leeftijd, BMI en IR. Dit doet vermoeden dat een lagere expressie van chemerine in visceraal vetweefsel 
van obese patiënten betrokken kan zijn in de pathofysiologie van NAFLD, hoewel prospectieve studies 
op grotere schaal noodzakelijk zijn om onze bevindingen te bevestigen.  
De link tussen disfunctioneel vetweefsel en geslachtshormonen werd onderzocht in ernstig obese 
mannen in vergelijking met gezonde controle mannen (hoofdstuk IV). Het doel was om mogelijke 
determinanten van totaal en vrij T (TT en FT) te bepalen, met de nadruk op disfunctioneel vetweefsel, 
metabole parameters en de expressie van het aromatase enzym in vetweefsel. In deze studie konden 
geen verschillen in de in situ aromatase expressie, zowel in subcutaan als visceraal vetweefsel, 
aangetoond worden tussen obese mannen (met of zonder type 2 diabetes) en mannen met een normaal 
gewicht. Deze bevinding werkt de hypothese rond verhoogde aromatase activiteit tegen. Echter, de 
vetcelgrootte in subcutaan vetweefsel was omgekeerd geassocieerd met zowel TT als FT spiegels, na 
multivariate regressieanalyse gecorrigeerd voor leeftijd, groep (controle versus obesitas/diabetes), IR en 
triglycerides. Deze resultaten suggereren een direct negatieve impact van de vetcelgrootte, maar niet IR, 
op de TT en FT gehaltes bij obese mannen, wat de mogelijke rol van disfunctioneel vetweefsel in het 
verstoord profiel van geslachtshormoonen bij obese mannen benadrukt. 
 
 
 
 
Finaal worden de belangrijkste bevindingen van onze studies samengevat en besproken in hoofdstuk V, 
met de nadruk op: de kenmerken van NAFLD bij obesitas, de associaties tussen adipokines en 
leverhistologie bij patiënten met NAFLD met een bijzondere belangstelling voor chemerine, en de 
mogelijke rol van disfunctioneel vetweefsel in lage T waarden bij obese mannen. Bovendien worden in 
dit hoofdstuk ook de klinische relevantie van deze bevindingen en perspectieven op toekomstig 
onderzoek besproken. 
Tot slot vormen de bevindingen van dit proefschrift aanvullend bewijs over de impact van disfunctioneel 
vetweefsel bij obesitas, met een mogelijke rol in de ontwikkeling van NAFLD en het verstoord profiel van 
geslachtshormonen bij obese mannen. Hoewel prospectieve studies op grotere schaal noodzakelijk zijn 
om deze bevindingen te bevestigen en uit te breiden, suggereren ze dat het herstellen van de normale 
functie van vetweefsel en/of het voorkomen van disfunctie zou kunnen helpen om de obesitas-
gerelateerde bijwerkingen tegen te werken. Bovendien zou de farmacologische manipulatie van 
adipokines in de toekomst een mogelijk alternatieve therapeutische optie kunnen bieden. 
  
 
 
 
  
 
 
 
 
  
 
 
SUMMARY 
Our society is challenged to combat with a continuously growing prevalence of obesity. This is due to 
ample food supplies and more sedentary lifestyles and is associated with important metabolic 
comorbidities such as type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) and cardiovascular 
disease (CVD). While obesity has been defined as abnormal and excessive accumulation of adipose 
tissue throughout the human body that interferes with health, the exact pathophysiology causing its 
consequences remains to be fully elucidated. Nowadays, it is becoming clear that a number of pathways 
may interact, resulting in the development of metabolic disease. In response to an excessive energy 
supply, adipose tissue depots will expand with larger adipocyte cell sizes. At a certain point, this leads to 
adipose tissue dysfunction, characterized by a disturbed lipid metabolism with elevated release of fatty 
acids, local tissue inflammation and an impaired release of adipokines. This overspill of lipids outside the 
‘classical’ adipose tissue depots leads to ectopic lipid deposition in organs and tissues such as the liver, 
pancreas, muscle and heart, contributing to the development of metabolic comorbidities. In addition, a 
contribution of inflammatory factors and the impaired adipokine profile to these consequences is 
suspected. 
NAFLD is often referred to as the hepatic manifestation of obesity, and encompasses a wide spectrum of 
liver diseases ranging from simple fatty liver disease (steatosis) to non-alcoholic steatohepatitis (NASH) 
and even end-stage liver disease. Although it is still incompletely understood how obesity leads to 
NAFLD, insulin resistance (IR) and adipose tissue dysfunction are suggested to be central pathogenic 
components of overall NAFLD. It is increasingly recognized that an impaired pattern in adipokine 
secretion could play a pivotal role in the development of metabolic diseases, including NAFLD and the 
progression to NASH. For instance, serum adiponectin levels are lowered in obesity and associated with 
both IR and NAFLD severity. However, many more adipokines (> 700) have been described recently, and 
their possible role in the development of obesity-related disorders such as NAFLD remains to be 
explored. 
Another well-known manifestation of obesity is disturbance of the normal sex steroid metabolism. 
Obese men often present with low levels of the principal male sex steroid testosterone (T). A major 
factor for these decreased T levels relies on lower levels of the sex hormone binding globulin (SHBG), 
probably resulting from hepatic IR. In morbid obesity, however, a true downregulation of the 
hypothalamic-pituitary-gonadal axis can be observed. Pathophysiology thereof is still unclear and 
several hypotheses still stand. For instance, disturbed hypothalamic signaling of another adipokine, 
 
 
 
 
leptin, has been proposed as a possible mechanism. Another possibility might be increased aromatase 
enzyme activity at the enlarged adipose tissue depot leading to an increased conversion of T to 
estradiol, which then would lead to enhanced suppression at hypothalamic-pituitary level. As T is 
considered to display important anabolic actions and might favorably influence body composition, 
insights in the pathophysiology of these low androgen levels and its consequences in obese men is of 
interest. 
To gain more insight into these obesity-related phenomena, this thesis aimed to examine adipose tissue 
dysfunction in obese subjects and to investigate its link with biopsy-proven NAFLD and disturbed sex 
steroid levels in men. In particular, we aimed to investigate the potential role of adipokines in NAFLD 
and to gain a better view on the complex relationship between body composition, sex steroid levels and 
metabolic parameters in obese men. 
In chapter I, a general background with a review of current available literature regarding the 
pathophysiology of obesity and its metabolic comorbidities is given together with our research aims. The 
study populations and methodology used throughout this thesis are reported in chapter II. 
In chapter III, we investigated the associations between non-classical adipokines and histopathological 
severity in biopsy-proven NAFLD patients. Firstly, a systematic review was performed to recapitulate 
current knowledge on recently described adipokines and their relation with liver histology in NAFLD 
patients (chapter 3.1.). Although chemerin, adipocyte-fatty-acid-binding protein (AFABP) and resistin 
were independently associated with hepatic injury and steatosis in several reports, these studies were 
often too divergent to provide significant evidence on their potential involvement in NAFLD. Overall, 
data on the impact of these recently described adipokines on disease progression remain scarce with a 
major heterogeneity across study results and often confined to small patient numbers. The review 
highlights the urgent need for longitudinal studies on larger and homogenous patient groups with the 
use of standardized assays to measure adipokine levels.  
In chapter 3.2., a selection of more novel adipokines was made, of which a contribution to NAFLD was 
suspected based on in vitro data. Their serum levels and visceral adipose tissue (VAT) expression was 
associated with hepatic histological parameters in a cross-sectional cohort of obese middle-aged NAFLD 
patients. We aimed to investigate whether these adipokines were independently associated with 
steatosis grade, inflammation, hepatocyte ballooning and/or fibrosis grade of liver biopsies, in order to 
clarify their potential contribution to NAFLD development and/or progression. Because adipokines 
derived from VAT are considered to be delivered directly to the liver via its portal vein, we measured 
 
 
both circulating levels and VAT expression of adiponectin, omentin, chemerin, monocyte 
chemoattractant protein-1 (MCP-1) and secreted frizzled-related protein 4 (SFRP4). We confirmed that 
serum adiponectin levels were negatively associated with NAFLD activity score (NAS), however this was 
lost after correction for IR. This finding suggests that low circulating levels of adiponectin may contribute 
to IR, which in turn may influence NAFLD. Further, chemerin VAT expression in male NAFLD patients was 
reduced and inversely associated with overall NAS and hepatic steatosis independent of age, BMI and IR. 
This suggests that lower VAT expression of chemerin in obese patients may be involved in the 
pathophysiology of NAFLD, although larger-scaled prospective studies are needed to confirm our 
findings. 
The relation of dysfunctional adipose tissue with sex steroid profile was investigated in a cohort of 
morbidly obese and healthy control men (chapter IV). We aimed to explore potential determinants of 
total and free T (TT and FT) levels, focusing on adipose tissue dysfunction, metabolic parameters and 
adipose tissue aromatase expression. In this study, we could not find differences in in situ aromatase 
expression, both in subcutaneous adipose tissue (SAT) and VAT, between obese men (with or without 
type 2 diabetes) and normal-weight men, thus counteracting the increased aromatase activity 
hypothesis. SAT cell size, however, was independently inversely associated with both TT and FT levels 
after multivariate regression analysis corrected for age, group (control versus obesity/diabetes), IR, and 
triglyceride levels. These results suggest a direct negative impact of adipocyte size, but not IR, on TT and 
FT levels in obese men, highlighting a potential role of adipose tissue dysfunction in the disturbed sex 
steroid profile of obese male subjects. 
Finally, the main findings of our studies are summarized and discussed in chapter V, focusing on the 
characteristics of NAFLD in obesity, the associations between adipokines and liver histology in patients 
with NAFLD with a particular interest in chemerin, and the potential role of adipose tissue dysfunction in 
low T levels of obese men. In addition, clinical relevance of these findings is discussed as well as 
perspectives on future research. 
In conclusion, the findings in this thesis have provided additional evidence on the impact of adipose 
tissue dysfunction in case of obesity, with a potential role in the development of NAFLD and the 
impaired sex steroid profile of obese men. Although larger-scaled and prospective studies are needed to 
confirm and expand these findings, it suggests that restoring normal adipose tissue function and/or 
preventing dysfunction might help to counteract obesity-related consequences. Alternatively, the 
pharmacologic manipulation of adipokines might represent a future therapeutic option. 
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I. GENERAL INTRODUCTION 
1. Background  
Worldwide epidemic rates of overweight and obesity, due to ample food supplies and more sedentary 
lifestyles, result in a persistently increasing burden for modern society. Obesity is a major risk factor for 
the development of metabolic comorbidities such as type 2 diabetes, non-alcoholic fatty liver disease 
(NAFLD) and cardiovascular diseases (CVD) [1]. According to the World Health Organization (WHO), 
overweight and obesity are defined as abnormal or excessive fat accumulation that represents a risk to 
health [2]. The term ‘abnormal’ in this definition most likely represents the importance of adipose tissue 
dysfunction, rather than solely excess fat per se, in the pathogenesis of obesity-related metabolic 
complications.  
Adipose tissue dysfunction can develop when a nutritional overload leads to failure in storage of lipids, 
which might result in overspill of lipids outside the ‘classical’ adipose tissue depots and ectopic 
deposition into organs and tissues such as liver and muscle. This then causes local tissue dysfunction, 
called lipotoxicity [1]. Although the exact mechanism on how adipose tissue becomes dysfunctional is 
incompletely understood, several pathological mechanisms are considered to be implicated including 
mitochondrial damage, increased adipose cell size, decreased insulin sensitivity of fat cells and failure of 
their storage function with consequent peripheral lipotoxicity, but also adipose tissue macrophage 
infiltration, inflammation and changes in adipokine secretion [3]. In light of the epidemiologic burden of 
obesity and its metabolic consequences arising worldwide, a thorough understanding of the etiology 
and underlying mechanisms is necessary. 
NAFLD is often referred to as the hepatic manifestation of obesity, as its prevalence is simultaneously 
rising with the combined epidemic of obesity and type 2 diabetes. Although the exact pathophysiology 
of NAFLD remains to be fully elucidated, insulin resistance (IR) and adipose tissue dysfunction are 
suggested to play a central role in this. In addition, the potential impact of impaired adipokine release is 
currently a major point of interest in clarifying the development of metabolic diseases, including NAFLD 
and the progression to NASH. However, the range of discovered adipokines is currently enormously high 
(> 700), whereas knowledge of their function remains mainly unclear.  
A well-known association exists between body composition and sex steroids, the steroid hormones 
involved in the development of secondary sexual characteristics and reproductive functions, and which 
are at least partly responsible for the sexual dimorphism in body composition between men and women 
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[4]. In light of the increasing prevalence of obesity worldwide, the interest in sex steroids as potential 
determinants of body composition is similarly increasing. Obese men, who are often characterized by 
low levels of the principal male sex steroid testosterone (T), have increased levels of visceral and 
subcutaneous fat that accumulates preferentially in the abdominal region. Visceral fat in particular, is 
associated with increased metabolic risk [5, 6]. Consequently, there is a high need to understand and 
unravel the potential causal relationship between obesity and disturbed sex steroid levels. 
In this general introduction, an overview of current knowledge regarding the pathophysiology of obesity 
and its metabolic comorbidities is described in the first chapter. Secondly, the link between obesity and 
NAFLD, more specifically the contribution of IR and adipokines to the pathogenesis of NAFLD, is 
discussed in the following chapter. Finally, the regulation and synthesis of sex steroids in men as well as 
their interaction with adipose tissue and the disturbed sex steroid pattern in case of obesity is described 
in the last chapter.   
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2. Body fat: friend or foe?  
Obesity is characterized by excess body fat or adipose tissue and associated with a high risk of 
developing metabolic comorbidities such as IR, type 2 diabetes and CVD. However, patients with 
congenital lipodystrophy that are characterized with an almost complete absence of adipose tissue, 
have been described as having a similar metabolic profile with IR, type 2 diabetes, dyslipidemia and CVD 
[7]. This suggests that adipose tissue per se is not as harmful as it may seem but that its function is 
determining metabolic complications in obesity. Thus, more knowledge on the pathological 
consequences of excess adipose tissue accumulation is necessary in order to better understand, prevent 
and treat obesity-related complications. Humans mainly possess white adipose tissue (WAT), but semi-
recently the presence of brown adipose tissue (BAT) has been demonstrated. Both are involved in 
energy metabolism, but differ largely with respect to fuel utilisation. While WAT is excessively present 
throughout the whole body and stores surplus lipids as energy for times of metabolic need, BAT is only 
to a very limited extent and variably present in the human body and uses lipids as a source of heat 
production through thermogenesis [8]. Besides thermogenesis, the role of BAT is rather unclear and will 
not be the scope of this thesis as we will focus on WAT.  
 
2.1. Adipose tissue anatomy and histology 
The main biological function of adipose tissue is to manage lipid storage and availability, providing both 
long- and short-term regulation and delivery of stored lipids in response to the body’s energy need. 
These lipids are stored in the adipocytes within one large lipid droplet that occupies the majority of 
intracellular space, compressing the cytoplasm and nucleus into a thin border. Adipocytes are organized 
into adipose tissue together with fibroblasts, macrophages, small blood vessels, nerve tissue and 
adipocyte precursor cells (preadipocytes) [8]. The volume of an adipocyte is determined by a balance of 
3 processes occurring within the adipocyte: fatty acid (FA) uptake, lipogenesis and lipolysis, which will be 
described in the section of lipid handling and storage (section 2.2.1.).  
There are two major anatomic subdivisions of adipose tissue: intra-abdominal or visceral adipose tissue 
(VAT) and subcutaneous adipose tissue (SAT). While SAT is located beneath the skin, VAT is found within 
the abdominal cavity. VAT is further divided into intraperitoneal and retroperitoneal depots, although 
the borderline between them is not completely clear. The majority of VAT is composed of 
intraperitoneal fat, which comprises omental en mesenteric adipose tissue. In addition to the main SAT 
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and VAT compartments, several organs such as the heart and kidneys are surrounded by small amounts 
of adipose tissue [8, 9]. SAT can also be subdivided by region into abdominal or upper-body and 
gluteal/femoral or lower-body SAT, which in turn differ in fat uptake and release, and hormone 
production. Indeed, free fatty acid (FFA) release form upper-body SAT was higher than from lower-body 
SAT, both in men and women [10-12]. Intra-abdominal adipose tissue or VAT is characterized with more 
capillaries and efferent sympathetic axons per unit volume than SAT and unlike SAT, it drains directly 
into the hepatic portal vein. Excess VAT results in substantially higher metabolic risk for any amount of 
total body fat, at least because it is more resistant to insulin and insulin-mediated suppression of 
lipolysis, but perhaps also due to differences in its secretary factors. However, an important question 
remains whether VAT is a causal factor or simply a marker of a dysmetabolic profile [13-16]. In contrast, 
SAT, in particular lower-body SAT, is less associated with metabolic risk due to its enhanced ability to 
expand, allowing more storage of excess dietary FA, and due to reduced hypoxia and fibrosis [17, 18]. 
Although body mass index (BMI) - body weight divided by the square of the body height (kg/m2) - is 
associated with obesity-related health risks, it is not the most accurate marker of metabolic risk as it 
does not differentiate between muscle mass and fat mass and there is no discrimination between SAT 
and VAT despite the differential associated metabolic risk [19]. Waist circumference (WC) measured at 
the smallest circumference of the natural waist, appears to be a better estimate of abdominal obesity. 
However, caution is advised when interpreting these results because this measure of abdominal fat still 
does not differentiate between SAT and VAT [20]. In clinical practice, regional fat distribution can be 
estimated with skinfold measurements, ultrasound and Dual-energy X-ray absorptiometry (DXA), 
although the added clinical value seems limited. The differentiation between intra-abdominal fat (VAT) 
and abdominal SAT requires advanced imaging techniques such as computed tomography (CT) or 
magnetic resonance imaging (MRI), which are less easily used in clinical practice [21, 22]. The 
distribution of fat and particularly of VAT, may be influenced by aging, gender, smoking, sedentary 
lifestyle and nutritional status [23]. The relation between body composition, including fat distribution, 
and gender will be described more in detail in section 4.2. 
 
2.2. General physiology of adipose tissue 
2.2.1. Lipid handling and storage 
As mentioned before, the major function of adipose tissue is lipid storage. After a meal, dietary lipids or 
FA are absorbed from the intestine and released into general circulation as chylomicrons at the thoracic 
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duct. In the circulation, lipids are transported as triglycerides (TG) into specific transporting proteins 
such as chylomicrons and very-low-density lipoproteins (VLDL; synthesized by the liver). Once 
lipoproteins arrive at the target cell, lipoprotein lipase (LPL), an enzyme that resides on the endothelial 
cells of blood vessels, is activated and enables the adipocytes or other metabolically active cells to take 
up FA [24]. Once entered in the adipocytes, lipids are stored in the form of TG to provide a reservoir of 
energy. Synthesis of TG within the adipocyte consists of the esterification of 3 molecules of FA to one 
molecule glycerol - a process called lipogenesis. TG are hydrolyzed back into FFA and glycerol in case of 
fasting - a process called lipolysis. The FA released in the circulation after lipolysis, called non-esterified 
fatty acids (NEFA), serve as a fuel for metabolically active tissues where they are oxidized by 
mitochondria into energy in the form of adenosine triphosphate (ATP). Lipogenesis can also include de 
novo synthesis of FA and subsequently TG, a process that is catalyzed by acetyl coenzyme A carboxylase 
(ACC) and involves metabolized substrates of glucose. Each of these processes is strictly regulated by 
extracellular signals such as insulin, catecholamines, FFA and cytokines [8, 25] (Figure 1).  
 
 
Figure 1 Schematic presentation of the processes of FA uptake, lipogenesis and lipolysis within one adipocyte. 
Dietary lipids are transported in the circulation as lipoproteins, from which they are released as free fatty acids 
(FFA) by lipoprotein lipase (LPL). Once entered the adipocyte, FFA are transformed into triglycerides (TG) by acetyl 
coenzyme A synthetase (ACS) and binding with glycerol-3P, a substrate that is derived from glucose. Insulin 
normally enhances glucose uptake, providing storage of glucose in the form of glycogen and lipids. Indeed, more 
glucose results in higher amounts of substrates for both de novo lipogenesis as well as the conversion of entered 
FFA into TG. Consequently, the higher rates of lipogenesis increase the TG pool within the adipocyte, together with 
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synthesized glycogen providing long-term storage of energy. ACC: acetyl coenzyme A carboxylase; HSL: hormone-
sensitive lipase; IR: insulin receptor. Adapted from [8]. 
 
2.2.2. Regulatory factors of the metabolic system 
Metabolic homeostasis is normally strictly controlled, as illustrated for example by the link between 
alterations in the function of crucial transcription factors (TF) and the occurrence of major metabolic 
diseases. Organisms are able to adapt their metabolic activity to environmental (nutritional) changes by 
modifying the transcriptional control of gene expression of key enzymes. These modifications 
particularly occur in response to hormonal impulses and take place during the alternation between 
fasting and feeding to achieve energy homeostasis. Disruption of this transcriptional and hormonal 
control leads to the development of metabolic disease, reflecting the importance of a finely tuned 
glucose and lipid metabolism [26]. Blood glucose levels for instance, are strictly kept in a narrow range 
of 4 to 7 mM despite the strong differential supply between fasting and feeding. Indeed, a strict 
regulation of glucose availability is crucial for the correct functioning of different cell types (avoidance of 
hypoglycemia for e.g. erythrocytes which are exclusively dependent on glucose as a fuel), but also to 
efficiently store glucose for later use. After feeding, the pancreas senses glucose and insulin secretion is 
stimulated by increased glucose levels, inducing the quick removal of glucose by uptake in peripheral 
tissues. Simultaneously, insulin promotes energy storage by glycogen synthesis in liver and muscle as 
well as FA synthesis in liver and adipose tissue. In times of fasting or physical activity, insulin levels 
remain low and the contraregulatory hormone glucagon stimulates the hepatic production of glucose 
(gluconeogenesis) and its release from glycogen (glycogenolysis). While the liver functions as a “buffer” 
that provides glucose when energy is needed and stores energy when glucose is abundant, muscle tissue 
mainly consumes glucose as an energy source and the intramyocellular glycogen is in fact only available 
for local use [27].  
Insulin and glucagon are thus considered to be major regulatory hormones involved in metabolic 
homeostasis. Firstly, pro-insulin is synthesized by β-cells of the pancreas, which is cleaved into insulin 
and peptide C by proconvertases. Insulin is then stored in secretory vesicles, of which secretion is 
directly linked to the sensing of glucose levels [28]. Released insulin proteins circulate to insulin-
responsive tissues such as adipose tissue, liver and muscle, where they interact with the membrane 
insulin receptor, a tyrosine kinase receptor. Receptor activation results in the phosphorylation of insulin 
receptor substrate 1 and 2 (IRS1 and IRS2), followed by several sequential phosphorylation steps that 
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subsequently activate the Ras/mitogen-activated protein kinase (MAPK) pathway. This pathway seems 
to be mostly involved in cellular growth and proliferation rather than metabolic homeostasis. 
Simultaneously however, the activated IRS proteins induce activation of phosphatidylinositol 3-kinase 
(PI3K), which converts phosphatidylinositol (4,5)-bisphosphate (PIP2) into phosphatidylinositol (3,4,5)-
trisphosphate (PIP3). This results in a phosphorylation cascade that leads to the activation of 
phosphoinositide-dependent kinase 1 (PDK1) and Akt/protein kinase B (PKB). In metabolically active 
tissues such as the liver and skeletal muscle, PDK1 and Akt/PKB regulate glucose and lipid metabolism by 
increasing glucose uptake and the synthesis of glycogen and lipids and by decreasing hepatic 
gluconeogenesis [27]. 
 
 
Figure 2 Insulin signaling in healthy individuals. Insulin-mediated activation of the insulin receptor results in the 
phosphorylation of insulin receptor substrate 1 and 2 (IRS1 and IRS2), followed by the initiation of a 
phosphorylation cascade that ultimately activates the mitogen-activated protein kinase (MAPK) pathway and the 
Akt/protein kinase B (PKB) pathway. While the MAPK pathway regulates cell growth and differentiation, 
phosphoinositide-dependent kinase (PDK) and Akt/PKB activation leads to an increased glucose uptake, glycogen 
and lipid synthesis as well as a decreased gluconeogenesis in metabolically active tissues such as the liver, skeletal 
muscle and adipose tissue. aPKC, atypical protein kinase C; FOXO1, forkhead box protein O1; GSK3, glycogen 
synthase kinase 3; PI3K, phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol (4,5)-bisphosphate; PIP3, 
phosphatidylinositol (3,4,5)-trisphosphate; PKA, protein kinase A. Adapted from [29] 
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2.2.3. Adipose tissue as an endocrine organ 
Besides the storage and mobilization of lipids, adipose tissue operates as an endocrine organ expressing 
steroid metabolizing enzymes and secreting numerous regulatory products, named adipokines, which 
exert local, peripheral and central effects. In literature, numerous adipokines have been described 
already and their number is still rising. The discovery of more than 700 different proteins have been 
indicated as adipokines in literature and the research group of Lehr et al. has recently reported another 
44 novel adipokines as secretary products in medium of differentiated primary adipocytes derived from 
healthy individuals [30]. Adipokines are polypeptides that are mainly, but not exclusively, produced by 
adipocytes. Some inflammatory cytokines, such as tumor necrosis factor (TNF)-α and interleukin (IL)-6, 
are additionally secreted by immune cells infiltrating the adipose tissue [31]. Although the function of 
many adipokines remains unknown, certain adipokines have been described to have a role in regulating 
whole body energy homeostasis and metabolism and/or inflammatory responses. Therefore, adipokines 
are generally subdivided into pro-inflammatory and anti-inflammatory adipokines, of which the balance 
in their secretion pattern is strictly regulated in normal physiological conditions [32, 33]. Important 
differences in the adipokine secretion pattern exist among the distinct regional adipose tissue depots. 
Leptin for instance, has been described as an important regulator of the energy balance and food intake. 
Higher leptin levels are more closely correlated with SAT expression than with VAT expression [34, 35]. 
While adiponectin, a known anti-inlfammatory adipokine, is predominantly produced in SAT, You T et al. 
reported that its expression was higher in abdominal compared to gluteal SAT of abdominally obese 
women and weight loss preferentially increased this abdominal SAT expression and release [11].  
Additionally, adipose tissue is also an important site of steroid hormone metabolism, as several steroid 
metabolizing enzymes are expressed. For example, adipose tissue expresses both aromatase enzyme, 
which converts T into estradiol (E2), and 11β-Hydroxysteroid dehydrogenase (11β-HSD) enzyme, which 
catalyzes the conversion of cortisone to cortisol [36]. This relation between adipose tissue and sex 
steroid metabolism will be described more in detail in chapter III. 
 
2.3. Obesity and metabolic consequences  
As mentioned, obesity is defined as a medical condition in which there is surplus accumulation of fat in 
the body, which is linked to metabolic disturbances resulting in increased illness, disability, and even 
mortality. The WHO classified obesity according to BMI categories into class I (30-34.9 kg/m2; mild), class 
II (35-39.9 kg/m2; moderate) and class III (≥ 40 kg/m2; severe). In 2013, approximately 50% of the adult 
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population in developed countries was either overweight (BMI > 25 kg/m2) or obese (BMI > 30 kg/m2) 
[37]. According to the WHO, the global prevalence has doubled between 1980 and 2014, with 20-30% of 
the European adults being obese [38]. This prevalence is still rising worldwide, increasing health care 
costs and leading to a huge burden for modern society. Metabolic derangements associated with 
obesity include hypertension, dyslipidemia and IR, often collectively termed as the metabolic syndrome 
(MetS). The MetS thus comprises a cluster of cardiometabolic risk factors, with IR and excess body fat as 
central features. MetS is considered a practical tool to describe this cluster of factors that regardless of 
cause, identifies individuals at risk of CVD and type 2 diabetes. Following criteria for MetS have been 
identified by the National Cholesterol and Education Program (NCEP) - the Adult Treatment Panel III 
(ATPIII) criteria: central obesity (indicated by WC > 40 inches for men, > 35 inches for women), 
dyslipidemia with high TG (≥ 150 mg/dl) and/or low high-density lipoprotein (HDL) cholesterol (< 40 
mg/dl for men, < 50 mg/dl for women), hypertension (blood pressure ≥ 130/85 mmHg) and impaired 
fasting glucose (≥ 110 mg/dl). The presence of at least 3 of these features is considered sufficient to 
diagnose MetS [39, 40]. Based on the National Health and Nutrition Examination Survey (NHANES), 
approximately 35% of all US adults and 1 out of 10 US adolescents currently have MetS [41, 42]. 
Furthermore, >40% of adults over the age of 50 have MetS [43]. It is generally known that the presence 
of MetS generates an increased risk of all-cause mortality and CVD, and results in a 7-fold increased risk 
of developing type 2 diabetes [44, 45]. Although obesity is a well-known risk factor for IR, type 2 
diabetes and CVD, not every obese patient is insulin resistant or at high risk of diabetes and CVD. This 
explains why obesity is not an obligatory component in the definition of MetS and thus not necessarily 
present in patients with MetS. Indeed, both metabolically healthy obese phenotypes as well as 
metabolically obese but normal-weight phenotypes have been identified, depending on their fat 
distribution and insulin sensitivity, which are presented as the main factors that define phenotypes 
within the same BMI range. Metabolically healthy obese patients may represent an adaptation to 
reestablish a new homeostatic state by expanding adipose tissue and maintain a normal glucose and 
lipid metabolism in case of high availability of caloric-rich food [46]. However, major inconsistency still 
exists on this topic. Besides its role in energy storage, adipose tissue has impact on whole-body 
metabolism at least in part by secreting adipokines and influencing immune cell functions, as we will 
discuss in following sections.  
 
 
 
 
10 
 
2.3.1. Adipose tissue dysfunction  
In obesity, the excessive energy supply initially results in adipose tissue expansion both at SAT and VAT 
depots. Adipose tissue is highly plastic and can respond rapidly to changes in energy balance through 
adipocyte enlargement (hypertrophy) or increasing the number of adipocytes (hyperplasia), depending 
on the fat depot and initial adipocyte size. Although the number of abdominal adipocytes is often 
suggested to remain constant during adulthood, recent reports suggest that mainly lower-body SAT may 
also expand through hyperplasia. However, in upper-body or central obesity this adipose tissue 
expansion is mainly characterized by larger adipocyte cell sizes [18, 47, 48]. If not counterbalanced, this 
adipocyte enlargement can lead to adipose tissue dysfunction, potentially due to an insufficient blood 
supply and a higher rate of macrophage infiltration. Adipose tissue dysfunction is characterized by a 
disturbed lipid metabolism with an elevated release of NEFA, inflammation and an impaired release of 
adipokines. As these processes can cause IR and local inflammation in other organs, it is also called 
lipotoxicity [49].  
2.3.1.1. Non-esterified fatty acids (NEFA) and lipid metabolites 
NEFA are released into the circulation after lipolysis within the adipocytes. In case of obesity, increased 
lipolysis as a result of resistance to the anti-lipolytic effect of insulin, may lead to elevated NEFA levels in 
serum. Elevated NEFA have been indicated as important mediators of adverse metabolic effects 
including IR and a disturbed glucose and lipid metabolism, by playing a key role in the process of fat 
overflow to ectopic tissue sites. NEFA entering skeletal muscle cells – intramyocellular lipids – may 
impair insulin sensitivity and glucose uptake. In the liver, excess NEFA are converted into TG 
(lipogenesis) and glucose (gluconeogenesis), contributing to the development of hepatic steatosis, IR 
and hyperglycemia [16, 50]. Although a higher proportion of hepatic NEFA delivery is expected as VAT 
increases - because of the direct delivery via the hepatic portal vein, the importance of VAT-derived 
NEFA delivery to the liver is still controversial. On the contrary, it has been reported that the proportion 
of portal NEFA derived from VAT was lower than the relative amount derived from lipolysis in SAT. Both 
fat depots are thus suggested to be important suppliers of NEFA to the liver and other organs, and other 
factors than VAT-derived lipid deposition might explain the worsened metabolic profile of viscerally 
obese patients [51]. Moreover, in some obese individuals, the release of NEFA per kilogram of adipose 
tissue was downregulated instead of increased, suggesting that obesity-related hepatic and systemic IR 
can also occur without the elevation of NEFA concentrations [52].  
Introduction |  
 
11 
 
In addition to the elevated NEFA release, the oxidative capacity of adipocytes fails to sufficiently 
compete with excess supply of lipids. Consequently, this impaired lipid oxidation results in the 
production of lipid metabolites such as fatty acyl-CoA, diacylglycerol (DAG) and ceramides. These 
metabolites and DAG in particular, are suggested to interfere with insulin signaling by activating protein 
kinase C (PKC) locally as well as in muscle and liver. Activated PKC phosphorylates IRS1 and IRS2 at 
serine residues, thereby inhibiting insulin signal transduction and glucose uptake [53].  
2.3.1.2. Inflammation 
Accumulating evidence suggests that an inflammatory response in the adipose tissue may play a critical 
role in the development of obesity-related metabolic comorbidities [54, 55]. FA for instance, may induce 
intracellular inflammation by stimulating nuclear factor-κB (NFκB), a known inflammatory TF that 
induces the transcription of inflammatory cytokines, and by activating c-Jun N-terminal kinase (JNK), 
which interferes with insulin signaling and also activates NFκB. Extracellularly, FA can also serve as 
ligands for the toll-like receptor 4 (TLR4) and stimulate cytokine production of macrophages, which 
additionally contributes to systemic inflammation [56]. Furthermore, the increased mitochondrial 
oxidation of FA in adipocytes can result in reactive oxygen species (ROS) production leading to oxidative 
stress, which together with endoplasmatic reticulum (ER) stress stimulates inflammatory pathways and 
may induce IR [57]. These results suggest that inflammation is closely linked with mechanisms of IR. The 
expanded adipose tissue of obese subjects is indeed characterized by more and different infiltrating 
immune cells, contributing to an increased local and systemic inflammatory response [58].   
2.3.1.3. Adipokines 
As described earlier, adipose tissue produces numerous adipokines, of which the secretion may 
influence metabolic homeostasis. It is generally accepted that the adipose tissue of obese subjects has a 
different secretion pattern of adipokines as compared to normal-weight subjects, leading to the release 
of more pro-inflammatory and less anti-inflammatory adipokines. Adipose tissue dysfunction thus 
results in dysregulation of the adipokine secretion pattern, which in turn might contribute to the 
development of metabolic dysfunction by altering glucose and lipid homeostasis as well as the 
inflammatory response [32, 59]. Although a substantial amount of discrepancy still exists throughout 
literature, several adipokines have gained particular interest for their suspected role in the 
pathophysiology of obesity and its metabolic comorbidities. Adiponectin for instance, is a well-known 
adipose tissue-specific adipokine with insulin-sensitizing and anti-inflammatory effects. Its adipose 
tissue expression and serum levels are lower in obese and insulin resistant patients and upregulation of 
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adiponectin secretion has increased insulin sensitivity in animal models [60]. Leptin is another 
adipokine, specifically expressed by adipocytes, that normally inhibits appetite and food intake and 
stimulates energy expenditure [61]. In obesity however, higher expression and serum levels were 
reported and the existence of (partial) leptin resistance was hypothesized, as some beneficial effects of 
leptin were lost while pro-inflammatory effects were induced in these patients [62, 63].  
In addition, adipocytes and immune cells, particularly adipose tissue-infiltrating macrophages, are the 
primary sources of inflammatory molecules such as cytokines and chemokines [64]. Cytokines are 
known to induce an inflammatory response and to interfere with insulin signaling. A well-known 
cytokine is TNF-α, of which higher expression and serum levels were found in obese patients and a 
positive association was found with IR [65]. However, it has been suggested that the effects of TNF-α on 
IR are attributable to a complex inflammation network that is capable to initiate different cytokine 
cascades and synergistically interfere with insulin signaling [66]. Chemokines, for example monocyte 
chemoattractant protein-1 (MCP-1), play a major role in selectively recruiting immune cells to the site of 
inflammation (chemotaxis) and chemokine receptors are highly expressed in adipose tissue of obese 
subjects [67]. Table 1 gives an overview on functions of other adipokines that have been suggested to be 
implicated in obesity.  
Overall, it is accepted that adipokines play an important role in the crosstalk between adipose tissue and 
other tissues including skeletal muscle, liver and even the brain. However, considering the wide 
spectrum of both anti- and pro-inflammatory adipokines, it is likely that a crosstalk of several adipokines 
in turn may be involved in metabolic dysfunction [68]. Further studies are needed to elucidate 
important crosstalk pathways. 
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Table 1 Functions of adipokines that have been implicated in obesity 
Adipokine 
Serum and/or 
expression in 
obesity 
Target tissue/cells Main effects of adipokines in target tissue References 
Chemerin ↑ [69] Adipose tissue Increased adipogenesis, glucose uptake, FA 
synthesis and secretion of adiponectin and leptin; 
increased or decreased insulin signaling; 
decreased lipolysis and IL-6 secretion  
[70, 71] 
  Skeletal muscle Decreased insulin signaling and glucose uptake; 
increased activation of NFκB with an initiated 
inflammatory response  
[69] 
  Macrophages and 
dendritic cells 
Increased chemotaxis  
[72, 73] 
Omentin ↓ [74] Cardiomyocytes Increased insulin sensitivity and cardiac function [75] 
  Adipose tissue Increased insulin sensitivity and glucose uptake [76] 
  Endothelial cells Decreased inflammatory response [77, 78] 
MCP-1 ↑ [79] Adipose tissue Lowered insulin signaling and activated 
chemotaxis 
[80, 81] 
  Liver Promoted hepatic fibrosis [82] 
IL-6 ↑ [83] Adipose tissue Lowered insulin signaling and glucose uptake and 
higher circulating fasting glucose levels 
[83-85] 
  Skeletal muscle  Higher glucose uptake and fatty acid oxidation [86] 
  Liver Lowered insulin signaling and glycogen synthesis [87] 
Resistin ↑ [88] Adipose tissue Lowered insulin signaling and activated FA and 
cytokine release  
[89-91] 
  Liver Lowered insulin signaling, glycogen synthesis and 
glucose uptake; increased glucose production, 
circulating fasting glucose levels and 
inflammatory response 
[92-97] 
  Macrophages Increased pro-inflammatory response [98] 
Visfatin ↑ [99] or ↓ 
[100] 
Adipose tissue Stimulated insulin signaling and glucose uptake; 
lowered circulating glucose levels 
[101, 102] 
  Hypothalamus Increased insulin signaling and glucose uptake [103] 
  Monocytes Increased cytokine release and pro-inflammatory 
response 
[104] 
RBP4 ↑ [105] Skeletal muscle Lowered insulin signaling [106] 
  Liver Increased glucose production [106] 
Vaspin ↑ [107] Adipose tissue Increased insulin signaling and normalized 
cytokine expression and serum glucose levels 
[108] 
  Hypothalamus Decreased food intake and blood glucose levels [109] 
AFABP ↑ [110] Adipose tissue Lowered insulin signaling and adiponectin 
secretion; increased lipolysis 
[111, 112] 
  Macrophages Increased pro-inflammatory response [112] 
FA, fatty acids; MCP-1, monocyte chemoattractant protein-1; IL-6, interleukin-6; RBP4, retinol-binding protein 4; AFABP, 
adipocyte-fatty-acid-binding protein. 
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2.3.2. Insulin resistance (IR) 
In general, IR is defined as the decreased ability of tissues to respond to insulin action and is known to 
be a major predictor of the development of type 2 diabetes. In adipose tissue, insulin normally 
stimulates storage of TG, uptake of glucose and FFA (derived from lipoproteins), lipogenesis and inhibits 
lipolysis, all of which are dysregulated in obesity. In case of IR in myocytes, insulin-mediated glucose 
uptake is impaired with subsequent reductions in glycogen synthesis. In hepatocytes, IR is manifested by 
defects in the ability of insulin to suppress glucose production and promote glycogenesis [113]. As 
described in the preceding sections, several factors such as FFA and impaired adipokine release from 
adipose tissue have been directly or indirectly involved in the development of aberrant insulin signaling. 
Accumulating evidence suggests that these factors may synergistically contribute to IR. For instance, 
saturated FA, but not unsaturated FA, as well as TNF-α both can induce the synthesis of ceramide, a 
well-known metabolite that interferes with insulin signaling [114, 115]. Except for the impaired FA and 
adipokine release, obesity-associated systemic inflammation is characterized by the activation of several 
inflammatory kinases and TF such as JNK and NFκB, which in turn interfere with insulin action in 
adipocytes and hepatocytes [116]. Although VAT is more metabolically active and often more closely 
associated with IR compared to SAT, evidence proved that dysfunctional SAT remains a key player in the 
development of IR and inflammation by contributing to the circulating levels of FFA and adipokines [117, 
118]. In response to the insulin resistant state, pancreatic β-cells initially secrete more insulin, 
attempting to overcome the hyperglycemia, resulting in hyperinsulinaemia (high blood insulin levels). 
Although hyperinsulinaemia may in part compensate for some IR, it may contribute to other 
complications, i.e. hypertension and hepatic steatosis [119]. Furthermore, this compensatory effort will 
ultimately fail in most obese patients, leading to development of glucose intolerance and diabetes. 
2.3.3. Ectopic lipid deposition 
Intracellular lipid content of organs and tissues that constitute lean body mass (skeletal muscle, liver, 
heart, kidneys) is normally tightly regulated. A small reservoir of FA is needed in all cells, because of 
their essential role to form phospholipid bilayers of cell membranes and the phospholipid messengers 
that transmit intracellular signals. Any lipid overload however, may lead to cell dysfunction by 
lipotoxicity and lipid-induced programmed cell death (lipoapoptosis) [120]. Because these tissues have a 
limited oxidative capacity, any FA surplus must enter non-oxidative pathways with the production of 
toxic lipid metabolites such as ceramide as a consequence. Together with FA-induced inhibition of anti-
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apoptotic factors, ceramide induces, for instance through activation of NFκB and increased nitric oxide 
production, lipoapoptosis in β-cells, cardiomyocytes and hepatocytes [121].  
 
2.4. Therapeutic approaches counteracting obesity 
2.4.1. Lifestyle interventions: diet and physical activity 
The primary recommended interventions towards obesity consist of lifestyle modifications that result in 
weight loss such as diet adjustments, exercise and behavioral changes. Weight loss is associated with an 
improvement of metabolic and cardiovascular risk. Over a period of one to three years, lifestyle 
interventions have contributed to an improvement of IR, diabetes, hypertension and dyslipidemia [122-
125]. Furthermore, at a pre-clinical level weight loss has been shown to decrease macrophage 
infiltration and pro-inflammatory gene expression in adipose tissue of obese subjects [126]. The weight 
loss goal is considered to be at least 10 % of initial body weight in order to improve health and prevent 
or ameliorate comorbidities [127]. Recently, a meta-analysis reported that lifestyle interventions with 
more physical activity in (morbidly) obese patients (BMI ≥ 35 kg/m2; WHO class II or III), result in 
significant improved effects on weight loss, fat mass, WC, blood pressure, total cholesterol, low-density 
lipoprotein (LDL) cholesterol, TG and fasting insulin [128]. However, a major disadvantage of lifestyle 
modifications (with diet and exercise) is that subjects often fail to achieve long-term weight loss [129]. 
Once the weight goal is achieved, weight maintenance remains a lifetime challenge for these patients 
and requires long-term support to sustain diet, physical activity and behavioral changes. The important 
role of physical activity and behavioral changes herein should not be underestimated. Even when 
patients achieved weight loss through pharmacological or surgical interventions, lifestyle modifications 
remain important to achieve treatment goals and maintain their favorable body weight [130]. For 
example, a randomized controlled trial (RCT) compared obese patients that received an intensive and 
guided lifestyle intervention program, including dietary changes and increased physical activity, with 
obese patients on metformin or placebo who only received information on diet and exercise. After three 
years, the lifestyle intervention group showed greater weight loss (-5.6 kg) compared to those on 
metformin (-2.1 kg) or placebo (-0.1 kg). The incidence of type 2 diabetes and MetS was reduced by, 58 
% and 41 %, respectively, in comparison with the placebo group [123]. Weight loss followed by weight 
maintenance with lifestyle modification is, although challenging, possible but often requires intensive 
and long-term support.  
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2.4.2. Pharmacological interventions 
Up till now, there are no truly effective pharmacological agents to fully treat morbid obesity. 
Pharmacological therapy is often directed at correcting metabolic comorbidities such as insulin-
sensitizing and lipid-lowering drugs, but a detailed description thereof is beyond the scope of this thesis. 
Some insulin-sensitizing drugs however, are frequently used in pharmacological treatment of 
overweight and obesity. The most familiar drugs in this category for treating patients with obesity are 
metformin and glucagon-like peptide-1 (GLP-1) receptor agonists [131]. The mechanism of metformin 
action predominantly involves reducing hepatic glucose production and improving peripheral insulin 
sensitivity [132, 133]. Metformin provides a low risk of hypoglycemia but gastrointestinal adverse events 
such as nausea and diarrhea are common [134, 135]. GLP-1 receptor agonists such as liraglutide and 
exenatide are incretin mimetic drugs that cause slower stomach emptying, stimulate glucose-dependent 
insulin secretion, reduce glucagon secretion and reduce glucose production in the liver. As a result, they 
lead to lowering of hyperglycemia and are associated with weight loss. Common adverse events of GLP-
1 receptor agonists however, again include nausea and vomiting. Furthermore, these drugs need to be 
administered in parenteral manner [136, 137]. 
Orlistat is one of the most familiar drugs to induce weight loss. It acts as a gastrointestinal lipase 
inhibitor and thus leads to dietary fat malabsorption. The use of orlistat promotes significant weight loss 
and has been shown to minimize weight regain after a period of intensive lifestyle intervention. Orlistat 
in addition to lifestyle changes resulted in a lower incidence of type 2 diabetes and lowered both total 
and LDL cholesterol, independent of weight loss, in patients with obesity. However, orlistat has adverse 
effects on gastrointestinal tract and is expensive, limiting its current use [138-140]. Currently, there are 
some additional weight loss-inducing drugs available that act centrally, such as lorcaserin, 
phentermine/topiramate and naltrexone/bupropion. These drugs are mainly involved in the regulation 
of food intake and/or energy expenditure but several adverse effects, such as dizziness, anxiety, 
depression, vomiting and more, were reported. Therefore, long-term studies investigating safety, 
benefits and the better understanding of the mechanisms of action of these drugs are needed [141]. 
Importantly, clinical trials have reported that the combination of pharmacotherapy and lifestyle 
interventions promotes greater and longer sustained weight loss in comparison with lifestyle 
interventions only [142].    
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2.4.3. Bariatric surgery 
Bariatric surgery is a worldwide recognized invasive approach to achieve significant weight loss in class II 
or III obese patients. Weight loss is induced by restricting the amount of food a stomach can hold 
(gastric restriction), creating malabsorption or a combination of both. Three commonly performed 
bariatric procedures are gastric banding, sleeve gastrectomy and Roux-en-Y gastric bypass, all of which 
are carried out laparoscopically. In Belgium, patients can only qualify for bariatric surgery 
reimbursement if they fulfill current eligibility criteria, which require candidates to have (i) BMI ≥ 40 
kg/m2 or BMI ≥ 35 kg/m2 in conjunction with one or more obesity-induced comorbidity (diabetes, sleep 
apnea, therapy resistant hypertension,..), (ii) acceptable surgical risks, (iii) an ability to participate in 
long-term follow-up and (iv) an understanding of the surgical procedure and the lifestyle changes that 
they will need to make [143]. Surgically induced weight loss is associated with improvement or even 
resolution of obesity-related comorbidities in 75-100% of patients and results in less overall mortality 
compared to medically treated patients [144, 145]. Although bariatric surgery generally leads to 
successful weight loss and recovery of metabolic risk factors on short-term, limited data are available 
about the long-term outcomes per surgery method [146]. Moreover, adverse outcomes of bariatric 
surgery depend upon the surgical procedure and may vary up to 20% in high-risk patients. Based on 
current available data, peri-operative mortality rates are very low, with 0.1% for gastric banding and 
0.5% for gastric bypass [144]. However, only a few studies reported the amount of reoperations (due to 
insufficient results) that were needed after bariatric surgery, which ranged from 2% to 40% of the 
participants depending on the procedure [147]. Bariatric surgery also contains potential procedure risks 
such as bleeding, internal hernia, anastomosis ulceration and stenosis. A multidisciplinary team is thus 
needed to evaluate the patients preoperatively and to provide postoperative care if necessary. 
Altogether, long-term follow-up is highly required for patients after surgery to assess weight loss, 
resolution of comorbidities, long-term complications and to provide continuing education and 
nutritional support [143]. 
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3. Non-alcoholic fatty liver disease (NAFLD) as a hepatic manifestation of obesity 
NAFLD is currently the most common chronic liver disease in developed countries and it is often referred 
to as the hepatic manifestation of obesity, due to its well-established association with obesity-related 
metabolic abnormalities [148-151]. In Western countries, NAFLD is estimated to affect 20-30% of the 
general adult population. The prevalence of NAFLD might even rise up to 70% in obese and diabetic 
subjects, who represent a high-risk population [152]. NAFLD is generally asymptomatic and as an entity 
encompasses a broad spectrum of pathologic mechanisms and disease states, with FA infiltration as the 
initial insult. Pure fatty liver or simple steatosis (SS) is considered to be the first phase of NAFLD and is 
characterized by the presence of lipid droplets in at least 5% of hepatocytes. This initial phase of hepatic 
steatosis is considered as relatively benign with a low likelihood of disease progression. In the more 
advanced form of NAFLD however, named non-alcoholic steatohepatitis (NASH), there is additional 
development of inflammation and hepatocellular damage, with or without fibrosis [153, 154]. Disease 
progression to NASH (with or without fibrosis) occurs only in a fraction of patients, with approximately 
10-25% of patients with SS evolving to NASH and a prevalence of 3-5% in the general population [152]. 
Once NASH has developed, disease progression can proceed potentially leading to cirrhosis in 15-30% of 
the cases and even hepatocellular carcinoma in 5-13% of the patient with cirrhosis [153, 155]. As 
mentioned, the progression of NAFLD occurs mainly asymptomatic and only when cirrhosis has 
developed, clinical manifestations and liver failure may develop as a result of portal hypertension; e.g. 
esophageal and gastric varices or bleedings, edemas, splenomegaly, jaundice, weakness, weight loss … 
[156]. An overview of the different stages in NAFLD is displayed in Figure 3, together with the major 
characteristics per stage. In addition to the liver-related disease morbidity and mortality, presence of 
NAFLD has been associated with an increased cardiovascular risk [157]. Although the pathophysiology of 
NAFLD is incompletely understood, age [158, 159], race, gender [159] and components of the metabolic 
syndrome have been independently associated with advanced disease [150, 158-162]. For example, a 
large study with 26 527 Asian subjects showed that the prevalence of NAFLD was 31% in men and 16% 
in women [163]. Indeed, there is a higher risk to develop NAFLD if subjects are older and male, with a 
potential link between NAFLD and sex steroids [164]. Most important features in NAFLD 
pathophysiology are described in detail in following sections 3.1. and 3.2. As the prevalence of NAFLD is 
rising along with the epidemic of obesity and type 2 diabetes, identifying the patients that are more 
likely to progress to advanced stages of disease is becoming increasingly important [165, 166]. 
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Figure 3 Stages of non-alcoholic fatty liver disease (NAFLD). The first stage, termed hepatic steatosis, merely 
involves fat accumulation caused by an imbalance between lipid storage and lipid removal. When additionally 
hepatic inflammation, hepatocyte ballooning and/or fibrosis are present, the liver damage is collectively termed as 
non-alcoholic steatohepatitis (NASH). NASH can further evolve to cirrhosis with concomitant liver failure or even 
result in hepatocellular carcinoma (HCC). 
 
3.1. Fatty liver and insulin resistance 
NAFLD is independently associated with IR, which in turn is often positively associated with the severity 
of fatty infiltration and liver damage in those patients with NAFLD [167, 168]. This suggests that IR may 
play a role in the pathogenesis and/or progression of liver disease, or that both features have a common 
pathogenic mechanism. Since fat accumulation is the common histological feature among all forms of 
NAFLD, it is of high importance to understand the critical step when this surplus of lipids results in 
hepatocellular damage. Fat accumulation in the liver is dependent on the intrahepatic pool of lipids that 
are stored as TG, which results from following sources: i) FA release by the adipose tissue, due to 
lipolysis; ii) dietary fat; iii) de novo lipogenesis [169].  
In normal physiological conditions, the intrahepatic TG levels are kept at low steady-state 
concentrations by a tightly regulated balance between FA/TG influx and efflux. In addition, the liver 
functions as a “buffer system” which provides glucose when nutrients are scarce (via gluconeogenesis) 
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and stores glucose as glycogen when food is abundant. Once the hepatic glycogen storage is full, glucose 
is converted into lipids for long-term energy storage as fat by de novo lipogenesis [26]. Insulin normally 
regulates these processes by inhibiting gluconeogenesis and inducing de novo lipogenesis by stimulating 
sterol regulatory element-binding protein 1c (SREBP-1c), an important lipogenic TF. In case of IR, 
however, the expression of genes involved in glucose metabolism is altered, i.e. genes involved in 
glycogen synthesis are downregulated and those of gluconeogenesis (e.g. phosphoenolpyruvate 
carboxykinase (PEPCK) and glucose-6-phosphatase (G6P)) are upregulated, promoting hyperglycemia. As 
discussed the pancreatic betacells try to compensate for these phenomena by increasing the production 
of insulin and in order to maintain normal glucose levels, this leads to hyperinsulinemia. This 
subsequently results in an overstimulation of SREBP-1c, promoting de novo lipogenesis [57, 170]. These 
findings suggest that de novo lipogenesis and glucose metabolism are regulated through divergent 
signaling pathways and that IR is mainly affecting the pathway(s) involved in glucose metabolism, 
whereas the resulting hyperinsulinemia can continue to stimulate the lipogenesis [171].  
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Figure 4 Insulin resistance and hepatic steatosis, a vicious circle. Insulin resistance (IR) results in an elevated 
release of adipose tissue-derived free fatty acids (FFA) and steatogenic adipokines. Furthermore, the disturbed 
glucose and lipid metabolism as a result of IR stimulates the pancreas to produce excess insulin (hyperinsulinemia), 
inducing an elevated hepatic de novo lipogenesis by stimulating sterol regulatory element-binding protein 1c 
(SREBP-1c) and carbohydrate-responsive element-binding protein (ChREBP). Together with an increased dietary fat 
intake, this excess triglyceride accumulation leads to hepatic steatosis. This hepatic lipid accumulation may in turn 
result in hepatic IR, exacerbating the overall IR state and leading to a vicious cycle.  
 
Besides from increased de novo lipogenesis, hepatic fat accumulation also results from a higher FA influx 
that originates both from an elevated dietary intake as well as enhanced adipose tissue FA release in 
case of IR. Furthermore, VAT-derived FA can directly enter the liver via the portal vein [172]. It is thus 
generally accepted that IR contributes to hepatic steatosis through multiple mechanisms. This hepatic 
TG accumulation (steatosis) further deteriorates the metabolic balance in the liver, resulting in hepatic 
IR and activating its resident macrophages, termed Kupffer cells, which results in hepatic inflammation. 
This suggests that besides the evidence of IR-related development of hepatic steatosis, hepatic lipid 
accumulation in turn aggravates glucose and lipid metabolism. This contributes to IR leading to a vicious 
circle that deteriorates metabolic state (Figure 4) [173]. The relation between steatosis and IR has been 
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emphasized in several mice models with liver-specific defects in genes involved in hepatic lipid 
metabolism [174, 175]. 
 
3.2. Local inflammatory and fibrogenic mechanisms 
Similar to adipose tissue, excessive fat accumulation in the liver can lead to hepatic inflammation. Fat 
accumulation in the liver can generate inflammatory signals by activating JNK and NFκB pathways and 
can lead to increased ROS production and ER-stress by inadequate lipid oxidation [53]. This 
inflammatory response amplifies liver injury and may stimulate fibrosis. Activated Kupffer cells are key 
players in the pathophysiology of NAFLD and NASH, as mice models in which Kupffer cells were depleted 
showed resistance to steatosis, inflammation, hepatic injury and fibrosis [176, 177]. In case of NAFLD, 
Kupffer cells are known to shift towards a more inflammatory phenotype in response to several stimuli 
such as fat accumulation (both by FA and their toxic metabolites), cytokines and IR. These activated 
Kupffer cells in turn may enhance hepatic steatosis by inhibiting FA oxidation and enhance inflammation 
by recruiting monocytes via chemokine secretion. In addition, Kupffer cells and the recruited monocytes 
may further contribute to hepatic fibrosis, both by perpetuating inflammatory cell recruitment and 
triggering hepatic stellate cells (HSC) activation. HSC can generate pro-fibrotic signals such as elevating 
the expression of type I collagen and connective tissue growth factor (CTGF) [178]. These HSC are also 
known to express receptors for insulin, insulin-like growth factor-1 and glycolysed end-products, 
suggesting that IR and the associated hyperglycemia may also promote fibrosis [179]. A schematic view 
of the suggested pathways on how lipid accumulation in the liver results in inflammation and fibrosis 
(steatohepatitis) is presented in Figure 5. 
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Figure 5 Schematic presentation of the suggested pathways in the development of steatohepatitis with or 
without fibrosis. Insulin resistance causes the adipose tissue to release more fatty acids (FA) and inflammatory 
adipokines and less non-inflammatory adipokines (such as adiponectin), resulting in an elevated hepatic 
accumulation of triglycerides (TG) together with the high circulating levels of glucose and insulin. Consequently, 
inadequate oxidation of FA leads to the accumulation of lipotoxic metabolites, reactive oxygen species (ROS) and 
endoplasmatic reticulum (ER) stress. All these factors can activate inflammatory pathways as well as the resident 
hepatic macrophages named Kupffer cells. This escalated inflammatory response in turn may activate hepatic 
stellate cells (HSC), which promote development of fibrosis. Adapted from [180]. 
 
3.3. A pivotal role for adipokines? 
Emerging data indicate that an impaired release of adipokines from dysfunctional adipose tissue may 
underlie NAFLD development and NASH progression. Insulin-sensitizing adipokines such as adiponectin 
are found to be reduced in NAFLD patients, whereas some inflammatory adipokines including TNF-α and 
IL-6 are elevated. Inflammatory adipokines are found to be involved in the recruitment and activation of 
Kupffer cells and are responsible for the transformation of hepatic stellate cells (HSC), contributing to 
hepatic injury and potentially modulating steatosis, inflammation and fibrosis [181]. Leptin for instance, 
has been found to promote hepatic inflammation and fibrogenesis, whereas its anti-steatotic effects 
may be lost in NAFLD patients due to leptin resistance [182]. Reduced adiponectin levels have been 
frequently reported in NAFLD patients, of which disease severity was inversely associated with 
adiponectin [183]. Adiponectin infusion in an obese mouse model resulted in reduced steatosis by 
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activating AMP-activated protein kinase (AMPK; a kinase that elevates lipid oxidation and glucose 
uptake and inhibits lipogenesis) and attenuated inflammation by suppressing TNF-α expression [184]. 
Currently, many clinical trials and experimental research are focused on more recently described 
adipokines, exploring their potential role in NAFLD. Some examples of these adipokines are resistin, 
vaspin, visfatin, omentin, and chemerin, of which a link with obesity has been reported (section 2.3.1.3.) 
[181]. Recently, a rather new class of adipokines has been described, which may also be involved in 
NAFLD development and/or progression, i.e. modulators of the Wnt signaling pathway named secreted 
frizzled-related proteins (SFRP). The Wnt family of signaling molecules are extracellular ligands that bind 
to frizzled (Fz) receptors at the cell membrane and induce a canonical or noncanonical signaling cascade. 
It has been reported that several Wnt pathway components are associated with lipid and glucose 
metabolism and with inflammation, suggesting a potential involvement in the development of diabetes 
and NAFLD. SFRP are proteins that can bind Wnt ligands directly and prevent their interaction with Fz 
receptors [185]. Ehrlund et al. recently reported that SFRP1, SFRP2 and SFRP4 were expressed and 
secreted from both SAT and VAT from lean and obese individuals, and that an elevated expression of 
SFRP4 correlated with IR in patients with obesity [186]. Mice models provided evidence that a 
downregulation of the noncanonical Wnt pathway may result in a higher risk of NAFLD [187, 188]. This 
makes SFRP interesting candidate adipokines to investigate their potential relation with NAFLD.   
 
3.4. Current challenges in the diagnosis and treatment of NAFLD 
As NAFLD is mainly asymptomatic and its pathophysiology is not completely understood, both the 
diagnosis and treatment of NAFLD remain true challenges in clinical practice. In sections 3.4.1. and 3.4.2. 
we describe the methods that are currently used for diagnosing and treating NAFLD patients, including 
potential pitfalls.  
3.4.1. Diagnosis of NAFLD 
The diagnosis of NAFLD requires evidence of hepatic steatosis, preferentially on liver biopsy, and the 
exclusion of other causes of hepatic steatosis such as excessive alcohol consumption or viral infections. 
Because hepatic steatosis has no specific symptoms, it is often detected incidentally via abnormal liver 
function tests in serum or by visualization of steatosis on imaging [189]. Abnormal liver function tests in 
NAFLD are described as mildly raised aminotransferase (with alanine aminotransferase (ALT) > aspartate 
aminotransferase (AST)) and/or ɣ-glutamyltransferase (GGT) levels. Although these abnormal liver 
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function tests have already been associated with presence of NAFLD, they do not specifically distinguish 
NAFLD from other liver diseases and studies have demonstrated that levels within the normal range do 
not exclude presence of NAFLD [190, 191]. Detection of hepatic steatosis by imaging is widely used in 
clinical practice. Especially ultrasound is a low-cost and low-risk widely available diagnostic tool for the 
assessment of steatosis. However, ultrasound can only detect steatosis when > 33% of hepatocytes are 
steatotic so that normal liver on ultrasound does not rule out mild steatosis [192]. Other imaging 
techniques to diagnose hepatic steatosis are CT or MRI. Although they are considered as the most 
accurate non-invasive tool for the quantification of steatosis, they are not commonly available, 
expensive and CT imaging leads to radiation exposure [193]. Importantly, none of these imaging 
techniques were found to be able to distinguish NASH from NAFLD, because they can only detect 
hepatic steatosis and do not measure inflammation, hepatocyte ballooning or fibrosis. Furthermore, the 
practical use of those measurement devices is limited in case of morbid obese patients (WHO class II or 
III obesity) [192]. Transient elastography, also known as FibroScan®, is another non-invasive method to 
assess liver fibrosis and cirrhosis by specifically measuring liver stiffness using pulsed-echo ultrasound. 
This method is not able to detect steatosis, inflammation or hepatocyte ballooning and again is less 
reliable to use in morbidly obese patients [194]. Overall, histological analysis of liver biopsy specima 
continues to be the gold standard to diagnose NAFLD and NASH with or without fibrosis, as it provides a 
definitive assessment of hepatic steatosis, hepatocellular injury, inflammation and fibrosis. Patients with 
NAFLD are often classified into SS, borderline NASH or NASH based on NAFLD activity score (NAS), a 
scoring system of Kleiner et al. [195]. NAS is the unweighted sum of scores for the intensity of steatosis 
(0-3), lobular inflammation (0-3), and hepatocellular ballooning (0-2), ranging from 0 to 8. However, 
performing a biopsy in each patient with suspected NAFLD would not be reasonable and is suggested to 
be limited to patients with high susceptibility or indeterminate noninvasive measurement [196]. 
Furthermore, some limitations of liver biopsy are procedure-related complications, sampling error, high 
costs as well as inter- and intra-observer variability [197]. Since the prevalence of NAFLD continues to 
rise worldwide it is of great importance to identify high-risk patients with low risk at reasonable costs. 
Therefore, several non-invasive and routinely measurable parameters such as serum adipokine levels 
are of interest to develop a potential diagnostic tool. 
3.4.2. Promising therapeutic targets 
Current treatment of NASH mostly relies on the reduction of body weight, at least by consuming a more 
healthy diet and increasing physical activity, because there is currently no specific pharmacologic 
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treatment approved yet. Weight loss of 7-10 % through lifestyle intervention in obese patients with 
NASH, resulted in improvement of steatosis, lobular inflammation, ballooning injury and overall NAS. 
The magnitude of weight loss correlated strongly with improvements in histological disease markers of 
NASH, suggesting an intensive lifestyle intervention with a minimum weight loss goal of 7 % represents 
an attractive therapy for this disease [198, 199]. Experimental data suggests that the addition of omega-
3 fatty acids to the diet may improve hepatic steatosis, IR and inflammation in NAFLD patients. 
However, evidence in human trials is insufficient due to small sample sizes and limitations in 
methodology [200]. Some recent studies investigated the effect of exercise without dietary modification 
on hepatic steatosis using MR spectroscopy. Exercise programs up to 12 weeks resulted in diminished 
liver fat content without a significant change in body weight, whereas its ability to improve other 
aspects of liver histology remains unknown [201, 202]. In addition, physical activity with vigorous 
intensity in combination with dietary restrictions improved grade of inflammation and oxidative stress in 
obese middle-aged patients with NAFLD, independent of weight reduction [203].   
Because of the strong association with IR, insulin-sensitizers are interesting candidate therapies in case 
of NAFLD and NASH. Meta-analysis and systematic reviews have reported conflicted findings with no 
significant effects of metformin on liver histology. Thiazolidinedione (TZD) treatment however, showed 
an elevated adiponectin release and a reduction in transaminase levels, hepatic steatosis and 
inflammation, whereas effects on fibrosis were inconsistent [204, 205]. More specifically, a RCT with 
pioglitazone reported improvement of hepatic steatosis, lobular inflammation and hepatocyte 
ballooning in patients with NASH [206, 207]. Furthermore, GLP-1 receptor agonists may also reverse the 
progression of NAFLD not only by an indirect incretin effect such as improving insulin sensitivity and 
weight loss, but also by directly affecting hepatic lipid metabolism, inflammation and inducing 
adiponectin secretion [208]. Finally, the administration of anti-oxidant supplements is currently of 
interest to treat patients with NAFLD. However, a systematic review reported that evidence-based data 
was too limited to draw any definite conclusions on the effectiveness of these agents [209]. Only vitamin 
E has been found to ameliorate NAFLD histology, with a similar or even better improvement of NAS 
compared to pioglitazone treatment as shown in a RCT. However, long-term treatment with vitamin E is 
hampered by adverse effects on insulin sensitivity and TG levels [210, 211]. Altogether, these 
inconsistent findings suggest that treating solely IR by therapeutic agents may not be sufficient to 
reverse the complex pathophysiology of NAFLD. 
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A meta-analysis evaluated the effect of bariatric surgery on liver histology in NAFLD patients in studies 
using paired liver biopsies before and after surgery. They reported an improvement of steatosis, 
inflammation and even fibrosis as well as complete resolution of NASH in 69.5 % of cases [212]. 
However, although beneficial effects of bariatric surgery on NASH have been described, surgery remains 
an invasive procedure and even progression of steatohepatitis has been reported as a potential 
complication due to the rapid major weight loss [213]. 
Because of adiponectin its insulin-sensitizing effects together with the known downregulation in NAFLD 
patients, this adipokine represents an attractive target for the treatment of NAFLD and/or NASH. 
Indeed, several drugs including TZD exert at least part of their actions by modulating adiponectin or its 
intracellular targets (such as AMPK). Once more research proves the role of certain other adipokines in 
NAFLD, their receptors may be targeted by the use of agonists or antagonists in order to treat the 
pathology of NAFLD. However, the relevance of findings first needs to be validated in larger prospective 
trials because often inconsistent results are found throughout literature [178].   
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4. Obesity and sex steroids: how do they interact?  
The widely spread presence of sex steroid receptors throughout many different tissues, indicates the 
importance of sex steroid exposure on bone, fat and muscle mass in both men and women [214]. It is 
generally known that features of obesity are associated with disturbed sex steroid levels, both in 
females and males. While obese women (pre- and postmenopausal) are characterized with higher 
androgen levels compared to lean controls (hyperandrogenism) [215-217], obese men develop 
hypogonadism with low levels of androgens [218, 219]. This part of the thesis will only focus on men, 
because of the complex gender-related differences in sex steroid metabolism and its effects on body 
composition. In the following section, we will describe the regulation and synthesis of sex steroids in 
men and focus on their contribution to body composition, fat tissue in particular, as well as on sex 
steroids in male obesity.   
 
4.1. Sex steroid metabolism in men  
Androgens are male sex hormones (sex steroids) that are mainly responsible for the development of 
primary and secondary sex characteristics. Testosterone (T) is the major biologically active androgen, 
almost exclusively produced by testes (95%) and to a lesser extent by adrenal cortex (5%). From puberty 
onwards, a rise in gonadotropins triggers androgen production. Gonadotropin-releasing hormone 
(GnRH) is secreted by the hypothalamus and stimulates secretion of gonadotropins luteinizing hormone 
(LH) and follicle stimulating hormone (FSH) from the anterior pituitary. In turn, LH stimulates Leydig cells 
to produce T and FSH is mainly involved in spermatogenesis and production of inhibin B by Sertoli cells. 
This hypothalamic-pituitary-gonadal (HPG) axis is regulated by a negative feedback loop. Circulating T 
and E2 inhibit GnRH release on hypothalamic level and LH secretion by the pituitary, whereas inhibin B 
inhibits FSH secretion of pituitary [220] (Figure 6). In serum, normal total T reference levels in men range 
from 300 to 1000 ng/dl (10.4 to 34.7 nmol/L) and free T (FT) ranges from 30 to 200 pg/ml, although 
these values may slightly vary depending on the measurement tool [221]. 
Synthesis of T involves sequential cytochrome P450-dependent (CYP) and hydroxysteroid 
dehydrogenase-dependent (HSD) enzymatic reactions, with the first rate-limiting step being the 
conversion of cholesterol to pregnenolone. Once produced, T can be further metabolized into 
dihydrotestosterone (DHT) and E2 [222] (Figure 7). DHT is a biologically potent androgen, of which the 
conversion from T occurs both in testes (20%) as well as in peripheral tissues (80%) by the enzyme 5α-
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reductase. In some tissues with high 5α-reductase activity such as the prostate, it has been suggested 
that DHT amplifies the effects of T on androgen receptor (AR). However, tissues such as skeletal muscle 
have low expression of 5α-reductase, suggesting T effects are more important compared to DHT [223].  
 
 
Figure 6 Hypothalamic-pituitary-gonadal axis in men. GnRH: Gonadotropin releasing hormone; LH: Luteinizing 
hormone; FSH: Follicle stimulating hormone; T: Testosterone; E2: Estradiol. 
 
In men, E2 is synthesized in testes as well as in a number of extragonadal sites such as adipose tissue, 
muscle, brain, and bone, by aromatase conversion of T and acts locally as a paracrine or intracrine 
factor. The aromatase enzyme, encoded by CYP19 gene, is differentially expressed in many different 
tissues due to its tissue-specific promotors [224, 225]. Approximately 1% of the daily produced amount 
of T in men is converted into E2, accounting for 80% of circulating E2. The remainder of E2 is secreted 
directly by Leydig cells or is converted from estrone, which in turn results from the aromatization of 
adrenal derived androstenedione [226] (Figure 7). Due to this local aromatization, serum E2 
 
 
30 
 
concentrations do not always reflect tissue exposure to E2. In conjunction with T, E2 is also an important 
regulator of the negative feedback loop of HPG axis [227]. 
Sex steroids act on tissue level via binding to their respective nuclear receptor, which is AR for T and 
DHT and the estrogen receptors α (ERα) and β (ERβ) for E2. Steroid hormone action thus requires the 
steroid to enter the cell and bind with high affinity to its specific intracellular receptor, resulting in 
nuclear transcription of steroid-dependent genes [228]. However, 50-60% of T is strongly bound to sex-
hormone-binding globulin (SHBG), a carrier protein secreted by the liver, and is believed not to be 
readily available for biological action. The remaining fraction of T in circulation is weakly bound to 
albumin (40-50%) and only 1-2% is circulating freely (FT). Both albumin-bound T and FT represent bio-
available T, which can enter target cells rapidly to exert biological effects. Although binding affinity of 
SHBG for estrogens is lower, circulating E2 levels have a similar distribution [229, 230]. SHBG is a major 
determinant of total T and E2 levels and regulates their bio-availability at tissue levels. Circulating SHBG 
levels are altered in several conditions such as obesity and polycystic ovarian syndrome (PCOS) and 
factors that influence hepatic SHBG production may similarly have an impact on total androgen and 
estrogen levels [231]. Altogether, local steroid action depends on the resultant of freely available and 
bound circulating levels, expression of nuclear receptors and local steroid metabolism.   
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Figure 7 Major pathways in male sex steroid biosynthesis. CYP11A1: Cholesterol side chain cleavage enzyme; 
CYP17: 17α-hydroxylase; 3β-HSD: 3β-hydroxysteroid dehydrogenase; DHEA: Dehydroepiandrosterone; 17β-HSD: 
17β-hydroxysteroid dehydrogenase; CYP19: Aromatase enzyme. Data based on Federman et al. [222]. 
 
4.2. Sex steroids and body composition 
Body composition consists of lean mass (skeletal muscle and organs), fat mass and bone mass. Profound 
differences in body composition exist between men and women, suggesting a contribution of sex 
steroids to this sexual dimorphism. In adulthood, men are generally characterized with more muscle 
mass and less fat mass at the limbs, although having similar amounts of absolute abdominal fat mass 
compared to women. With aging, the amount of fat mass in both sexes increases in a sex-specific 
manner. Men store fat preferentially in the abdominal region, with a substantial amount of both visceral 
and subcutaneous fat mass. They are often referred to as having a so-called apple or android body 
shape, whereas (premenopausal) women are more characterized by a pear or gynecoid body shape with 
subcutaneous fat stored mainly at the thighs [4]. Men are thus characterized with greater amounts of 
visceral and abdominal subcutaneous fat, which may at least in part explain the more than twofold 
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increased risk of developing cardiovascular disease in comparison with women [5]. Moreover, T levels in 
aging men are known to decrease progressively and are associated with a redistributed body 
composition. Low T exposure in aging men result from a combined occurrence of testicular failure, 
disturbed HPG axis, increased SHBG production, lifestyle and disease factors [6, 232]. Overall, we can say 
that a well-known association between sex steroids and body composition exists, with increasing 
interest in their potential role in a detrimental body composition as seen within the context of obesity 
[233]. Furthermore, models of androgen and estrogen insufficiency have revealed new and unexpected 
roles for sex steroids, of which main effects on fat tissue of men will be described in following sections. 
4.2.1. Testosterone and adipose tissue  
Adiposity and more specifically the location of adipose tissue appears to be related to total T and also FT 
levels in men. Indeed, in abdominal obese men with reduced lean mass, a strong inverse association 
exists between body fat and both total T and FT levels [6, 234]. Using CT and MRI scanning, some study 
groups found an inverse association between total T levels and VAT accumulation, whereas other fat 
depots were not or less associated [234-237]. Low total T levels independently predicted an increase in 
VAT accumulation after 7.5-year follow-up in a community-based population, simultaneously increasing 
metabolic risk [235]. In contrast, Abate et al. reported inverse associations between FT levels and SAT, 
rather than visceral fat accumulation, in eugonadal diabetic and nondiabetic men [238]. However, these 
men had FT levels within the normal range, suggesting the impact of T on the accumulation of VAT may 
only apply to men that have both low total T and low FT levels. AR sensitivity can additionally affect fat 
accumulation, as a polymorphic CAG repeat sequence within the AR gene has been linked with obesity 
and type 2 diabetes. It has been reported that an increased CAG repeat length and thus less sensitive AR 
in men with type 2 diabetes, was associated with a higher WC, BMI and serum leptin levels [239]. These 
results were confirmed in a mice model with AR deficiency - AR knockout (ARKO) mice, which developed 
late onset obesity with increased fat mass in subcutaneous and gonadal pads and became insulin 
resistant [240, 241]. 
Although the precise role of androgens in regulating body fat and metabolism has not been completely 
clarified, some experimental and clinical studies have revealed potential mechanisms of T action in 
adipose tissue. For instance, abdominal adipose tissue LPL activity was inversely associated with 
circulating bio-available T levels in sedentary obese men [242]. Moreover, androgen replacement 
therapy in hypogonadal men resulted in a decreased LPL activity and TG uptake, which was more 
apparent in VAT compared to SAT. This suggests that TG storage in VAT is enhanced due to low T levels 
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in men [243]. Additionally, T was found to possess both stimulatory effects on lipolysis and inhibitory 
effects on lipogenesis in mice and rats, also promoting increased fat mass in case of low T levels [244, 
245]. Adipogenesis was also influenced by T, normally inhibiting the differentiation and formation of 
new adipocytes via reduced expression of peroxisome proliferator-activated receptor gamma (PPARɣ) 
[246]. In models of obesity and MetS, T replacement was able to reverse the negative impact of a high-
fat diet on VAT expansion and adipocyte size by increasing the expression of several lipogenic, lipolytic 
and adipogenic genes to restore visceral adipocyte maturation and correct cell turnover [247]. An 
overview of the effects of T on targets in adipose tissue is displayed in Table 2. Finally, T levels seem to 
influence adipokine secretion patterns of adipose tissue, as inverse associations were reported between 
T and pro-inflammatory adipokines/cytokines (TNF-α, IL-6 and IL1β) and androgen replacement therapy 
reduced these cytokines [248, 249]. Although these results indicate a definite contribution of T to 
metabolic homeostasis, its relationship with fat mass and the effects of T deficiency are complicated and 
require further investigation. 
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Table 2 Effects of testosterone on adipose tissue 
Target Abbreviation Target function 
Testosterone 
action 
References 
Acyl-CoA synthetase ACS de novo lipogenesis ↓ [250] 
Acetyl-CoA carboxylase ACC fatty acid synthesis ↓ [251] 
Adipose triglyceride lipase ATGL lipolysis ↓ [252] 
Diglyceride acyltransferase 2 DGAT2 triglyceride synthesis ↑ [247] 
Fatty acid synthase FAS fatty acid synthesis ↓ [251, 252] 
Hormone-sensitive lipase HSL 
triglyceride breakdown; 
lipolysis 
↓ [252, 253] 
Insulin receptor substrate 1 IRS1 insulin signaling ↑ [252] 
Lipoprotein lipase LPL triglyceride uptake ↓ 
[242, 243, 
252, 254] 
   ↑ [247] 
Peroxisome proliferator-
activated receptor gamma 
PPARɣ adipogenesis ↓ [246] 
   ↑ [247] 
Adapted from [255] 
 
4.2.2. Estradiol and adipose tissue  
The major driver of E2 action in men is the aromatization of androgens to estrogens, of which the 
responsible aromatase enzyme is highly expressed in adipose tissue. While for decades researchers have 
focused mainly on the link between androgens and body composition in men, experimental models of E2 
deficiency have revealed effects of E2 on body composition. For example, a mouse deficient in 
aromatase - aromatase knockout (ArKO) mouse - and thus also deficient in E2 developed obesity 
independent of hyperphagia or reduced energy expenditure. Male ArKO mice developed truncal obesity 
with an increased adiposity in gonadal and visceral fat pads, IR and even hepatic steatosis, whereas E2 
administration to these mice reduced VAT and hepatic steatosis [256, 257]. Although not obese, an 
adult man described with a natural mutation in aromatase had an identical phenotype of MetS that 
recovered after E2 but not T therapy [258]. Similarly, ERα deficiency in mice - ERα knockout (ERαKO) 
mice - caused increased body weight and fat mass with an almost doubled VAT depot, though these 
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mice displayed reduced energy expenditure and a slightly increased food intake [259, 260]. This suggests 
that E2 may influence food intake and energy expenditure and indeed, ERα has been localized on several 
brain areas that control these actions [261]. Based on these results, estrogen is indicated as another 
hormone that is synthesized by adipose tissue and acts to regulate energy homeostasis [262]. 
Importantly, both models of E2 deficiency – ArKO and ERαKO – also exhibited a marked increase in 
serum T levels. Since ERβKO mice were not obese, E2 induced ERα activation is pointed out as a more 
important regulator of adipose tissue distribution compared to ERβ activation [263]. Concerning human 
studies, Finkelstein et al. highlighted the role of estrogens in fat mass distribution/accumulation in a 
group of healthy men with suppressed endogenous sex steroids receiving a variety of T doses with and 
without concomitant aromatase inhibition. They reported that changes in lean mass were mainly 
attributable to variations in T levels, whereas changes in fat mass measures were primarily related to 
variations in E2 levels [264]. Furthermore, administration of E2 to individuals (and rodents) with IR has 
resulted in increased insulin sensitivity, though physiological and genetic evidence argue that E2 and ER 
favor insulin sensitivity only when E2 concentrations stay within a tight physiological range [265, 266]. 
Experimental studies have evidenced the direct effects of E2 on cultured adipocytes. E2 is found to inhibit 
lipogenesis and adipogenesis, by suppressing LPL, fatty acid synthase (FAS), ACC and PPARɣ [267].  
 
Overall, although not completely clarified we can say that both androgens and estrogens exhibit 
regulatory effects on adipose tissue deposition and distribution. Potentially, both the presence of 
androgens and estrogens is needed to obtain a normal body fat distribution. Clearly, additional studies - 
both experimental as well as studies in rodents and humans - are necessary not only to better 
understand pure androgen and estrogen effects on adipose tissue and metabolic risk, but also to unravel 
the interplay of sex steroids between themselves and their actions.  
 
4.3. Low testosterone levels in male obesity  
It is generally known that features of obesity are negatively associated with total T levels, FT and bio-
available T fractions in men [218, 219, 268-270], which is maintained throughout all age groups and is 
independent of the presence of MetS [271, 272]. T deficiency or hypogonadism, characterized by low 
levels of total T and FT measured before 10:00 am, is considered a common comorbidity in male obesity 
and is associated with BMI, WC, IR and type 2 diabetes [236, 270, 273-275]. A bidirectional relationship 
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between T and obesity underpins these associations, as indicated by the “hypogonadal-obesity cycle” 
[255]. Low T levels are suggested to be a consequence of obesity, as evidenced by weight loss 
interventions such as diet, exercise or bariatric surgery that resulted in significantly increased T levels in 
men [276]. This increase in T levels was proportional to the amount of weight lost, as reviewed recently 
and presented in Figure 8 [255, 276, 277]. However, minor weight loss is only associated with increased 
SHBG and total T levels, whereas increased FT levels, suggesting a recovered HPG axis, were only 
reported after more pronounced weight loss [278].  
 
 
Figure 8 Effect of weight loss on serum total testosterone levels. Each data point represents an individual study, 
of which the size of the point is proportional to the size of the study that ranges from 10 (i) to 58 (d) men. Black 
points indicate studies reporting diet-induced weight loss, white points indicate exercise-induced weight loss and 
gray points indicate bariatric surgery-induced weight loss. a, Stanik et al. [279]; b, Pritchard et al. [280]; c, Kaukua 
et al. [281]; d, Niskanen et al. [282]; e and f, Khoo et al. [283] (Khoo et al. included 2 distinct obese male 
populations, with (f) and without (e) diabetes); g, Globerman et al. [284]; h, Hammoud et al. [285]; i, Omana et al. 
[286]. Adapted from [255, 277]. 
 
Several mechanisms contribute to low T levels in male obesity. Firstly, obesity-related hepatic IR is 
associated with reduced hepatic expression and production of SHBG, which in turn is a major 
determinant of circulating total T levels. This explains why men with mild obesity are reported to have 
decreased total T and SHBG levels. Only with increasing degrees of obesity, additional reduction in FT 
levels occurs by a downregulated HPG axis [287, 288]. One hypothesis explaining this downregulation 
involves the high expression of aromatase in adipocytes. Studies have suggested that the increased 
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amount of body fat in obese subjects results in elevated aromatase activity, leading to a higher T to E2 
conversion rate. Elevated E2 levels in turn act upon the HPG axis as a negative feedback regulator to 
suppress GnRH and subsequent LH release, reducing gonadal T production [227, 289, 290]. However, 
data on E2 levels in obese men are inconsistent, as reports on increased E2 levels have not been 
confirmed by more recent studies reporting normal or even lower E2 levels [238, 291-294]. Next, pro-
inflammatory adipokines such as TNF-α, IL-1β and IL-6, of which the expression is elevated in adipose 
tissue of obese subjects, have been found to inhibit T secretion by suppressive effects both on HPG axis 
as well as directly on testicular level [295-297]. Indeed, decreased T production in men has been 
described in acute and chronic inflammatory states [249]. Other adipose tissue-derived adipokines that 
have been reported to influence T secretion are leptin, adiponectin and chemerin. Especially leptin has 
been indicated as an important regulator of reduced androgens in male obesity, as influences of 
elevated leptin on the HPG axis and its direct testicular effects were reported by in vitro and in vivo 
studies [298-300]. Adiponectin normally stimulates Leydig cell steroidogenesis and T production, which 
is reduced as a result of obesity-related lowering of adiponectin levels [301]. A recent study also 
reported the suppression of T secretion in primary Leydig cells after the addition of chemerin, a novel 
adipokine of which elevated levels have been associated with both obesity and diabetes in humans 
[302].  
Extending the “hypogonadal-obesity cycle” theory, sex steroids themselves are known to influence body 
composition as described above, suggesting their potential role in detrimental body compositions like 
obesity or sarcopenia. Men with prostate cancer undergoing androgen deprivation therapy (ADT) 
constitute a well-described cohort that allows investigating the direct effects of lowering T levels. In 
these patients, ADT leads to a decreased lean mass together with an increased total fat mass and is 
associated with a lowered insulin sensitivity that may evolve to the development of MetS after long-
term treatment [303-305]. Recently, ADT was reported to result in increased subcutaneous abdominal 
as well as visceral fat mass after 12 months of therapy, and total T levels were inversely associated with 
visceral fat independent of E2 [306].  
Similar effects were reported in male-to-female trans persons who receive anti-androgen therapy in 
combination with estrogens to induce feminization. In general, at least one year of treatment resulted in 
an increased body weight or BMI, with a higher total and regional fat mass and a decreased lean body 
mass compared to age- and height matched control men [307-309]. Elbers et al. additionally reported 
higher SAT and VAT levels after one year of treatment in these male-to-female trans persons [307]. 
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Furthermore, trials with androgen replacement therapy in (obese) hypogonadal men with MetS 
reported that the correction of T levels resulted in a lowered body weight, BMI, WC, VAT and total fat 
mass [254, 310-313]. 
In summary, different mechanisms seem to contribute to the obesity-related disturbed sex steroid 
profile in men including changes in local sex steroid metabolism, IR, impaired adipokine secretion 
patterns and inflammation. Furthermore, lowering T levels in men causes loss of lean mass and gain of 
fat mass, together with an increased incidence of IR and MetS. This increase in (especially visceral) fat 
mass followed by increased metabolic risk itself again contributes to a disturbed sex steroid profile, 
terminating the “hypogonadal-obesity cycle” (Figure 9). Up till now, it is unclear to what extent each of 
these mechanisms individually contributes and whether the effects on body composition are pure 
androgen or estrogen effects or a combination of both.  
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Figure 9 The hypogonadal-obesity cycle. Obesity develops when caloric intake increases and energy expenditure 
decreases, resulting in an expanded adipose tissue. This higher amount of adipose tissue may lead to a higher 
aromatase activity, impaired adipokine secretion pattern and insulin resistance, which in turn results in the 
lowering of testosterone (T) levels. Low T levels in obese men have been associated with an elevated triglyceride 
(TG) uptake, adipogenesis, lipogenesis and the secretion of pro-inflammatory adipokines, leading to a higher fat 
mass and thus terminating the hypogonadal-obesity cycle. +: positive effect; -: negative effect. SHBG: sex-
hormone-binding globulin; GnRH: gonadotropin-releasing hormone; LH: luteinizing hormone; IL: interleukine; TNF-
α: tumor necrosis factor-α. Adapted from [314]. 
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5. Aims 
5.1. General aims 
Overall it can be stated that the maintenance of metabolic homeostasis is critical for health. However, 
from this introduction it became clear that major inconsistency still exists regarding the pathophysiology 
of metabolic comorbidities resulting from obesity. Although adipose tissue represents a central culprit 
within this topic, it comprises an embroiled complex of several pathological mechanisms such as 
decreased insulin sensitivity of fat cells, peripheral lipotoxicity, inflammation and changes in adipokine 
secretion. Elucidating the pathways on how each of these dysregulations contributes to the overall 
disturbed metabolic profile is of major importance given the obesity epidemic. The combination of 
human data together with experimental data investigating the molecular mechanisms involved in the 
pathophysiology, can lead to the development of effective therapeutic or even preventive strategies.  
We have conducted human studies in order to gain more insight into some specific aspects of the broad 
scope of obesity-related consequences. Our intention was to examine adipose tissue characteristics 
specifically in adipose tissue biopsies of obese subjects and to investigate its possible links with biopsy-
proven NAFLD and disturbed sex steroid levels. In particular, we aimed to investigate the potential role 
of adipokines in NAFLD and to gain a better view on the complex relationship between body 
composition, sex steroid levels and metabolic parameters in obese men. 
 
5.2. Specific research aims 
Both VAT and SAT biopsies were collected in a cohort of morbidly obese (WHO class II and III obesity) 
and control men to investigate adipose tissue characteristics of both fat depots. More specifically, we 
wanted to explore how these characteristics and the degree of NAFLD and IR are linked. Especially the 
adipokine secretion of VAT, considering direct portal delivery of these secretory factors to the liver, was 
investigated in an obese cohort with biopsy-proven NAFLD. This topic is explored in chapter III. While 
classic adipokines such as adiponectin, leptin and the cytokines TNF-α and IL-6, have been extensively 
investigated within the context of NAFLD, knowledge on other recently described adipokines remains 
scarce. Therefore, literature was first reviewed to summarize current knowledge on the potential link 
between these recently described adipokines and NAFLD. More specifically, all human studies that 
investigated non-classical adipokines and their association with histopathological severity in biopsy-
proven NAFLD patients were collected and reviewed. Results were combined into a systematic review, 
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as discussed in chapter 3.1. Secondly, a selection of more novel adipokines was made, of which we 
suspected a contribution to NAFLD, to test their association with hepatic histological parameters in a 
cross-sectional cohort of obese middle-aged NAFLD patients. We aimed to investigate whether the 
adipokines were independently associated with steatosis grade, inflammation, hepatocyte ballooning 
and/or fibrosis grade of liver biopsies, in order to clarify their potential contribution to NAFLD 
development and/or progression. These findings are reported in chapter 3.2. 
Finally, we aimed to examine the impact of (dysfunctional) adipose tissue on sex steroid levels in a 
cohort of morbidly obese men. In order to investigate this and other potential determinants of low T 
levels in obese men, focus was made on several events that have been associated with sex steroid levels 
such as adipose tissue characteristics and aromatase expression, parameters of the HPG axis and 
metabolic alterations. Although the contribution of higher aromatase activity to lowering T levels in 
obese men has been hypothesized by many researchers since decades, few have truly examined in situ 
aromatase expression in hypertrophied adipocytes of obese men. Adipose tissue and metabolic 
characteristics as well as sex steroid levels were determined in a cross-sectional study cohort of obese 
men (BMI > 30 kg/m2) and healthy control men, as discussed in chapter IV. 
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II. STUDY DESIGN AND METHODS 
This chapter describes the study populations and methodology used throughout this thesis. For more 
technical details on the methodology, we refer to chapter III and IV. Depending on the research question 
and the time point of the analysis, the number of included patients will vary in the following chapters.  
 
1. Study populations  
Throughout this thesis three different study populations were analyzed, which included obese patients 
that were scheduled for bariatric surgery. In two studies, (non-obese) healthy controls scheduled for 
elective abdominal surgery were included in addition to the obese patients. A general overview of the 
study populations is given in Figure 10, with a description of the participants as well as the collected 
samples for analysis. All three study protocols were approved by the institutional ethics committee and 
were conducted according to the principles of the Declaration of Helsinki. Participants gave their written 
informed consent before inclusion.  
 
 
Figure 10 Overview of the study populations analyzed throughout this thesis. OBSTER, OBesity and sex STERoids; 
HEPOBSTER, HEPatic disease in OBesity and sex STERoids; NASH, Non-Alcoholic SteatoHepatitis; SAT, subcutaneous 
adipose tissue; VAT, visceral adipose tissue. 
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Analyses presented in chapter III were performed on the Hepobster and NASH study cohorts, whereas 
chapter IV describes analyses performed on the Obster study cohort and a subgroup of the Hepobster 
study cohort (N = 24; the amount of patients recruited in Hepobster study up till then). 
 
1.1. Obster study 
The Obster study is a case-control study, established at the Department of Endocrinology of Ghent 
University Hospital to investigate SAT and VAT depots as well as sex steroid levels in obese middle-aged 
men. The study cohort consisted of 36 obese men scheduled for gastric bypass surgery and 22 normal-
weight control men undergoing surgery for adhaesiolysis, rupture of the stomach, intestinal resection, 
stomach closing or Nissen fundoplication, all between 22 and 70 years old. Obese (BMI > 30 kg/m2) 
participants were recruited at the entry of a multidisciplinary care plan for morbidly obese patients, if 
they were found suited to undergo bariatric surgery at the Department of Gastrointestinal Surgery of 
Ghent University Hospital. Participants with primary hypogonadism, abnormal thyroid function, 
hepatitis or malignancies, serum total cholesterol > 300 mg/dl and/or serum TG > 450 mg/dl were 
excluded. None of the subjects used steroids or insulin, and oral glucose lowering-medication were 
discontinued prior to surgery.  
 
1.2. Hepobster study  
The Hepobster study sequels the Obster study. Otherwise having an overall identical study protocol, an 
additional liver biopsy is performed during surgery of obese participants in order to obtain histological 
NAFLD status. Between 2011 and 2015, we recruited 51 obese men undergoing gastric bypass surgery 
and 18 control men undergoing Nissen fundoplication surgery between 20 and 66 years of age. In- and 
exclusion criteria were similar to the Obster study but additionally, patients with other causes of liver 
disease, e.g. hepatitis B or C, viral or autoimmune hepatitis, Wilson disease or any drug-induced liver 
disease, or evidence of excessive alcohol consumption (≥ 20 g per day) were specifically excluded for this 
study. None of the subjects used steroids, insulin or thiazolidinediones and other oral glucose lowering-
medication were discontinued prior to surgery.  
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1.3. NASH study 
The Department of Gastroenterology and Hepatology of Ghent University Hospital recruited 39 obese 
patients (6 males and 33 females) between 32 and 68 years old, that were scheduled for gastric banding 
or gastric bypass surgery for inclusion in the NASH study. They all met the criteria for bariatric surgery of 
the International Federation for the Surgery of Obesity: BMI ≥ 40 kg/m2 or BMI ≥ 35 kg/m2 in 
conjunction with obesity-induced co-morbid conditions. Again, patients with other causes of liver 
disease, e.g. hepatitis B or C, viral or autoimmune hepatitis, Wilson disease or any drug-induced liver 
disease, evidence of excessive alcohol consumption (≥ 20 g per day), abnormal thyroid function, 
malignancies or cancer, serum total cholesterol > 300 mg/dl and/or serum TG > 450 mg/dl were 
excluded for this study.  
 
2. Methods 
2.1. Anthropometry and biochemical analysis 
Anthropometrics were measured in the three study populations during a pre-operative examination. 
Body weight (kg) was measured to an accuracy of 0.1 kg in light indoor clothing without shoes. Standing 
height was measured to the nearest 0.1 cm using a wall-mounted stadiometer. BMI was calculated as 
body weight divided by squared height (kg/m2). Blood samples were collected after overnight fasting, 
prior to surgery, and were centrifuged, fractionated and stored at -80°C until batch analysis. 
Measurement of TG, glucose, insulin, AST, ALT, GGT and CRP was routinely performed using a 
commercially available immunoassay or using a conventional automated analyzer. Homeostasis model 
of the assessment for insulin resistance (HOMA-IR) was calculated with the following formula: (fasting 
glucose [mmol/L] x fasting insulin [µU/mL])/22.5] [315].  
2.1.1. Measurement of adipokines  
Serum levels of adipokines including chemerin, omentin, MCP-1, adiponectin and SFRP4 were measured 
using commercial enzyme-linked immunosorbent assay (ELISA) kits, according to the manufacturer’s 
instructions. Measurements were performed at the Institute for Clinical Biochemistry and 
Pathobiochemistry in the German Diabetes Center at Duesseldorf (Deutches Diabetes Zentrum, DDZ) 
supervised by Prof. Dr. Ouwens.  
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2.1.2. Measurement of sex steroids 
Total T and E2 were measured in serum using liquid chromatography tandem mass spectrometry (LC–
MS/MS). LC-MS/MS is a technique that combines the physical separation of components in a sample 
according to their polarity, electrical charge or molecular size (liquid chromatography (LC)), with 
measurement of the mass-to-charge ratio of charged particles after ionization (mass spectroscopy (MS)). 
The advantages of LC-MS/MS are the high sensitivity and specificity and limit of quantification (LOQ) is 
very low. Unlike immunoassays, LC-MS/MS allows for measuring whole steroid profiles in one single run 
for one sample and requires only small sample volumes (50 to 200 µl) [316]. 
Free T levels were measured using a validated equilibrium dialysis method, as described previously by 
Vermeulen et al. [317]. Free E2 levels were calculated from total E2, SHBG, and albumin concentrations 
as described elsewhere [318]. Commercial immunoassays were used to determine SHBG, LH, and FSH. 
 
2.2. Adipose tissue processing 
At the end of the surgical intervention, abdominal SAT and VAT biopsies were obtained from the male 
subjects of the Obster and Hepobster study. Biopsies were immediately stored at −80 °C until further 
gene expression analysis or fixated in formol (buffered 4 % paraformaldehyde solution; Klinipath, 
Belgium) at room temperature for microscopic analysis.  
2.2.1. Subcutaneous adipocyte cell size assessment 
Adipocyte cell size was measured in SAT samples that were obtained in the Obster study. After paraffin 
impregnation, the SAT samples were stained with Hematoxylin–eosin and were completed into 3 μm 
slides. Digital photographs of the paraffin slides were taken with an Axioskop 20 light microscope (Zeiss, 
Jena, Germany), on which the mean surface area of adipocytes was measured by indicating the margins 
of the cell membrane of all complete adipocytes. As adipocytes were assumed to be spheres, as many as 
possible complete imaged adipocytes were measured in order to calculate the median surface area as 
expressed in µm2 per study patient, followed by calculation of the median SAT cell size per study group. 
Cell size assessment was blinded to grouping and was determined in 50 subjects of the Obster study. 
2.2.2. Gene expression analysis of aromatase and adipokines 
Aromatase expression was determined in the frozen SAT samples of 36 subjects (a subgroup of subjects 
from the Obster and Hepobster study cohort). Expression of the adipokines chemerin, omentin, MCP-1 
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and SFRP4 was determined in the frozen VAT samples of all 69 subjects of the Hepobster study cohort.  
Gene expression analysis was measured using real-time polymerase chain reaction (real-time PCR). After 
RNA isolation from 100 mg of the frozen fat biopsies, contaminating genomic DNA was removed and 
cDNA was synthesized. Next, aromatase and adipokine expression was quantified by real-time PCR using 
specific primer assays and PCR Master Mix on a StepOne Plus system (Applied Biosystems). Obtained 
threshold cycle (Ct) values were normalized for the expression of the stable reference genes. 
 
2.3. Liver tissue processing and histopathological analysis 
In the Hepobster and NASH study, liver biopsies were obtained during surgery and immediately 
processed. After formalin fixation, biopsies were routinely processed and stained with hematoxylin-
eosin and Masson trichrome. An experienced pathologist from the Department of Pathology at Ghent 
University Hospital established the histological diagnosis of NAFLD according to the scoring system of 
Kleiner et al. [195], blinded to characteristics of participants. At least 6 complete portal tracts in liver 
specimen are required for adequate histological evaluation. Steatosis was assessed as the percentage of 
hepatocytes containing fat droplets, with a minimum of 5 %. NAS has been introduced as the 
unweighted sum of scores for the intensity of steatosis (0-3), lobular inflammation (0-3), and 
hepatocellular ballooning (0-2), ranging from 0 to 8. NAS of 0 – 2 was considered as SS and scores of 5 or 
greater were considered as definite NASH. Intermediate scores of 3 or 4 were considered as borderline 
NASH. Additionally, stage of fibrosis was also scored using a 4-point scale. 
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Abstract 
The prevalence of non-alcoholic fatty liver disease (NAFLD) is rising, as is the prevalence of obesity and 
type 2 diabetes. It is increasingly recognized that an impaired pattern in adipokine secretion could play a 
pivotal role in the development of NAFLD. We performed a systematic review to evaluate the potential 
link between newly described adipokines and liver histology in biopsy-proven NAFLD patients. A 
computerized literature search was performed in PubMed, EMBASE and Web of Science electronic 
databases. Thirty-one cross-sectional studies were included, resulting in a total of seven different 
investigated adipokines. Studies included in this review mainly had a good methodological quality. Most 
adipokines were suggested to be involved in the inflammatory response that develops within the 
context of NAFLD, either at hepatic or systemic level, and/or hepatic insulin resistance. Based on 
literature, clinical studies suggest that chemerin, resistin and AFABP potentially are involved in NAFLD 
pathogenesis and/or progression. However, major inconsistency still exists and there is a high need for 
larger studies, together with the need of standardized assays to determine adipokine levels. 
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Introduction 
The growing epidemics of obesity and type 2 diabetes are associated with an increased incidence of 
non-alcoholic fatty liver disease (NAFLD) in the Western world. NAFLD is becoming one of the leading 
causes of chronic liver disease and can present as a broad spectrum of liver diseases, ranging from a 
simple fatty liver (steatosis) with a benign non-progressive clinical course to non-alcoholic 
steatohepatitis (NASH), which may progress to cirrhosis and ultimately end-stage liver disease or 
development of hepatocellular carcinoma (HCC). It is estimated that the prevalence of NAFLD has 
reached up to 75% in a high-risk Western population (1-3). The widespread increasing rates of obesity-
related NAFLD urges for a better understanding of its pathophysiology. NAFLD is associated with visceral 
obesity and is considered to be the hepatic component of metabolic syndrome, with insulin resistance 
(IR) playing a major role (1, 4). However, the pathogenesis remains incompletely understood.  
Adipose tissue has been found to secrete multiple regulating proteins, so called adipokines, as an 
endocrine gland, which exert local, peripheral and central effects. It is increasingly recognized that an 
impaired pattern in adipokine secretion could play a pivotal role in development of metabolic syndrome, 
including NAFLD and the progression to NASH. Visceral adipose tissue (VAT) has been proposed as a 
major contributor to NAFLD (5, 6). A study in Japan suggested that hepatic steatosis may be influenced 
by visceral fat accumulation regardless of body mass index (BMI), as the severity of hepatic steatosis by 
ultrasound was positively associated with visceral fat accumulation and IR in both obese and non-obese 
subjects (7). Furthermore, adipokines derived from visceral adipose tissue are considered to be 
delivered directly to the liver via its portal vein. Many investigators have attempted to demonstrate 
their role in the pathogenesis and progression of NAFLD and/or NASH. As an example, 
hypoadiponectinemia has been suggested to play a role in the progression from NAFLD to NASH, 
because of adiponectin its anti-inflammatory, antifibrogenic and insulin-sensitizing effects in the liver as 
well as its potential role in hepatic fatty acid metabolism (8-12). Also, several cross-sectional studies 
have indicated associations between NAFLD and serum levels of inflammatory cytokines including 
tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6) (13, 14). The role of these more classic 
adipokines has been reviewed frequently (12, 15-19). Relevance on the contribution of other known 
adipokines however, continues to be unclear. In view of this, the present review summarizes current 
knowledge on recently described adipokine levels in patients with biopsy-proven NAFLD and NASH, of 
which reports in the clinical setting of NAFLD is scarce. Whether or not these adipokines associate with 
liver histology and more specifically with the degree of steatosis, ballooning, fibrosis and/or 
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inflammation, could provide useful information and form the basis for experimental trials, leading to 
investigating new treatment approaches. 
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Methods 
Search strategy and study selection 
Search objectives included human studies with biopsy-verified NAFLD classification, the determination 
of adipokines and association analysis between adipokine levels and liver histopathologic severity. A 
computerized literature search was performed in PubMed, EMBASE and Web of Science electronic 
databases. Medical Subject Headings were used to form the combination of terminological terms, in 
order to retrieve relevant journal articles. After a preliminary search, a more specific query was used 
including ‘(((liver) AND histology) AND (adipokines OR adipocytokines)) AND (NAFLD OR NASH OR non-
alcoholic liver disease)’. Search was limited to human studies using the ‘Humans’ search filter but was 
not limited by publication time. After removing duplicates, the literature search was extended by 
checking references and citations of the retrieved articles.  
Articles were excluded from the systematic review if (i) article types were reviews, conference abstracts, 
case reports, editorials or letters; (ii) adipokine information was lacking; (iii) studies investigated gene 
polymorphisms; (iv) studies were interventional; (v) studies investigated other hepatic diseases 
(alcoholic fatty liver disease, unspecified cirrhosis, viral or autoimmune hepatitis), and adipokine data 
was missing for NAFLD subjects; (vi) patients were not subjected to liver biopsy; (vii) data on relations 
between adipokine levels and liver histology were absent; (viii) studies contained only paediatric data or 
(ix) there was a patient overlap. (x) Because this review was composed with the objective to investigate 
only recently described adipokines, articles were excluded when focusing on adiponectin, leptin or 
cytokines such as TNF-α and interleukines (IL-6), which have been extensively studied and/or reviewed 
over the last years (12, 13, 18-20). (xi) Finally, three out of ten found adipokines were additionally 
excluded because they were reported by only one respective study, leading to incomparable results. An 
overview of the search strategy is depicted in Fig. 1.  
Data on selected studies 
This review included studies reporting serum or expression levels of recently described adipokines in 
biopsy-proven NAFLD subjects. In most studies, histological classification was based on Brunt et al. (21) 
or Kleiner et al. (22) and controls were included when having a normal liver ultrasound and normal 
serum aminotransferases levels. The scoring system of Kleiner is known to be the successor of Brunt, 
with a more extensive range of histological parameters studied. According to the scoring system of 
Kleiner et al., a NAFLD activity score (NAS) has been introduced as the unweighted sum of scores for the 
intensity of steatosis, lobular inflammation, and hepatocellular ballooning, ranging from 0 to 8. Scores of 
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0 – 2 were considered as simple steatosis, and scores of 5 or greater were diagnosed with definite NASH. 
Intermediate scores of 3 or 4 were considered as borderline NASH (22). Three studies did not mention 
the scoring system used to define NAFLD and/or NASH, whereas one study referred to an alternative 
scoring system. The latter study performed histological classification according to Dixon et al. (23), of 
which criteria were steatosis (0-4), inflammation (0-4) and fibrosis (0-4) as a modification of the scoring 
system published by Brunt et al. (21) and Lee et al. (24).  
 
 
Figure 1 Flowchart of the search strategy 
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Serum adipokine levels were measured using commercial enzyme-linked immunosorbent assay (ELISA) 
kits in 26 studies, quantikine immunoassay in one study and nephelometry in one study. Furthermore, 
liver adipokine expression was determined in five studies, subcutaneous adipose tissue (SAT) adipokine 
expression was determined in two studies and VAT adipokine expression was determined in three 
studies. Comparison groups were mostly (i) control versus NAFLD subjects; (ii) control versus NASH 
subjects and/or (iii) NAFLD versus NASH subjects. 
Risk of bias 
Methodological quality of individual studies was evaluated by two independent researchers (M.B. and 
P.C.). Results of both researchers were compared, and differences were discussed and analyzed in a 
consensus meeting. Methodological quality of the studies was assessed using a standardized checklist 
for cohort studies of the Dutch Institute for Healthcare Improvement CBO (www.cbo.nl/en/). The 
checklist is presented in Table 1 and consists of seven criteria evaluating risk of bias. The checklist 
included questions concerning the description of study groups, risk of selection bias, clearly defined 
methods and risk of confounding factors. Every positive question was awarded by one point, leading to a 
maximum score of seven if all criteria were applicable. Finally, scores were converted into percentages 
to allow comparison of studies.  
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Table 1 Methodological quality assessment of individual studies 
Studies 1 2 3 4 5 6 7 
Score 
/7 
Score 
% 
Sell H et al, 2010, Germany (25) + + + + - + + 6 86 
Kukla M et al., 2010, Poland (26) + + + + - - + 5 71 
Yilmaz Y et al., 2011, Turkey (27) + + + + + + + 7 100 
Döcke S et al., 2013, Germany (28) + - + + + + + 6 86 
Musso G et al., 2005, Italy (29) + + + - - + + 5 71 
Pagano C et al., 2006, Italy (30) + + + + - - + 5 71 
Baranova A et al., 2006, USA (31) + + + + - - + 5 71 
Wong VW et al., 2006, China (32) + + + + + + + 7 100 
Younossi ZM et al., 2008, USA (33) + + + + - + + 6 86 
Jarrar MH et al., 2008, USA (34) - - + + - + + 4 57 
Aller  R et al., 2008, Spain (35) + + + + - + + 6 86 
Krawczyk K et al., 2009, Poland (36) + - + - - - - 2 29 
Argentou M et al., 2009, Greece (37) + + + + - - + 5 71 
Cengiz C et al., 2010, Turkey (38) + - + + + + + 6 86 
Senates E et al., 2012, Turkey (39) + + + + + - + 6 86 
Koehler E et al., 2012, USA (40) + + + + + + + 7 100 
Petta S et al., 2008, Italy (41) + + + + + + + 7 100 
Alkhouri N et al., 2009, USA (42) + - + + - + + 5 71 
Kashyap SR et al., 2009, USA (43) + + + + - + + 6 86 
Schina M et al., 2009, Greece (44) + + + + - - + 5 71 
Milner KL et al., 2009, Australia (45) + + + + - + + 6 86 
Terra X et al., 2013, Spain (46) - - + - - - + 2 29 
Aller  R et al., 2009, Spain (47) + + + + - + + 6 86 
Gaddipati R et al., 2010, India (48) + - + + + - - 4 57 
Kukla M et al., 2010, Poland (49) - + + + - - + 4 57 
Dahl TB et al., 2010, Norway (50)                                              + + + + + + + 7 100 
Genc H et al., 2013, Turkey (51) + + + + + + + 7 100 
Shen J et al., 2012, China (52) + - + + + + + 6 86 
Genc H et al., 2011, Turkey (53) + + + + + + + 7 100 
Aktas B et al., 2011, Turkey (54) + + + + + + + 7 100 
Ercin CN et al., 2010, Turkey (55) + + + + + + + 7 100 
1, study groups are clearly defined; 2, selection bias can be sufficiently excluded; 3, exposure (adipokine levels) and 
method of assessment are clearly described; 4, output (liver histology) and method of assessment are clearly 
described; 5, output is blindly assessed; 6, potential confounders are identified and corrected for analysis; 7, 
results are valid and applicable. 
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Results 
Search results  
A flowchart summarizing search results is depicted in Fig. 1. The 31 included studies were published 
between 2005 and 2013 and had a cross-sectional study design (25-55). Table 2 shows the main clinical 
and biochemical data of all 31 included studies, grouped per adipokine. Apart from adipokine levels, 
method of histological classification, group classification, male-to-female ratio, number of patients with 
type 2 diabetes, adjusted confounding factors and main conclusions were summarized. Following 
adipokines were described: chemerin in four studies, resistin in 12 studies, retinol-binding protein 4 
(RBP4) in seven studies, visfatin in seven studies, adipocyte-fatty-acid-binding protein (AFABP) in two 
studies, vaspin in three studies and apelin in two studies. 
Risk of bias 
The risk of bias of the individual studies was evaluated using a seven-item checklist, of which results are 
presented in Table 1. The final score of each study was calculated and converted into a percentage. 
Methodological quality varied between 29% and 100%, with only two studies scoring beneath 50%. In 
general, 26 out of 31 included studies had good quality with a score above 70%. Most studies lost points 
on blinding of output assessment and on correcting for potential confounders.  
Chemerin 
Chemerin was suggested to be related with the progression of NAFLD in four studies reporting 
associations with histological parameters that may indicate disease progression. Presence of portal 
inflammation and the combined severity of fibrosis and inflammation were positively associated with 
serum chemerin levels, a correlation that persisted after BMI adjustments, in a study cohort of morbidly 
obese women by Sell et al. (25). A positive association between chemerin levels and both NAS and 
hepatocyte ballooning was shown in obese NAFLD and NASH patients by the study of Kukla et al. (26). 
Although Yilmaz et al. (27) suggested a positive association with liver fibrosis in non-obese NAFLD 
patients, significance did not persist after allowance for potential confounders. In a cohort of obese 
undefined and defined NASH patients, Döcke et al. (28) reported a positive association of hepatic 
chemerin expression with overall histological NAS, as well as an independent association with liver 
fibrosis, steatosis, inflammation and hepatocyte ballooning.  
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Table 2 Main adipokine-related data and conclusions of all studies included in the systematic review, grouped per adipokine  
Adipokine Reference Histology Group M/F Adipokine determination 
T2D 
patients 
Adjusted 
confounding 
factors 
Main conclusions 
Chemerin 
Sell et al., 
2010, 
Germany 
(25) 
Kleiner and 
fibroinflam
mation 
score 
Healthy control                         
 
 
Obese non-NAFLD    
Obese NAFLD                   
Obese NASH      
0/13                    
 
 
0/13                 
0/44                        
0/3 
191 ± 14 ng/ml (vs total 
obese group 354 ± 18 
ng/ml*)  
NA                                            
NA                                
487 ± 18 ng/ml* 
21 BMI 
Chemerin serum concentrations were highly 
associated with the presence of portal 
inflammation and the combined severity of 
fibrosis and inflammation, a correlation that 
persisted after BMI adjustments. Authors 
suggest that chemerin could be a link between 
adipose tissue inflammation and liver pathology 
in obesity. 
 
Kukla et al., 
2010, 
Poland (26) 
Kleiner 
Healthy control    
 
 
Obese NAFLD                   
Obese NASH      
10/10                   
 
 
NA (n=21)                 
NA (n=20) 
6.1 ± 2.5 ng/ml (vs total 
NAFLD group 24.7 ± 17.1 
ng/ml**)  
16.3 ± 10.9 ng/ml**   
33.0 ± 18.5 ng/ml
##
 
10 / 
Chemerin was positively associated with NAS 
and hepatocyte ballooning. No association 
between the severity of hepatic fibrosis and 
chemerin levels was found. Authors suggest that 
chemerin and IR play a role in NAFLD 
progression. 
 
Yilmaz et 
al., 2011, 
Turkey (27) 
Kleiner 
Healthy control      
NAFLD 
37/38              
50/49 
159 ± 43 ng/ml 
219 ± 83 ng/ml *** 
29 
Age, sex, BMI, 
HOMA-IR, T2D, 
MetS, systolic and 
diastolic BP, AST, 
ALT, TG, total, 
HDL and LDL Chol, 
hs-CRP 
Chemerin serum levels were associated with the 
degree of liver fibrosis. After allowance for 
potential confounders, however, this result did 
not persist. Chemerin may play a role in the 
pathophysiology of NAFLD but does not seem to 
be a key biomarker of liver fibrosis in this entity. 
 
Döcke et al., 
2013, 
Germany 
(28) 
Kleiner and 
Ishak 
fibrosis 
scoring 
system 
No NASH              
Obese undefined 
NASH     
Obese definite 
NASH 
14/20               
4/6  
                 
1/2 
 
Liver mRNA (qPCR):
A  
                                                                                      
1.06 AU 
1.3 AU 
 
2.76 AU** 
##
 
 
 
9 
Age, sex, BMI, 
alcohol 
consumption, oral 
anti-diabetics 
Although circulating chemerin levels were not 
correlated with hepatic histology and mRNA 
levels, its mRNA expression was correlated with 
NAS. Linear regression analysis confirmed an 
independent association of liver fibrosis, 
steatosis, inflammation, and hepatocyte 
ballooning with hepatic chemerin mRNA 
expression. 
Resistin 
Musso et 
al., 2005, 
Italy (29) 
Brunt 
Healthy controls           
NASH 
23/2                               
23/2 
4.28 ± 0.21 ng/ml              
4.12 ± 0.37 ng/ml 
Excluded 
 
Age, BMI, WC, 
WHR, insulin, ISI, 
TNF-α, 
adiponectin, 
leptin 
 
No statistical correlations were found between 
resistin and histological findings of NASH 
patients. 
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Pagano et 
al., 2006, 
Italy (30) 
Brunt 
Healthy control  
Obese non-NAFLD          
NAFLD                   
ELISA:                         
30/3                   
26/4                    
26/2                      
 
qPCR:                       
NA (n=9)                    
NA (n=9)                     
NA (n=10)       
ELISA:                                        
4.30 ± 0.20 ng/ml  
4.37 ± 0.27 ng/ml 
5.87 ± 0.49 ng/ml**
$$ 
 
 
SAT mRNA (qPCR): 
A
                              
7 AU
4 AU                                    
20 AU*
$
 
Excluded / 
In patients with NAFLD, a positive correlation 
was found between resistin and histological 
NASH score and not with steatosis score, 
suggesting resistin is related to histological 
severity of liver disease but does not support a 
link with IR or BMI in these patients 
 
Baranova et 
al., 2006, 
USA (31) 
NA 
Obese IR (4 
NASH)                  
Obese non-IR (0 
NASH)                         
2/9                     
 
1/9                  
 
ELISA:                                                        
6.91 ng/ml 
3.9 ng/ml**    
 
VAT mRNA (qPCR):                                       
9.04 AU                                   
9.23 AU 
NA NA 
Resistin did not correlate with histological 
parameters but serum resistin associated with 
markers of IR. 
 
Wong et al., 
2006, China 
(32) 
Brunt 
 
Healthy controls     
SS 
NASH 
 
17/24                    
19/9                                
33/19  
Quantikine immunoassay: 
15 ± 8 ng/ml 
18 ± 14 ng/ml 
14 ± 13 ng/ml 
47 
Age, sex, BMI, 
T2D, WHR, TNF-α, 
adiponectin, 
leptin 
Resistin levels did not correlate with histological 
parameters.  
 
Younossi et 
al., 2008, 
USA (33) 
NA 
Obese controls                         
Obese SS                  
Obese definite 
NASH 
3/29                             
1/14                                  
9/13 
 
7.9 ± 4.1 ng/ml                     
7.9 ± 3.4 ng/ml 
5.9 ± 3.0 ng/ml 
 
NA 
M30, M65-M30, 
adiponectin 
Multivariate analysis revealed that histological 
NASH could be predicted by a combination of 
Cleaved CK-18 (marker of apoptosis), a product 
of the subtraction of Cleaved CK-18 level from 
Intact CK-18 level (marker of necrosis), serum 
adiponectin and serum resistin. 
 
Jarrar et al., 
2008, USA 
(34) 
Kleiner 
Healthy controls            
Obese non-NAFLD          
Obese SS          
Obese NASH 
6/6                                  
5/33                        
2/17                    
11/15 
NA                                           
7.6 ± 3.8 ng/ml                    
7.8 ± 4.3 ng/ml  
6.0 ± 2.9 ng/ml 
NA 
Age, sex, BMI, 
ethnicity, WHR, 
AST, ALT, TG, 
Chol, glucose, 
insulin, TNF-α, 
adiponectin, IL-6, 
IL-8, visfatin 
No statistically significant findings related to 
serum resistin levels were found in NASH, SS and 
obese controls. This study confirmed the 
absence of an association between NAFLD 
subtypes and resistin and showed the 
complexity of the interactions between various 
adipokines, IR and the pathogenesis of NAFLD. 
 
Aller et al., 
2008, Spain 
(35) 
Brunt 
Low grade 
steatosis 
High grade 
steatosis 
10/2 
                        
10/2 
 
2.36 ± 0.6 ng/ml 
 
2.8 ± 0.6 ng/ml* 
 
Excluded 
Age, sex, BMI, 
HOMA-IR, dietary 
intake 
High levels of resistin could be found as a 
surrogate marker of IR, as including HOMA-IR to 
multivariate logistic analysis resulted in a lack of 
association between resistin and steatosis. 
 
Krawczyk et 
al., 2009, 
Poland (36) 
Dixon 
Healthy controls              
NASH 
NA (n=16)                   
16/2 
25.78 ± 26.02 ng/ml              
22.94 ± 6.3 ng/ml 
3 / 
Resistin did not correlate with histological 
findings of NASH patients. However, a 
correlation between resistin and TNF-α suggests 
a role for resistin in the inflammatory process.  
 
 
82 
 
 
Argentou et 
al., 2009, 
Greece (37) 
Kleiner 
Obese controls         
Obese SS                                 
Obese NASH 
2/7                       
9/22            
6/4 
0.94 ± 0.31 ng/ml              
0.91 ± 0.33 ng/ml 
0.98 ± 0.55 ng/ml              
18 / 
In the NAFLD group, resistin levels were 
negatively associated with the grade of steatosis 
and percentage of liver parenchym involved by 
steatosis. Resistin levels are related to liver 
histology in bariatric patients and may be 
indicative of the extent of hepatic steatosis. 
 
Cengiz et 
al., 2010, 
Turkey (38) 
Kleiner and 
Brunt 
Healthy controls           
Ultrasound 
steatosis         
Biopsy-proven 
NAFLD  
NA (n=24)                  
NA (n=76) 
                         
NA (n=34) 
 
1.3 ± 0.9 ng/ml                       
2.2 ± 0.9 ng/ml***                       
NA 
 
Excluded 
Age, BMI, HOMA-
IR, AST, ALT, GGT, 
TG, Chol, 
adiponectin, 
leptin, RBP4 
Although resistin was not related to HOMA-IR, 
on multivariate logistic regression analysis 
resistin remained a risk factor for the 
development of steatosis. Furthermore, resistin 
was found as a predictive factor independently 
associated with the degree of 
necroinflammation. 
 
Senates et 
al., 2012, 
Turkey (39) 
Kleiner 
Healthy controls        
 
 
SS 
Borderline NASH           
Definite NASH 
33/33  
 
                       
NA (n=12)                                        
NA (n=34)                                     
NA (n=51)                                             
26.57 ± 13.60 ng/ml (vs 
NAFLD 32.10 ± 
10.0ng/ml**)  
20 ± 10 ng/ml         
26 ± 15 ng/ml             
29 ± 13 ng/ml
#
                                      
24 / 
Resistin levels were associated with histological 
steatosis, portal inflammation and NASH scores, 
regardless of potential confounders. Although 
subject to future confirmation, this preliminary 
data suggests resistin could discriminate SS from 
definite NASH and may be useful as a non-
invasive marker for more advanced forms of 
NAFLD. 
 
Koehler et 
al., 2012, 
USA (40) 
Brunt 
Obese no NAFLD  
Obese SS             
Obese NASH with 
fibrosis stage 0-1                 
Obese NASH with 
fibrosis stage ≥ 2 
4/12                           
8/64                    
8/52                        
4/8 
 
15.1 (13.7-23.4) ng/ml 
15.3 (12.7-19.0) ng/ml 
14.9 (12.6-17.8) ng/ml 
 
17.5 (14.2-19.7) ng/ml 
 
59 
QUICKI, GH, CK-
18, adiponectin, 
IL-6 
Resistin levels were not correlated with 
histological findings of NASH patients. However, 
authors did not look for predictors or 
associations with necroinflammation grade.  
RBP4 
Petta et al., 
2008, Italy 
(41) 
Kleiner and 
Brunt 
Healthy controls          
Hepatitis C 
NAFLD 
19/11                  
76/67 
29/8 
28.9 ± 12.1 µg/L                                                
36.8 ± 17.5 µg/L*                  
35.2 ± 9.3 µg/L* 
Excluded 
Age, sex, HOMA-
IR, WC, HC, ALT, 
GGT, total and 
HDL Chol, TG, 
glucose, insulin, 
ferritin, platelet 
count 
In the NAFLD group, low degree of fibrosis and 
necroinflammation were associated with high 
RBP4 levels, but only low necroinflammatory 
activity was maintained in multiple linear 
regression analysis. Authors suggest that in 
NAFLD the elevated RBP4 levels are more closely 
associated with IR and obesity, in keeping with a 
general metabolic disorder. 
 
Alkhouri et 
al., 2009, 
USA (42) 
Kleiner 
Obese SS                            
Obese NASH 
9/7                      
15/18 
26.9 ± 13.4 mg/L                      
21.4 ± 10.3 mg/L 
15 
Age, BMI, HOMA-
IR, AST, ALT, 
glucose, insulin 
There was an inverse association between stage 
of fibrosis and RBP4 levels, with the lowest 
levels in patients with advanced fibrosis or 
cirrhosis. These results identify RBP4 as a 
potential novel marker to assess fibrosis 
progression in patients with NAFLD. 
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Kashyap et 
al., 2009, 
USA (43) 
Kleiner 
Obese no NAFLD                                 
Obese SS            
Obese borderline 
NASH               
Obese NASH 
6/37         
10/23                     
9/31                         
 
5/21 
41.61 ± 21.18 mg/L                         
41.63 ± 13.61 mg/L               
39.24 ± 10.57 mg/L                     
 
44.80 ± 15.83 mg/L 
55 
Age, BMI, systolic 
BP, AST, ALT, TG, 
HDL Chol, TNF-α, 
glucose, leptin, 
adiponectin 
RBP4 could be linked to BMI and TG levels but 
not to liver histology, suggesting that these 
levels relate to IR indexes but not to severity of 
liver injury. 
 
Schina et 
al., 2009, 
Greece (44) 
Kleiner and 
Brunt 
Healthy controls                
SS 
NASH 
ELISA:               
13/17                 
5/8                      
13/4                   
IHC:     
3/2                            
5/8                        
13/4 
ELISA:                                        
34.66 (27.04-43.6) µg/ml 
22.9 (19.5-33) µg/ml***                                  
25.2 (22.9-26.9) µg/ml*** 
IHC: 
1.7 ± 0.67                         
4.69 ± 0.95***                   
6.35 ± 0.99***
###
 
Excluded / 
No correlation was found with respect to serum 
RBP4 and disease activity or metabolic 
parameters. However, liver expression of RBP4 
was found to correlate with the extent of 
steatosis, grade of NASH activity and fibrosis 
stage. Serum RBP4 is not a clinically valid marker 
of IR in patients with NAFLD, but the hepatic 
expression of RBP4 probably is.  
 
Milner et 
al., 2009, 
Australia 
(45) 
Kleiner and 
Brunt 
Healthy controls                  
 
SS 
NASH 
71/58                     
 
22/9                      
38/31 
16.9 ng/ml (vs total NAFLD 
group 16.3 ng/ml) 
16.9 ± 3.6 ng/ml 
16.0 ± 4.6 ng/ml 
28 
BMI, HOMA-IR, 
WC, TG, HDL, Chol 
Serum RBP4 levels did not correlate with the 
degree of liver steatosis, inflammation or 
fibrosis in patients with NAFLD. 
 
Cengiz et 
al., 2010, 
Turkey (38) 
Kleiner and 
Brunt 
Healthy controls           
Ultrasound 
steatosis         
Biopsy-proven 
NAFLD  
NA (n=24)                   
NA (n=76) 
                         
NA (n=34) 
 
18.0 ± 0.6 µg/ml                       
18.1 ± 0.7 µg/ml 
NA 
 
Excluded 
Age, BMI, Chol, 
HOMA-IR, AST, 
ALT, GGT, TG, 
adiponectin, 
leptin, resistin 
This study suggests that there is no significant 
relationship between NAFLD, as determined by 
both ultrasound and liver histology, and serum 
RBP4 levels, although it may be correlated with 
IR. 
 
Terra et al., 
2013, Spain 
(46) 
Kleiner and 
Brunt 
Healthy controls          
Obese non-NAFLD       
Obese SS                               
Obese NASH 
0/4                               
0/11                         
0/13                                
0/21 
Serum nephelometry:             
2.5 ± 0.2 mg/dl 
2.7 ± 0.2 mg/dl                   
3.8 ± 0.4 mg/dl*
$ 
               
3.3 ± 0.2 mg/dl*
$ 
SAT mRNA (qPCR):                        
2.22 ± 0.24 AU
& 
               
4.17 ± 1.24 AU                 
4.09 ± 1.12 AU                 
2.77 ± 0.47 AU 
VAT mRNA (qPCR):                      
3.73 ± 0.36 AU
&
                  
1.72 ± 0.27 AU                 
2.38 ± 0.34 AU 
1.88 ± 0.22 AU                
Liver mRNA (qPCR)
§
:                          
8.85 ± 0.56 AU                 
10.51 ± 2.28 AU               
7.34 ± 0.83 AU 
6.57 ± 0.72 AU 
10 NA 
Authors only found an association between 
systemic levels of RBP4 and TG levels in MO 
women but not with histological findings. This 
study also indicated that mRNA RBP4 expression 
in SAT and VAT appeared to be unrelated to IR 
or NAFLD histology and liver had the highest 
expression of RBP4 in all physiological states 
studied, but there was a lack of correlation 
between hepatic expression and systemic levels.  
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Visfatin 
Younossi et 
al., 2008, 
USA (33) 
NA 
Obese controls                         
Obese SS                  
Obese definite 
NASH 
3/29                             
1/14                                 
9/13 
 
25.8 ± 18.0 pg/ml                     
52.5 ± 67.0 pg/ml               
16.7 ± 6.3 pg/ml
##
 
 
NA 
M30, M65-M30, 
adiponectin 
Visfatin levels did not correlate with histological 
findings in patients with NAFLD.  
 
Jarrar et al., 
2008, USA 
(34) 
Kleiner 
Healthy controls  
                               
Obese non-NAFLD  
 
Obese SS           
 
Obese NASH 
6/6  
                            
5/33 
 
2/17       
 
11/15 
11.4 ± 5.7 pg/ml (vs NAFLD 
28.9 ± 41.6**)                                         
26.8 ± 19.0 pg/ml** (vs 
NAFLD 28.9 ± 41.6 NS)                             
45.1 ± 60.9 pg/ml (vs non-
obese controls**)                   
17.1 ± 6.2 pg/ml*
#
 
NA
Age, sex, BMI, 
ethnicity, WHR, 
AST, ALT, TG, 
Chol, glucose, 
insulin, TNF-α, 
adiponectin, IL-6, 
IL-8, resistin 
Although visfatin was not independently 
associated with NAFLD, multivariate analysis 
showed a positive correlation between TNF-α 
and NAFLD that was interdependent of visfatin. 
Visfatin may play a protective role in NAFLD and 
this study showed the complexity of the 
interactions between various adipokines, IR and 
the pathogenesis of NAFLD. 
 
Aller et al., 
2009, Spain 
(47) 
Brunt and 
Masson 
trichome 
stain 
(fibrosis) 
Obese with low 
grade steatosis 
Obese with high 
grade steatosis 
21/10   
                     
16/8 
 
14.1 ± 6.6 ng/ml 
 
15.7 ± 7.3 ng/ml 
 
Excluded 
Age, sex, fat 
mass, insulin 
Serum visfatin levels were not related to 
steatosis grade or fibrosis in overweight and 
obese patients with NAFLD. However, visfatin 
predicted the presence of portal inflammation. 
 
Gaddipati et 
al., 2010, 
India (48) 
Brunt 
 
Non-NAFLD                    
SS 
Moderate 
steatosis  
NASH 
 
NA (n=38)                     
NA (n=35)                                
NA (n=30) 
NA (n=12)                  
VAT ELISA: 
210.4 ± 93.2 ng/ml  
87.3 ± 75.2 ng/ml*         
61.4 ± 54.5 ng/ml*** 
31.8 ± 29.4 ng/ml*** 
Excluded / 
There was an inverse association between the 
level of visceral visfatin and occurrence of SS in 
NAFLD. These findings point out the protective 
role of visfatin in NAFLD. 
 
Kukla et al., 
2010, 
Poland (49) 
Kleiner and 
Scheuer 
(inflammato
ry) 
 
Obese SS             
Obese NASH                                         
 
OR 
                                      
Obese non 
fibrosis                          
Obese fibrosis 
 
NA (n=16)                          
NA (n=24)
 
OR 
 
NA (n=7) 
                     
NA (n=33) 
Liver IHC: 
0.62 ± 0.19 AU 
1.11 ± 0.71 AU   
 
OR 
 
0.36 ± 0.03 AU 
  
1.09 ± 0.65 AU* 
NA / 
This study showed a positive association 
between liver visfatin expression and fibrosis 
stage in NAFLD patients, but not with liver 
steatosis and inflammation. This observation 
suggests a potential role of visfatin in the 
pathogenesis and progression of fibrosis in 
NAFLD patients. 
 
 
Dahl et al., 
2010, 
Norway (50) 
Brunt 
 
Healthy controls              
Obese SS              
Obese NASH                                    
 
ELISA:                             
14/13                    
12/14                   
19/13                        
 
qPCR:     
NA (n=6)                            
NA (n=6)                               
NA (n=7) 
ELISA:
A 
 
15 ng/ml 
7 ng/ml*** 
7.5 g/ml***                              
 
Liver mRNA (qPCR): 
A 
                                        
2.5 AU                                       
1 AU**                                       
0.9 AU** 
26 Age, sex, BMI, ALT 
NAFLD was a significant predictor of serum 
visfatin levels, independent of all the measured 
metabolic parameters. This study suggests a role 
for decreased visfatin levels in hepatocyte 
apoptosis in NAFLD-related disease 
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Genc et al., 
2013, 
Turkey (51) 
Kleiner 
Healthy controls           
SS           
Borderline NASH            
NASH 
60/0                   
31/0                 
35/0                        
48/0 
13.33 ± 2.73 ng/ml                
13.2 (10.8-17.0) ng/ml 
14.3 (9.2-19.1) ng/ml 
14.0 (8.6-21.2) ng/ml 
Excluded BMI 
Plasma visfatin levels were not associated with 
histological findings of NAFLD patients. 
However, it is inversely associated with TNF-α, 
suggesting a role for visfatin in protection 
against liver injury during the inflammatory 
process. 
AFABP 
Milner et 
al., 2009, 
Australia 
(45) 
Kleiner and 
Brunt 
Healthy controls                  
 
SS 
NASH 
71/58                     
 
22/9                      
38/31 
23.1 ng/ml (vs total NAFLD 
group 33.5 ng/ml***) 
28.5 ± 11.8 ng/ml                           
35.8 ± 15.0 ng/ml***
#
 
28 
BMI, HOMA-IR, 
WC, TG, HDL, Chol 
Serum AFABP predicted inflammation (lobular 
inflammation and ballooning) and fibrosis in 
NAFLD patients, even when measurements of IR, 
VAT and other adipokines were considered. 
These results suggest AFABP may have a direct 
pathogenic link to disease progression. 
 
Shen et al., 
2012, China 
(52) 
Kleiner 
Healthy controls     
 
 
Simple NAFLD                                   
NASH 
40/34                     
 
 
36/28           
45/37 
15.4 (12.4-19.1) ng/ml (vs 
total NAFLD group 19.2 
(14.9-25.8) ng/ml***) 
18.9 (13.1-25.4) ng/ml 
19.4 (16.0-27.4) ng/ml 
71 
Age, BMI, MetS, 
TG, Chol, glucose 
AFABP positively associated with lobular 
inflammation, ballooning and NAS, of which 
ballooning remained independently associated 
with AFABP on multiple linear regression. The 
utility of AFABP in diagnosing NAFLD is limited 
by the relatively low accuracy. 
 
Vaspin 
Kukla et al., 
2010, 
Poland (26) 
Kleiner 
Healthy control    
 
 
Obese NAFLD                   
Obese NASH      
10/10                   
 
 
NA (n=21)                 
NA (n=20) 
1.6 ± 0.8 ng/ml (vs total 
NAFLD group 1.0 ± 0.7 
ng/ml)                                    
0.9 ± 0.6 ng/ml                                  
1.2 ± 0.7 ng/ml 
10 / 
A relationship between serum vaspin and 
hepatocyte ballooning was found in NAFLD 
patients, a known hallmark of NASH. Up-
regulation of vaspin could be a compensatory 
mechanism associated with obesity and IR. 
 
 
Genc et al., 
2011, 
Turkey (53) 
Kleiner 
Healthy control             
NASH 
30/0                                       
50/0 
0.44 ± 0.29 ng/ml                     
0.99 ± 0.84 ng/ml** 
Excluded 
BMI, HOMA-IR, 
WC, lipid 
parameters, 
glucose 
Vaspin levels did not associate with histological 
findings namely steatosis, ballooning 
degeneration, lobular inflammation and fibrosis. 
These results suggest that in the absence of 
metabolic risk factors, vaspin per se may not be 
involved in the pathogenesis of NASH. 
 
Aktas et al., 
2011, 
Turkey (54) 
Kleiner 
Healthy control              
NAFLD 
39/42                       
43/48 
0.4 (0.2-0.7) ng/ml              
0.6 (0.3-1.1) ng/ml** 
22 
Age, sex, BMI, 
HOMA-IR, T2D, 
MetS, systolic and 
diastolic BP, AST, 
ALT, TG, total, 
HDL and LDL Chol, 
hs-CRP, 
albuminuria, 
smoking 
 
Results of the present study indicate that vaspin 
is a predictor of liver fibrosis, independent of 
potential confounders including metabolic 
parameters. 
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Apelin 
Ercin et al., 
2010, 
Turkey (55) 
Kleiner 
Healthy control               
NAFLD 
 
30/0                           
50/0 
 
0.21 (0.2-0.4) ng/ml           
0.26 (0.09-0.5) ng/ml*** 
Excluded 
Age, BMI, HOMA-
IR 
Although apelin-12 concentration was 
associated with the degree of IR and body 
composition, no relation with liver histology 
could be found. 
 
Aktas et al., 
2011, 
Turkey (54) 
Kleiner 
Healthy control              
NAFLD 
39/42                       
43/48 
1.1 (0.8-1.5) ng/ml                  
1.4 (0.9-2.1) ng/ml** 
22 
Age, sex, BMI, 
HOMA-IR, T2D, 
MetS, systolic and 
diastolic BP, AST, 
ALT, TG, total, 
HDL and LDL Chol, 
hs-CRP, 
albuminuria, 
smoking 
Apelin-36 could be linked to IR but not with liver 
histology. However, after allowance for 
potential confounders this relation did not 
persist. Findings suggest that apelin does not 
seem to play a major role in the 
pathophysiology of NAFLD and does not point 
towards a major independent association of 
apelin with metabolic liver disease.   
Adipokine serum levels were determined using commercial enzyme-linked immunosorbent assay (ELISA) kits, unless mentioned otherwise.  
AFABP, adipocyte fatty acid binding protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AU, arbitrary units; BMI, body mass index; BP, 
blood pressure; Chol, cholesterol; GGT, gamma-glutamyl transferase; GH, growth hormone; HC, hip circumference; HDL, high-density lipoprotein; HOMA-IR, 
homeostasis model of assessment for insulin resistance; hs-CRP, high-sensitivity C-reactive protein; IHC, immunohistochemistry; IL, interleukin; IR, insulin 
resistance; LDL, low-density lipoprotein; MCP-1, monocyte chemoattractant protein-1; MetS, metabolic syndrome; M/F, male-to-female ratio; MO, morbidly 
obese; NA, not available; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NS, not significant; RBP4, retinol binding protein-4; SAT, 
subcutaneous adipose tissue; SS, simple steatosis; T2D, type 2 diabetes; TNF-α, tumor necrosis factor-α; VAT, visceral adipose tissue; WC, waist circumference. 
* vs. corresponding (obese) controls; # vs. simple NAFLD; $ vs. obese non NAFLD, & vs. whole obese group; § vs. SAT and VAT mRNA  
*, < 0.05; **, < 0.01; ***, < 0.001 
 
A
 estimation based on Figure.
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All studies except for Döcke et al. reported significantly elevated serum chemerin levels in NAFLD 
patients compared with healthy or obese controls, whereas Döcke et al. found significantly elevated 
hepatic chemerin expression in patients with definite NASH versus no or undefined NASH. Overall, 
although inconsistency exists in histological parameters, all studies had a good methodological quality 
above 70% and suggest that chemerin may be involved in NAFLD progression with regard to liver 
inflammation and hepatocyte ballooning. Although results were similar, the study of Kukla et al. used a 
different ELISA and did not adjust analysis for potential confounders in comparison with the other 
studies. Based on these results, contribution of chemerin in the development of NASH is possible and 
may involve its hepatic expression, as reported by the study group of Döcke.  
Resistin 
We found 12 studies in literature evaluating the association between resistin and liver histology in 
patients with NAFLD and/or NASH, of which six showed statistically significant results. Circulating resistin 
levels were positively associated with histological steatosis, portal inflammation and NAS in patients 
with NAFLD and NASH, reported by Senates et al. (39). On multivariate regression analysis, Cengiz et al. 
(38) also found serum resistin as a positive correlate for the development of steatosis and degree of 
necroinflammation in non-diabetic NAFLD patients. The association between resistin and the grade of 
hepatic steatosis was additionally analyzed by two other study groups, Aller et al. and Argentou et al. 
Although initially associated, including homeostasis model of assessment for insulin resistance (HOMA-
IR) to the multivariate logistic analysis resulted in a loss of the association between resistin and the 
grade of steatosis in non-diabetic NAFLD patients who participated the study of Aller et al. (35). Because 
they found a positive association between resistin and HOMA-IR, resistin was suggested to be a mere 
surrogate marker of IR. Besides Senates et al. (39), two studies similarly reported a positive association 
between serum resistin and histological NAS. In the first study, by Pagano et al. (30), univariate 
correlation analysis revealed that serum resistin was associated with the histological NAS in non-diabetic 
patients with NAFLD, whereas no association was found with steatosis score. Secondly, Younossi et al. 
(33) proposed a diagnostic biomarker panel to predict histological NASH within a cohort of obese NAFLD 
patients and obese controls, including serum resistin levels next to serum adiponectin, cleaved CK-18 (a 
marker of apoptosis) and a product of the subtraction of cleaved CK-18 from intact CK-18 (a marker of 
necrosis). In contrast, while all other studies reported positive associations concerning resistin and liver 
histology, Argentou et al. (37) was the only study group indicating a negative association between 
resistin serum levels and the grade of steatosis as well as percentage of liver parenchym involved by 
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steatosis in obese patients with NAFLD. Despite these inconsistent findings, the differences in 
associations between resistin and histological parameters could not be reflected to patterns found in 
study design of the different studies. Among the 12 studies, five different ELISA were used. However, 
usage of the same assay among independent studies did not result in similar results. Significantly 
elevated circulating resistin levels in patients with NAFLD were described in four studies, compared with 
healthy or obese controls. The presence of definite NASH resulted in even higher serum levels compared 
with patients with simple steatosis in two of these studies. Pagano et al. also reported an up-regulated 
resistin mRNA expression in SAT of patients with NAFLD, although they were not associated with 
histological parameters. Finally, the remaining six studies that were found to investigate resistin in 
relation to NAFLD did not show a correlation between this adipokine and liver histological parameters in 
obese and non-obese patients with NAFLD and/or NASH (29, 31, 32, 34, 36, 40). Baranova et al. (31) was 
the only study group that measured resistin mRNA expression in VAT of obese patients with NAFLD, 
although expression levels were also not associated with liver histology. Altogether, of the six studies 
reporting relations between resistin and liver histology in NAFLD patients, grade of steatosis was 
presented as the strongest associated parameter in most studies followed by portal inflammation and 
necroinflammation as well as histological NAS. Contribution of adipose tissue (SAT or VAT) to circulating 
resistin levels and liver histology of NAFLD patients could not be confirmed by the studies described 
earlier. Four out of 12 studies did not adjust analysis for confounders, and the potential link between IR 
and resistin was also inconsistent among different studies. All positive studies had a methodological 
quality above 70%, while only two studies that did not report significant results scored below 70%. 
Retinol-binding protein 4 
Of all seven studies from our search results, only three effectively reported an association between 
serum RBP4 levels and liver histology in patients with biopsy-proven NAFLD. Liver RBP4 expression but 
not serum levels was shown to positively associate with the extent of steatosis, grade of NASH activity 
and fibrosis stage in non-diabetic non-obese patients with NAFLD, reported by Schina et al. (44). Petta et 
al. (41) was the first study group that found a negative association between serum RBP4 and the stage 
of fibrosis as well as necroinflammation in non-diabetic non-obese NAFLD patients. However, after 
multivariate regression analysis including BMI, alanine aminotransferase (ALT), ɣ-glutamyltransferase 
(GGT) and cholesterol, only necroinflammation remained to be negatively associated with serum RBP4. 
Subsequently, in obese NAFLD patients participating the study of Alkhouri et al. (42), serum RBP4 levels 
were inversely associated only with the stage of fibrosis. Only two study groups indicated significantly 
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altered RBP4 levels in NAFLD patients, whereas other studies reported no differences. Petta et al. 
reported higher serum RBP4 levels in NAFLD patients versus healthy controls, whereas Schina et al. 
reported lower serum levels but an up-regulated hepatic RBP4 expression in patients with simple 
steatosis or NASH versus healthy controls. Four studies did not demonstrate any association between 
RBP4 and NAFLD-related histological parameters in both obese and non-obese patients with NAFLD 
and/or NASH (38, 43, 45, 46). Besides serum RBP4 levels, Terra et al. (46) measured liver, SAT and VAT 
RBP4 mRNA expression levels in morbidly obese women with NAFLD but could not relate them to liver 
histology. They reported significantly higher serum levels in obese patients with NAFLD compared with 
obese and healthy controls but found no significant results in tissue expression. This last study indicated 
that liver had the highest expression of RBP4 in all physiological states studied, but there was a lack of 
correlation between hepatic expression and systemic levels. In summary, considering results from the 
literature, the contribution of circulating RBP4 to NAFLD progression appears to be unlikely, as two out 
of seven studies found associations with divergent histological parameters. Furthermore, five different 
ELISA were used among seven studies, and two studies did not mention potential confounding factors. 
Presence of this adipokine in the liver, however, could contribute to the extent of steatosis, NAS level 
and fibrosis stage but needs confirmation in more (prospective) studies. Except for Terra et al., all 
studies had a good methodological quality score above 70%.  
Visfatin 
Although four studies out of seven search results reported associations of visfatin with NAFLD 
histological parameters, results were inconsistent among the different studies. Gaddipati et al. (48) 
examined visfatin levels in VAT biopsies of non-diabetic patients with and without NAFLD and found a 
significant decline in patients with NAFLD versus controls, which was positively associated with the 
degree of steatosis. One year before, Aller et al. (47) had indicated that serum visfatin levels may predict 
the presence of portal inflammation in non-diabetic obese patients with NAFLD, while they could not 
demonstrate relations with steatosis or fibrosis. Kukla et al. (49) only measured hepatic visfatin 
expression in relation to NAFLD and showed a positive association with fibrosis stage in morbidly obese 
patients with NAFLD, but not with liver steatosis and inflammation. They could not demonstrate 
significant differences in hepatic visfatin expression between patients with simple steatosis and NASH, 
although patients with fibrosis had a significantly higher visfatin expression versus no fibrosis. The 
presence of NAFLD itself has been proposed to be a significant predictor of serum visfatin levels by Dahl 
et al. (50), independent of sex, BMI, age and serum ALT. Within this obese NAFLD patient group, liver 
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visfatin mRNA expression and its serum levels were markedly decreased compared with healthy 
controls, with no difference between simple steatosis and NASH. The three remaining studies that 
investigated visfatin in both obese and non-obese patients with biopsy-proven NAFLD did not find 
significant associations with liver histology (33, 34, 51). While one study reported no differences in 
concentration among patient groups, both Jarrar et al. (34) and Younossi et al. (33) showed significantly 
lower serum visfatin levels in NASH patients compared with patients with simple steatosis or (obese) 
controls. Overall, three studies suggested a protective role of visfatin in NAFLD progression, of which 
one study had a methodological quality score of 100% and others only had 57%. Two other study groups 
described hepatic visfatin levels as a potential contributor of fibrosis progression or hepatocyte 
apoptosis, with a quality score of 57% and 100%, respectively, while another study group suggested that 
serum visfatin may predict portal inflammation, which had a quality score of 86%. Potential contribution 
of serum, adipose tissue or liver visfatin to NAFLD progression could not be concluded from literature 
results. Confounding factors such as BMI, age and sex were mostly taken into account, whereas insulin 
(resistance) was only included in two studies, and two remaining studies indicated no confounding 
factors. Most studies used the same ELISA.   
Adipocyte-fatty-acid-binding protein  
Two study groups suggested that AFABP may play a role in NAFLD progression. Milner et al. (45) 
indicated serum AFABP as an independent positive correlate of lobular inflammation, hepatocyte 
ballooning and fibrosis in non-obese patients with NAFLD, even when measurements of IR, visceral fat 
and other adipokines were considered. In another study, serum AFABP had a positive association with 
lobular inflammation, hepatocellular ballooning and NAS, of which hepatocellular ballooning remained 
independently associated with AFABP on multiple linear regression also correcting for age, BMI, fasting 
glucose, total cholesterol, triglyceride, MetS, steatosis and fibrosis. These findings were reported by 
Shen et al. in a non-obese cohort of NAFLD patients (52). Both studies showed significantly elevated 
serum AFABP levels in patients with NAFLD versus healthy controls, although only Milner et al. reported 
additionally elevated levels in patients with NASH compared with simple steatosis. Both studies applied 
the same ELISA. Overall, according to literature, AFABP was suggested to associate most strongly with 
hepatocyte ballooning degeneration, and methodological quality of both studies was equally very good, 
with a score of 86%. 
 
 
Potential role of adipokines in NAFLD |  
 
91 
 
Vaspin 
Vaspin was suggested to associate with liver histology in two studies with biopsy-proven NAFLD 
patients. The first study was performed by Kukla et al. (26), who found a positive relationship between 
serum vaspin levels and hepatocyte ballooning degeneration in an obese NAFLD cohort. Secondly, Aktas 
et al. (54) indicated vaspin as a positive correlate of liver fibrosis, independent of potential confounders 
such as sex, age, metabolic and histological parameters. While the latter study group described 
significantly elevated serum vaspin levels in NAFLD patients compared with healthy controls, Kukla et al. 
only found significantly higher levels in NAFLD patients with versus without hepatocyte ballooning. 
Serum vaspin levels were not found to be associated with histological findings in a last study with non-
diabetic non-obese NASH patients by Genc et al. (53). Although they also reported significantly higher 
levels in NASH patients versus healthy controls, significance disappeared after adjustment with 
metabolic risk factors. Altogether, out of three studies that evaluated associations of vaspin with liver 
histology, each study was reporting different outcomes. Therefore, the role of vaspin in NAFLD, if any, 
remains unclear. While the study of Kukla et al. had a methodological quality score of 71% and used a 
different ELISA, the two remaining studies both had a maximum score of 100% and applied similar ELISA.  
Apelin 
Two studies that investigated apelin in relation to liver histology in NAFLD patients did not show 
significant associations with histological parameters. Ercin et al. (55) have indicated in their preliminary 
study that serum apelin-12 levels were not altered in male non-diabetic subjects with NAFLD when 
findings were adjusted according to BMI and HOMA-IR indexes. Also apelin-36, the longest biologically 
active secreted form of apelin, could not be linked to histological findings of NAFLD patients, reported 
by Aktas et al. (54). In this study, serum apelin-36 levels were significantly higher in patients with NAFLD 
versus healthy controls. Concluding from these two studies, the contribution of apelin to NAFLD 
progression is suggested to be negligible. Both studies used the same ELISA and had a maximum score of 
100% on methodological quality.  
Major findings 
Except for two, studies included in this review had a good or average (>50%) methodological quality. 
Furthermore, they all had category B in level of evidence because of the cross-sectional study design, 
meaning only suggestive and no conclusive findings can be made. Of all seven adipokines described 
earlier, findings with chemerin and AFABP were most persisting with at least two study groups reporting 
similar results. Although only half of the studies reported significant associations with resistin, findings 
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were also promising with consistent results in different independent studies. Therefore, these three 
adipokines are suggested to be most probably related to NAFLD progression and/or pathogenesis. 
Omentin was also pointed out as a potential modulator of NAFLD by Yilmaz et al. (27), although they 
were the only study group investigating this adipokine. These results could thus not be confirmed by 
other independent studies and were omitted from this review. Visfatin, RBP4 and vaspin were 
investigated by several studies (visfatin and RBP4, N = 7; vaspin, N = 2), with each study reporting 
different or no associated histological parameters. These results were too divergent to suggest any 
potential involvement of the adipokines in NAFLD. Finally, no significant findings were found concerning 
apelin. Altogether, major inconsistent results were found among different studies, which impede making 
conclusions or even suggestions from these findings. An overview of the positively and/or negatively 
associated histological parameters among the different studies is presented in Table 3, grouped per 
adipokine. Efforts on finding any possible causes of this inconsistence revealed no results, as no patterns 
among the studies were found in, e.g. inclusion and exclusion criteria, age, number of patients, male-to-
female ratio, study groups or methods.     
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Table 3 Overview of the positively (+) or negatively (-) associated histological parameters, grouped per adipokine 
 Steatosis 
Portal 
inflammation 
Lobular 
inflammation 
Necroinflammation 
Hepatocellular 
ballooning 
Fibrosis 
Histological 
NAS 
Chemerin + ++   + + + + + + 
Resistin + + - +  +   + + + 
RBP4 +   -  + - + 
Visfatin - +    + - 
AFABP   +  + + +  
Vaspin     + +  
Apelin        
+, positive association; -, negative association; AFABP, adipocyte fatty acid binding protein; MCP-1, monocyte chemoattractant protein-1; NAS, nonalcoholic 
fatty liver disease (NAFLD) activity score RBP4, retinol binding protein-4.  
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Discussion 
This systematic review summarizes the growing body of literature suggesting that novel adipokines may 
modulate the clinical course of NAFLD. Of all seven novel adipokines described in literature as possible 
modulators of NAFLD, this review pointed out only three showing a potentially relevant association with 
disease progression. Both chemerin and AFABP were suggested to associate with hepatocyte ballooning 
degeneration in NAFLD patients, reported by at least two independent study groups. In case of 
chemerin, its hepatic expression was found to be associated with fibrosis, steatosis and inflammation as 
well, indicating a potential involvement of liver chemerin in the development of NASH. Although serum 
resistin had been most extensively studied throughout the last years, only half of the studies effectively 
reported significant associations with liver histology in NAFLD patients with grade of steatosis as the 
strongest associated parameter, followed by inflammation. Furthermore, contribution of SAT or VAT to 
serum resistin levels or NAFLD progression could not be derived from literature. Finally, contribution of 
RBP4, visfatin, vaspin and apelin to NAFLD progression could not be concluded from literature search, as 
results were mainly inconsistent or studies reported no significant findings. Although the pathogenesis 
of NAFLD remains unclear, it has been suggested that adipokines may promote hepatocellular damage, 
inflammation, fibrosis and progressive liver disease. Together with other recognized cytokines produced 
partially by inflammatory cells like macrophages infiltrating adipose tissue, they could play a role in 
pathogenesis of IR and NAFLD trough complex and interactive paracrine and endocrine mechanisms (56, 
57). Each adipokine, however, may have its specific molecular effects that will be discussed shortly in 
the following section and is summarized in Fig. 2.   
Increased levels of adipocyte-derived chemerin have been reported in patients with type 2 diabetes, an 
increase that parallels to the worsening of glucose tolerance status and associates with IR (58-60). 
Binding of chemerin to its chemokine-like receptor (CMKLR)-1 results in inflammatory effects by 
promoting the recruitment of cells of the innate immune system, i.e. macrophages and natural killer 
cells, to tissue injury sites (61). This could explain the results concerning a potential role of liver 
chemerin in the development of NASH, a well-known state of chronic inflammation. An elevated liver 
expression has also been demonstrated in NASH patients as well as NASH mice models compared with 
respective controls by Krautbauer et al., of which primary human hepatocytes were indicated as the 
major source of hepatic chemerin (62). Chemerin was also found to regulate adipocyte differentiation, 
lipid homeostasis and insulin sensitivity (60, 63, 64). In human skeletal muscle cells, chemerin was found 
to induce IR by inhibiting the insulin signaling pathway at the level of insulin receptor substrate-1 (IRS-1), 
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Akt and glycogen synthase kinase 3β (GSK3β). Furthermore, chemerin activated nuclear factor-κB 
(NFκB), a known inflammatory transcription factor (65). These effects on molecular level might similarly 
occur in hepatocytes, contributing to hepatic IR and inflammation that leads to NAFLD progression. 
 
 
Figure 2 Suggested adipokine-induced molecular regulation of signaling pathways in hepatocytes. In normal 
physiological conditions, insulin binding to its receptor induces a phosphorylation cascade. The phosphorylation of 
the insulin receptor substrates (IRS) and phosphatidylinositol 3-kinase (PI3K) followed by phosphorylation of 3-
phosphoinositide-dependent protein kinase (PDK), results in the phosphorylation and activation of Akt. Akt then 
phosphorylates numerous targets to promote glucose uptake, glycogen synthesis and inhibit hepatic glucose 
production (gluconeogenesis). Both chemerin and resistin are suggested to inhibit Akt phosphorylation and its 
downstream targets, interfering with insulin signaling and increasing glucose levels. Resistin has been found to 
activate peroxisome proliferator-activated receptor-γ co-activator 1α (PGC1α), leading to the transcriptional 
activation of gluconeogenic target genes, and to promote glucose-6-phosphatase to hydrolyse glucose-6-
phosphate into free glucose leading to an increased glucose output. Furthermore, it has been reported that 
resistin induces de novo lipogenesis by activating sterol regulatory element-binding protein-1 (SREBP-1), 
potentially promoting hepatic steatosis. Omentin is the only adipokine who is suggested to perform insulin-
sensitizing effects by stimulating Akt phosphorylation. Chemerin, resistin, adipocyte-fatty-acid-binding protein 
(AFABP) and monocyte chemoattractant protein-1 (MCP-1) are generally proposed to induce an inflammatory 
response by activating the nuclear factor-κB (NFκB) and c-Jun N-terminal kinase (JNK) pathway. Activation of NFκB 
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occurs primarily via activation of IκB kinase (IKK), leading to the release of its repressor IκB. Finally, these pro-
inflammatory adipokines were also found to promote the recruitment and activation of macrophages, resulting in 
the release of inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-12 (IL-12), IL-1β, AFABP 
and MCP-1, which in turn induce inflammation and even hepatic fibrogenesis. 
 
Although human data are still controversial, resistin is an adipokine that is predominantly secreted by 
adipocytes, inflammatory cells and hepatic stellate cells (HSC), which is believed to cause hepatic IR and 
bind immune cells (66-68). The liver has been suggested to be the major target site of resistin, with 
hyperresistinemia leading to increased glucose production and hepatic IR (69, 70). In rodent models, 
resistin has been reported to influence hepatic glucose and lipid metabolism and to play a major role in 
hepatic IR in response to a high-fat diet (71). On the basis of these animal studies, resistin has been 
proposed to represent a link among obesity, IR and NAFLD (66, 69, 72). In addition, resistin-deficient 
mice on a high-fat diet showed an ameliorated lipid profile and hepatic steatosis, suggesting a role of 
resistin in the induction of hepatic steatosis (73). Recently, Song et al. reported that resistin disrupted 
the phosphorylation of GSK3β in primary cultures of rat hepatocytes under high insulin and glucose 
levels, leading to lowered glycogen synthesis and hepatic insulin action (74). Furthermore, resistin is 
proposed to induce the secretion of inflammatory cytokines TNF-α and IL-12 from macrophages via an 
NFκB-dependent cascade (75).  
Increased levels of AFABP, a fatty-acid-binding chaperone that is mainly expressed by mature adipocytes 
and activated macrophages, have been associated with parameters of adiposity, IR and metabolic 
syndrome (76, 77). Similar to the results described in this review, studies have indicated an association 
of elevated serum AFABP levels with ultrasound-diagnosed NAFLD in both metabolically healthy (78) and 
type 2 diabetic subjects (79). Moreover, hepatic expression of AFABP has been shown to be elevated in 
chemically and diet-induced obese mice with NAFLD as well as in insulin resistant subjects with NAFLD 
(80, 81). Yoon et al. demonstrated a high expression of AFABP mRNA and protein in visceral fat and a 
higher ratio of visceral/liver for AFABP protein expression in patients with NASH versus non-NASH 
patients (82). In relation to NAFLD and metabolic syndrome, mice lacking AFABP were even protected 
against hepatic steatosis, IR and dyslipidemia in both genetic and diet-induced obesity (83, 84). 
Furthermore, the pharmacological inhibition of AFABP has led to an alleviation of both acute liver injury 
and NASH in mice (80). Notwithstanding the principal source of AFABP within the context of NAFLD is 
still contradictory, this adipokine is a key mediator of inflammatory response in macrophages. Its 
expression has been shown to be elevated in hepatic Kupffer cells in the presence of NAFLD, suggesting 
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that it may contribute to liver injury by recruiting a cluster of pro-inflammatory cytokines, including IL-
1β, IL-12 and TNF-α (85).   
Although not included in this systematic review because they were reported only once, two additional 
adipokines have been described in literature as potential modulators of NAFLD. Omentin is a VAT-
specific anti-inflammatory secretory protein that is synthesized by visceral stromal vascular cells, of 
which low serum levels have been reported in patients with obesity, IR and type 2 diabetes (86, 87). It is 
generally considered that omentin negatively associates with obesity and IR because of its insulin-
sensitizing effects, enhancing insulin-mediated glucose uptake and Akt phosphorylation in human 
adipocytes (88-90). Although these findings might predict a negative relation between omentin and 
NAFLD, Yilmaz et al. reported a positive association of elevated serum omentin levels with hepatocyte 
ballooning degeneration in patients with NAFLD (27). Because no additional studies were found that 
could confirm results, the possibility that higher omentin levels in these NAFLD patients merely result 
from a compensatory counter-regulatory mechanism to the increased IR could not be excluded. 
Secondly, the study group of Haukeland et al. analyzed serum levels of the inflammatory adipokine 
monocyte chemoattractant protein-1 (MCP-1) in healthy controls as well as biopsy-proven patients with 
NAFLD and NASH. They found that NAFLD and NASH significantly predicted higher MCP-1 levels 
independent of age, sex, BMI and metabolic syndrome and indicated the potential importance of MCP-1 
for the persistent inflammation in NAFLD (91). These findings corroborate those by Kirovski et al., 
reporting elevated serum MCP-1 in patients with ultrasound-diagnosed NAFLD and indicating elevated 
MCP-1 mRNA expression in liver and VAT of diet-induced steatotic mice (92). Two additional studies 
even reported elevated hepatic MCP-1 expression in patients with NAFLD but did not perform 
associations with liver histopathologic severity (93, 94). Animal models and human studies have 
reported that the expression and circulating levels of MCP-1 increase with obesity and associate with 
adiposity and IR (95-98). MCP-1 is known to play a pivotal role in the development of inflammatory 
responses as well as the recruitment of immune cells to sites of inflammation (99). Its role in 
inflammatory and fibrogenic processes has been demonstrated by inactivating MCP-1 or its receptor in 
experimental murine models of chronic liver injury. This resulted in a blockade of macrophage 
infiltration in the liver and inhibited HSC activation, which led to the suppression of hepatic 
inflammation and fibrosis (100, 101). Furthermore, an increased MCP-1 expression in adipose tissue has 
been suggested to contribute to macrophage infiltration, IR and hepatic steatosis in genetically as well 
as diet-induced obese mice (102).   
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In general, NAFLD has been proposed to develop according to a ‘multihit hypothesis’, with a 
dysregulated hepatic fatty-acid metabolism leading to simple steatosis as an initial insult (first hit). IR is 
suggested to play a central role in this first hit, contributing to an imbalance between the promotion of 
hepatic fat accumulation (fatty-acid influx and de novo lipogenesis) and its prevention (fatty-acid efflux 
and oxidation). Consequently, hepatocytes would become more susceptible to secondary insults, 
multiple hits like adipokines, inflammatory markers, oxidative stress and mitochondrial dysfunction, 
which lead to the progression of NAFLD to NASH (103, 104). Alterations in adipokine levels are thus 
suggested to be involved in this ‘multihit’ process, and their imbalance may play an important role in 
both the development of NAFLD and the progression to NASH (104). In the setting of liver injury, 
adipokines are suggested to induce increased reactive oxygen species (ROS) levels as well as activating 
the NFκB cascade, provoking HSC and Kupffer cells to produce inflammatory cytokines such as TNF-α 
and IL-6. Cytokines, in turn, promote collagen production, the progression of fibrosis, and inhibitory 
phosphorylation of IRS-1/2 that attenuates insulin signaling, leading to the development of NAFLD (Fig. 
2) (105). 
Although liver biopsy continues to be the gold standard in diagnosing NAFLD, there is a high need for 
less invasive diagnostic techniques because of the risk on comorbidities related to liver biopsy (106). 
This review cannot answer the question whether serum levels of these newly described adipokines are 
involved in NAFLD pathogenesis and whether they could be used as a non-invasive marker of NAFLD. 
Nevertheless, these results strengthen the potential role of several adipokines although future 
prospective studies are needed, evaluating their predictive and therapeutic potential within the clinical 
setting of NAFLD.   
This review has certain limitations, with the most crucial being the cross-sectional design of all included 
studies. This leads to inconclusive results concerning the potential role of studied adipokines in NAFLD 
progression, thereby not being able to indicate a cause-effect relationship. Up to date, no study has 
prospectively followed up adipokine levels in NAFLD patients, evaluating them when NAFLD progresses 
to NASH. Another limitation was the major heterogeneity observed across study results. Most 
importantly, the usage of different ELISA resulted in wide ranging adipokine amounts across different 
studies. Resistin levels, e.g. ranged from ±0.9 ng/ml in one study (37) to ±26 ng/ml in two other studies 
(36, 39). This leads to difficulties in comparing study results and even reduces the reliability of the 
results. Consequently, as a defined ‘normal range’ for adipokine serum concentrations does not exist 
yet, their potential usage as a disease biomarker is even more questionable. An important notification 
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concerning the inconsistent results of liver fibrosis is that the progression of liver fibrosis may occur over 
a longer period of time in NASH. Serum adipokine levels, however, are known to fluctuate over time, 
depending on the metabolic environment. Therefore, cross-sectional measurements of adipokines may 
variably correlate with the severity of liver fibrosis, depending on the time of determination (107). A 
final limitation is the heterogeneity across patient groups, reflecting the different study populations 
compared in studies or the lack of adjustment for several factors that may influence adipokine levels 
such as obesity or adiposity, IR, age or gender. 
In conclusion, clinical studies suggest that chemerin, resistin and AFABP are potentially involved in 
NAFLD pathogenesis and/or progression. Based on literature, most adipokines are suggested to be 
involved in the inflammatory response that develops within the context of NAFLD, at either hepatic or 
systemic level, and/or hepatic IR. However, data regarding the impact of these and other newly 
described adipokines on disease progression is still scarce and often confined to small patient numbers. 
There is a high need for longitudinal studies on larger and homogenous patient groups compared with 
carefully matched healthy controls, together with the need of a standardized assay to determine 
adipokine levels in serum. Once it has been clearly elucidated that adipokines are key players in the 
pathogenesis and progression of NAFLD, the pharmacologic manipulation of adipokines could be a 
feasible option in future therapeutics, and the use of adipokines as part of a non-invasive diagnostic tool 
for NAFLD could be of interest. 
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Abstract 
OBJECTIVE: We aimed to evaluate whether circulating levels and/or visceral adipose tissue (VAT) 
expression of recently described adipokines associate with histopathological severity of non-alcoholic 
fatty liver disease (NAFLD), independently from obesity and insulin resistance.  
METHODS: Serum levels of adiponectin, omentin, chemerin, monocyte chemoattractant protein-1 and 
secreted frizzled-related protein 4 were measured using enzyme-linked immunosorbent assay (ELISA) in 
81 patients with obesity and NAFLD and 18 lean control subjects. Expression in VAT was measured using 
real-time PCR and histopathological grading was scored using the NAFLD activity score (NAS).  
RESULTS: When NAFLD patients were subdivided into groups with simple steatosis, borderline NASH and 
NASH, adiponectin serum levels and omentin expression were lower in NASH versus simple steatosis 
patients. Serum adiponectin was generally lower with higher histopathological grading. Chemerin VAT 
expression was negatively associated with NAS (r=-0.331, P=0.022) and steatosis score (r=-0.335, 
P=0.020) independent of age, BMI and HOMA-IR. In addition, adjusting for chemerin VAT expression in a 
multivariate model explained part of the association between NAS and HOMA-IR. 
CONCLUSIONS: These findings suggest that lower VAT expression of chemerin in patients with obesity 
may be involved in the pathophysiology of hepatic steatosis, potentially by modulating the link between 
insulin resistance and NAFLD. 
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Introduction  
The growing epidemic of obesity has led to a simultaneously increased prevalence of non-alcoholic fatty 
liver disease (NAFLD), often referred to as the hepatic manifestation of metabolic comorbidity [1]. 
NAFLD is a chronic liver disease that encompasses a broad histopathological spectrum ranging from 
simple steatosis (SS) to non-alcoholic steatohepatitis (NASH), and is associated with a higher risk of 
developing cirrhosis and hepatocellular carcinoma [2]. To better address this growing health problem, 
more insight in the pathophysiology is needed.  
Recent data indicate that adipose tissue-derived secretory factors (adipokines) could play a role in the 
development of NAFLD and influence disease progression [3]. Many adipokines have already been 
described and several studies suggested that they play a role in whole body energy homeostasis and/or 
inflammatory responses [4], thus possibly influencing metabolic abnormalities in peripheral tissues in 
persons with obesity. Elevated chemerin levels have been described frequently in patients with 
metabolic syndrome and have been associated with body mass index (BMI), serum glucose, triglycerides 
(TG), high-density lipoprotein (HDL) cholesterol levels, and blood pressure [5]. Chemerin is also known 
to be involved in inflammation by inducing chemotaxis and to induce insulin resistance in skeletal 
muscle cells [6, 7]. In contrast, adiponectin and omentin have been found to display anti-inflammatory, 
insulin-sensitizing and cardioprotective properties [8, 9]. Monocyte chemoattractant protein-1 (MCP-1), 
an adipokine of which higher levels are described in obesity and insulin resistance, has also been 
suggested to play a role in hepatic inflammatory and fibrogenic processes [10, 11]. Finally, secreted 
frizzled-related protein 4 (SFRP4), a modulator of the Wnt signaling pathway, has also been described as 
an adipokine [12] and several Wnt pathway components are associated with lipid and glucose 
metabolism as well as inflammation [13]. Overall, hepatic insulin resistance, inflammation and 
modulation of the activity of Wnt signaling pathway have been reported repeatedly in NAFLD patients, 
suggesting a common link that potentially contributes to obesity-related NASH [1, 14, 15]. In this study, 
we assessed serum levels as well as visceral adipose tissue (VAT) expression of chemerin, adiponectin, 
omentin, MCP-1 and SFRP4 in patients with biopsy-proven NAFLD and lean controls. We hypothesized 
that a disturbed signature of these adipokines may contribute to the progression of SS to an 
inflammatory and insulin resistant NASH status. Therefore, we aimed to evaluate whether these 
adipokines associate with histopathological disease severity independently from known insulin 
resistance in obesity. 
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Subjects and methods 
Study design and subjects 
Ninety Caucasian patients with obesity (57 males and 33 females; mean BMI 41 kg/m2), aged between 
20 and 68, were recruited from the NASH and Hepobster cohort for evaluation in this study. All patients 
were scheduled for gastric banding or gastric bypass surgery and met the criteria for bariatric surgery of 
the International Federation for the Surgery of Obesity: BMI ≥40 kg/m2 or BMI ≥35 kg/m2 in conjunction 
with obesity-induced co-morbid conditions. Twenty men with obesity had type 2 diabetes. Liver and VAT 
biopsies were obtained during surgery and patients with other causes of liver disease, e.g. hepatitis B or 
C, viral or autoimmune hepatitis, Wilson disease or any drug-induced liver disease, or evidence of 
excessive alcohol consumption (≥20 g per day) were excluded. Additional exclusion criteria were primary 
hypogonadism, abnormal thyroid function, malignancies or carcinoma, serum total cholesterol >300 
mg/dl and/or TG >450 mg/dl. None of the subjects used steroids, insulin or thiazolidinediones, and oral 
glucose lowering-medication were discontinued prior to surgery. For comparison, 18 Caucasian control 
men (mean BMI 24 kg/m2; mean age 44±12 years) from the Hepobster cohort were recruited. These 
men underwent elective abdominal surgery for adhaesiolysis, hernia diaphragmatica, intestinal 
resection or Nissen fundoplication and VAT biopsies were obtained during surgery. Similar exclusion 
criteria as mentioned above were applied. In addition, all control subjects had overall good health 
without medication and with normal liver function tests (chronic elevation of transaminase levels 
indicates liver disease, i.e. >1.5 times the upper normal value for ≥3 months). The study protocol was 
approved by the Ethics Committee of Ghent University Hospital and conducted according to the 
principles of the Declaration of Helsinki. All participants gave their written informed consent. 
Anthropometry and biochemical assays 
Anthropometric measurements were performed during a pre-operative examination. Body weight was 
measured to an accuracy of 0.1 kg in light indoor clothing without shoes, whereas height was measured 
using a wall-mounted stadiometer. Blood samples were collected after overnight fasting, prior to 
surgery, and were centrifuged, fractionated and stored at -80°C until analysis. Triglyceride and glucose 
levels were determined colorimetrically (Roche Diagnostics, Mannheim, Germany) and insulin levels 
were measured using electrochemoluminescent immunoassay (Modular immunoassay, Roche 
Diagnostics). Homeostasis model of the assessment for insulin resistance (HOMA-IR) was calculated with 
the following formula: (fasting glucose [mmol/L] x fasting insulin [µU/mL])/22.5]. Aspartate 
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aminotransferase (AST), alanine aminotransferase (ALT), ɣ-glutamyltransferase (GGT) and C-reactive 
protein (CRP) were routinely measured using a conventional automated analyser. 
Measurement of adipokine levels 
Serum levels of adipokines were measured using commercial enzyme-linked immunosorbent assay 
(ELISA) kits, according to manufacturer’s instructions. Chemerin, MCP-1 and adiponectin were 
determined with kits provided by R&D Systems (Minneapolis, MN, USA). The respective intra- and 
interassay coefficients of variation (CV) were 2.8% and 6.4% for chemerin, 4.9% and 4.6% for MCP-1, 
and 4.7% and 4.9% for adiponectin. Omentin serum levels were assessed using the Human Omentin-1 
ELISA kit from BioVendor (Brno, Czech Republic). Intra- and interassay CV were 3.7% and 4.6%, 
respectively, for omentin. Circulating levels of SFRP4 were measured using the USCN Life Sience ELISA kit 
(Hoelzel Diagnostika, Cologne, Germany). Intra- and interassay CV for the SFRP4 were <10% and <12%, 
respectively. 
For gene expression analysis, VAT biopsies were collected from the gastrosplenic or gastrocolic 
ligaments at the end of surgery from 63 male subjects of the Hepobster cohort (13 controls and 50 
subjects with obesity), immediately frozen and stored at -80oC until further use. RNA was isolated from 
100 mg of the frozen fat samples with the Tripure Isolation Reagent kit (Roche Diagnostics) according to 
manufacturer’s instructions. Contaminating genomic DNA was removed with RNase-free DNase 
incubation (Qiagen, Hilden, Germany), followed by a clean-up step with the RNeasy Mini Kit (Qiagen). 
cDNA synthesis was carried out using the Go Script Reversed Transcription System (Promega, 
Mannheim, Germany) according to manufacturer’s instructions. Expression of MCP-1 and chemerin was 
quantified by real-time PCR using the following QuantiTect primer assays: Hs_CCL2_1_SG (MCP-1, CCL2 
gene; Cat#QT00212730), Hs_RARRES2_1_SG (chemerin, RARRES2 gene; Cat#QT00091945) (Qiagen). 
Primers to measure omentin (INTL1 gene) and SFRP4 expression were TCAGCTTCCTGCTGTTTCTCATA 
and GGAGACGAAGAACAGGTCCATT for omentin and CACCCATCCCTCGAACTCAA and 
TGTGTGGACACTGGCAAGAAG for SFRP4 (Eurogentec, Köln, Germany). Real-time PCR analysis was 
carried out on a StepOne Plus system (Applied Biosystems) with GoTaq qPCR Master Mix (Promega). 
Gene expression levels were calculated from the obtained threshold cycle (Ct) values after normalization 
for the expression of stable reference genes, UBE2D2, YWHAZ, (Eurogentec) and RPS18 (QuantiTect 
Primer Assay, Cat#QT02323251, Qiagen), using Qbase Plus software (version 2.6; Biogazelle, Ghent, 
Belgium). 
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Hepatic histopathological analysis 
Liver biopsies were obtained from all subjects with obesity at the end of surgery, each measuring 5 by 5 
mm, and were taken from the lateral edge of the left liver lobe (segment 3) using bipolar forceps. These 
were immediately fixated in formalin (buffered 4% paraformaldehyde solution; Klinipath, Belgium) at 
room temperature for microscopic analysis. Formalin fixed liver biopsies were routinely processed and 
stained with hematoxylin-eosin and Masson trichrome. An experienced pathologist (M.P.) established 
the histological diagnosis of NAFLD according to the scoring system of Kleiner et al. [16], blinded to 
characteristics of participants. At least 6 complete portal tracts in liver specimen were required for 
adequate histological evaluation. Steatosis was judged as the percentage of hepatocytes containing fat 
droplets, with a minimum of 5%. NAFLD activity score (NAS) is defined as the unweighted sum of scores 
for steatosis intensity (0-3; <5%, 5-33%, 33-66% or >66%), lobular inflammation (0-3; no, <2, 2-4 or >4 
inflammatory foci), and hepatocellular ballooning (0-2; no, few or many ballooning cells), ranging from 0 
to 8 (Figure 1). Scores of 0-2 were considered as SS and scores of >5 were considered as NASH. 
Intermediate scores of 3 or 4 were considered as borderline NASH [16]. Stage of fibrosis was scored 
using a 4-point scale.  
Statistics 
Statistical analysis was performed using IBM SPSS Statistics (version 21.0). Data distribution of 
continuous variables was evaluated with the Kolmogorov-Smirnov test. Normally distributed variables 
were expressed as mean +/- SD, whereas non-Gaussian distributed variables were described as median 
(interquartile range). Adipokines were compared among the different subject groups, i.e. lean subjects, 
subjects with obesity but without NAFLD and subjects with obesity and NAFLD. Furthermore, among 
NAFLD patients, adipokines were compared between patients with low, moderate or high level of 
histopathological severity, i.e. degree of steatosis, hepatocyte ballooning, lobular inflammation and 
fibrosis. For these comparison analyses among the different study groups and histological parameters, 
ANOVA and Tukey HSD post hoc test or Kruskal-Wallis and Mann-Whitney U test were applied. 
Categorical variables were analyzed with the Chi-square test and Fisher’s test. Multivariate analysis was 
performed to identify independent factors associated with disease severity in NAFLD patients. Our 
findings were adjusted for potential confounders such as age, BMI and insulin resistance, using 
multivariate linear regression analysis (ENTER model). 
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Figure 1 Three different examples of histopathological scoring according to non-alcoholic fatty liver disease (NAFLD) activity score (NAS). 1A is an example of a 
low NAS (steatosis, grade 2; ballooning, grade 0; lobular inflammation, grade 0; NAS 2) diagnosed as simple steatosis. 1B is an example of an intermediate NAS 
(steatosis, grade 2; ballooning, grade 1; lobular inflammation, grade 1; NAS 4) diagnosed as mild steatohepatitis or borderline NASH. 1C is an example of a high 
NAS (steatosis, grade 2; ballooning, grade 2; lobular inflammation, grade 1; NAS 5) diagnosed as definite steatohepatitis or NASH. (10X, Hematoxylin and 
Eosin).
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Results 
General characteristics, adipokine serum levels and VAT expression in controls and NAFLD patients 
A total of 108 subjects were included in the study cohort (75 males and 33 females), including 18 
normal-weight controls, 9 patients with obesity but without NAFLD and 81 patients with obesity and 
biopsy-proven NAFLD. NAFLD patients had higher BMI, insulin levels, HOMA-IR, ALT, GGT and CRP levels 
compared to normal-weight controls, while there were no differences in TG and AST levels. 25% of 
NAFLD patients had type 2 diabetes, whereas none of the controls or obese patients without NAFLD had 
diabetes (Table 1). 
Serum adiponectin levels were lowest in NAFLD patients compared to normal-weight controls and obese 
patients without NAFLD (P=0.004 and 0.020, respectively), whereas serum MCP-1 levels were lowest in 
the obese without NAFLD group versus controls and NAFLD patients (P<0.05). Chemerin serum levels 
were higher in NAFLD patients compared to normal-weight controls (P=0.020). Circulating omentin and 
SFRP4 levels were not different among the groups. With regard to adipokine VAT expression, omentin 
and SFRP4 were higher (P=0.043 and <0.001, respectively) and chemerin tended to be lower in NAFLD 
patients compared to normal-weight controls (P=0.053). MCP-1 expression was similar between control 
and NAFLD patients (Table 1). 
General characteristics and adipokine levels according to disease severity in NAFLD patients 
Potential differences in circulating adipokine levels and VAT expression were examined in relation to 
disease severity. From the 81 patients with obesity diagnosed with NAFLD, 32 subjects had SS, 24 
subjects borderline NASH and 25 subjects confirmed NASH. General characteristics as well as adipokine 
levels among groups are listed in Table 2. There were no differences in gender, age, BMI, fasting glucose 
and insulin, TG, ALT and CRP levels among the groups. HOMA-IR, AST and GGT levels were higher in both 
borderline and confirmed NASH patients as compared to those with SS (P=0.033, 0.023 and 0.002, 
respectively). There were no clinical or biochemical differences between borderline NASH and NASH 
patients. 
Serum levels of adiponectin were lower in NASH patients compared to patients with SS (P=0.030). The 
other serum adipokines were not different among the three NAFLD groups. Similarly, there were no 
differences in VAT expression of adipokines among the groups, except for lower omentin expression in 
patients with NASH versus patients with SS (P=0.043). 
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Table 1 General characteristics of healthy controls, obese patients without NAFLD and obese NAFLD 
patients 
Parameter 
Healthy controls 
(N=18) 
Obese w/o NAFLD 
(N=9) 
NAFLD patients 
(N=81) 
P value 
General characteristics     
M/F 18/0 2/7***
##
 55/26** < 0.001 
T2D 0  0  20 (25%)* 0.017 
Age, years 44 ± 12 45 ± 9 45 ± 10 0.995 
BMI, kg/m² 24 [22-26] 36 [34-41]***
#
 41 [38-44]*** < 0.001 
Glucose, mmol/L 5.44 [4.63-5.84] 5.11 [4.78-5.86] 5.33 [4.78-6.31] 0.766 
Insulin, pmol/L 25.7 [21.1-40.4] 57.1 [35.8-111.1]** 92.9 [57.5-150.9]*** < 0.001 
Triglycerides, mg/dl 
156.0 [111.5-204.9] 
104.0 [70.5-
139.5]*
###
 
185.0 [144.0-241.0] < 0.001 
HOMA-IR 0.87 [0.60-1.47] 1.79 [1.04-3.89]** 3.21 [1.92-6.10]*** < 0.001 
AST, IU/L 22.0 [17.8-33.0] 20.0 [15.5-22.0]
#
 28.0 [20.0-40.0] 0.023 
ALT, IU/L 11.3 [8.5-29.5] 21.0 [9.0-26.5] 25.0 [14.5-36.5]* 0.036 
GGT, U/I 22.2 [16.0-29.2] 15.0 [10.5-31.0]
#
 30.0 [19.5-50.5]* 0.009 
CRP, mg/L 1.05 [0.60-2.20] 0.50 [0.15-5.30] 3.00 [1.10-5.35]* 0.046 
Serum adipokine levels     
Omentin, ng/ml 398.2 [336.0-490.3] 394.9 [263.4-534.8] 391.6 [307.1-480.7] 0.894 
Adiponectin, mg/ml 6.15 [5.30-10.89] 9.45 [4.10-12.54]
#
 4.28 [2.94-7.11]** 0.002 
Chemerin, ng/ml 164.7 [112.1-211.0] 177.5 [155.2-235.4] 200.3 [146.6-256.1]* 0.063 
MCP-1, pg/ml 
288.6 [239.5-354.0] 
210.1 [192.0-
234.8]*
##
 
299.5 [252.4-395.6] 0.010 
SFRP4, pg/ml 4569.0 ± 2833.8 4255.6 ± 2351.4 4650.8 ± 1805.0 0.709 
Adipokine VAT expression, AU    
N 15  48  
Omentin 1.42 [0.07-13.98]  6.17 [1.98-22.28]* 0.043 
Chemerin 1.09 [0.81-1.46]  0.87 [0.62-1.07] 0.053 
MCP-1 1.91 [0.20-5.05]  0.58 [0.36-1.59] 0.488 
SFRP4 1.01 [0.67-1.23]  2.86 [1.75-4.32]*** < 0.001 
Data are presented as median [interquartile range] and were analyzed using Mann-Whitney U test and Chi-square test for 
categorical variables. * vs healthy controls; # vs NAFLD patients. * P < 0.05; ** P < 0.01; *** P < 0.001. ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CRP, C-reactive protein; GGT, gamma-
glutamyltransferase; M/F, male-to-female ratio; NAFLD, non-alcoholic fatty liver disease; T2D, type 2 diabetes; w/o, without. 
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Table 2 Clinical and biochemical characteristics of obese NAFLD patients with simple steatosis, borderline NASH and NASH  
Parameter SS (N=32) Borderline NASH (N=24) NASH (N=25) P 
Histological grading according to NAS   
NAS 1-2 3-4 5-8 < 0.001 
Steatosis grade (0/1/2/3) 0/26/6/0 0/8/15/1 0/0/5/20 < 0.001 
Lobular inflammation 
(0/1/2/3) 
27/5/0/0 4/20/0/0 2/16/6/1 < 0.001 
Hepatocellular ballooning 
(0/1/2) 
31/1/0 2/21/1 0/7/18 < 0.001 
Fibrosis (0/1/2/3/4) 23/8/1/0/0 6/11/7/0/0 2/12/6/3/1 < 0.001 
Clinical and biochemical characteristics    
M/F 19/13 17/7 19/6 0.384 
T2D 4 (12.5%) 10 (42%) 6 (24%) 0.043 
Age, years 43 ± 11 47 ± 11 46 ± 10 0.360 
BMI, kg/m² 42 [39-46] 39 [36-44] 42 [37-43] 0.302 
Glucose, mmol/L 5.25 [4.69-5.67] 5.39 [4.74-7.21] 5.56 [4.97-6.58] 0.376 
Insulin, pmol/L 78.0 [47.9-119.9] 107.6 [76.7-158.8]* 103.7 [57.1-229.2] 0.095 
Triglycerides, mg/dl 178.5 [118.8-215.2] 208.5 [161.8-258.5]* 174.0 [143.5-288.5] 0.129 
HOMA-IR 2.41 [1.70-4.08] 4.00 [2.20-7.00]* 3.50 [1.97-8.19]* 0.033 
AST, IU/L 24.5 [17.0-33.5] 25.5 [20.5-40.0] 34.0 [25.0-55.7]** 0.023 
ALT, IU/L 21.2 [15.3-34.0] 29.5 [11.5-35.8] 28.0 [10.0-45.4] 0.607 
GGT, U/I 23.2 [16.0-34.8] 32.0 [20.0-54.5]* 41.5 [28.5-66.5]** 0.002 
CRP, mg/L 2.30 [1.10-5.60] 2.10 [0.70-5.18] 4.10 [1.65-5.48] 0.436 
Serum adipokine levels   
Omentin, ng/ml 363.4 [301.8-492.5] 430.3 [313.5-519.7] 353.3 [293.5-437.9] 0.234 
Adiponectin, mg/ml 5.08 [3.56-8.36] 3.99 [2.83-6.39] 4.18 [2.37-4.75]* 0.063 
Chemerin, ng/ml 203.0 [154.0-271.5] 195.9 [147.6-255.7] 202.4 [139.9-232.2] 0.759 
MCP-1, pg/ml 282.7 [239.9-396.9] 319.9 [274.2-408.5] 300.7 [263.3-381.3] 0.531 
SFRP4, pg/ml 4725.7 ± 1414.3 4273.4 ± 1754.7 4939.9 ± 2167.4 0.673 
Adipokine VAT expression, AU (N=48)   
N 16 16 16  
Omentin 16.78 [3.59-36.15] 5.28 [1.59-26.11] 5.87 [1.63-10.86]* 0.166 
Chemerin 0.88 [0.65-1.25] 0.97 [0.66-1.07] 0.69 [0.56-0.92] 0.260 
MCP-1 0.52 [0.32-2.18] 0.54 [0.32-1.35] 0.66 [0.40-1.43] 0.896 
SFRP4 3.78 [1.85-4.59] 2.54 [1.68-3.96] 2.99 [2.07-4.38] 0.484 
* vs  SS. Data are presented as number of cases and median [interquartile range] and were analyzed using Kruskal Wallis and Mann-Whitney U test. ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CRP, C-reactive protein; GGT, gamma-glutamyltransferase; M/F, male-to-female ratio; MCP-1, 
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monocyte chemoattractant protein-1; NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD activity score; Sfrp4, secreted frizzled-related protein 4; T2D, type 2 diabetes; VAT, 
visceral adipose tissue. 
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Associations between adipokines and histopathological grading. 
We next examined whether adipokine levels and VAT expression were related to the various 
histopathological states. As shown in Figure 2, serum adiponectin levels (r=-0.308, P=0.005; Figure 2A), 
and chemerin VAT-expression (r=-0.331, P=0.022; Figure 2B) negatively associated with NAS. The other 
adipokines were examined similarly and showed no significant relations with NAS. 
 
 
Figure 2 The inverse relationship between disease severity, presented as the non-alcoholic fatty liver disease 
(NAFLD) activity score (NAS), and ln-transformed serum adiponectin (A; N = 81) as well as visceral adipose tissue 
expression of chemerin (B; N = 63) in biopsy-proven NAFLD patients. 
 
When considering the individual histopathological parameters, it was found that serum adiponectin 
levels and chemerin VAT expression were lower in patients with moderate or severe steatosis (>33%) 
versus patients with mild steatosis (<33%) (P=0.001 and 0.007, respectively; Figure 3 and Figure 4). 
Furthermore, serum adiponectin was lower in patients with higher grades of hepatocyte ballooning, 
lobular inflammation and fibrosis (all P<0.05; Figure 4). There were no differences in levels of other 
adipokines, both serum levels and VAT expression, according to histopathological grading. 
Finally, we investigated whether serum adiponectin and chemerin VAT expression function as 
independent predictors of NAS in addition to known confounders such as HOMA-IR and BMI. Among 
these NAFLD patients, BMI was similar in patients with different grades of histopathological parameters 
and did not correlate with overall NAS. In contrast, HOMA-IR was higher in patients with higher grades 
of steatosis, hepatocyte ballooning and lobular inflammation (all P<0.05) and was positively associated 
with NAS (r=0.285, P=0.010).  
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Figure 3 Chemerin VAT expression was inversely associated with steatosis grade (P=0.007; Kruskal Wallis test). 
Expression was highest in patients with < 33% of steatosis and was lower in patients with moderate (33-66%) to 
severe (> 66%) steatosis grade. * P < 0.05; ** P < 0.01. 
 
 
Figure 4 Adiponectin serum levels among the histopathological parameters in NAFLD patients. Serum adiponectin 
was inversely associated with the grade of steatosis (A), hepatocyte ballooning (B), lobular inflammation (C), and 
fibrosis (D) (P=0.001, P=0.033, P=0.027 and P=0.042 respectively; Kruskal Wallis test among groups), with lower 
levels in patients with higher grades. * P < 0.05; ** P < 0.01. 
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Multivariate linear regression analysis was performed to identify independent predictors of NAS in 
NAFLD patients (Table 3). Whereas the association between HOMA-IR and NAS was independent of sex, 
age and BMI (model 1), it lost significance after correcting for chemerin VAT. Chemerin VAT expression 
remained negatively associated with NAS independent of age, BMI and HOMA-IR in male NAFLD patients 
(model 2), whereas adiponectin serum levels were no longer associated with NAS after correcting for 
sex, age, BMI and HOMA-IR (model 3). In a final model, adjusting for adiponectin levels made the 
relation between chemerin VAT expression and NAS borderline significant (β=-0.284, P=0.072; model 4). 
 
Table 3 Multivariate linear regression model with NAS as dependent variable in biopsy-proven NAFLD 
patients 
 
 
Independent 
variables 
Model 1 
F 3.028; R
2
 0.139 
 
β (±SE); P value 
Model 2 
F 3.209; R
2
 0.234 
 
β (±SE); P value 
Model 3 
F 2.742; R
2
 0.156 
 
β (±SE); P value 
Model 4 
F 2.678; R
2
 0.246 
 
β (±SE); P value 
Sex 0.244 (±0.476); 0.035 Constant 0.209 (±0.511); 0.090 Constant 
Age 0.205 (±0.951); 0.085 0.103 (±1.172); 0.505 0.223 (±0.951); 0.062 0.114 (±1.182); 0.465 
HOMA-IR 0.275 (±0.265); 0.020 0.244 (±0.286); 0.088 0.210 (±0.302); 0.116 0.185 (±0.323); 0.248 
BMI -0.056 (±1.484); 0.643 -0.211 (±2.062); 0.150 -0.047 (±1.477); 0.693 -0.202 (±2.077); 0.170 
Chemerin VAT 
expression 
 -0.317 (±0.797); 0.038  -0.284 (±0.830); 0.072 
Serum 
adiponectin 
levels 
  -0.135 (±0.379); 0.313 -0.128 (±0.454); 0.422 
The independent variables in the different models were: Model 1: sex, age, HOMA-IR and BMI; Model 2: sex was constant, age, 
HOMA-IR, BMI and chemerin visceral adipose tissue (VAT) expression; Model 3: sex, age, HOMA-IR, BMI and serum adiponectin 
levels; Model 4: sex was constant, age, HOMA-IR, BMI, chemerin VAT expression and serum adiponectin levels. Data are 
presented as β coefficients with standard error (SE) of the predicted coefficients (B) and F and R
2
 values are given per model. 
Because VAT was only sampled from male patients with NAFLD, sex was constant in Model 2 and Model 4. HOMA-IR, 
homeostasis model of the assessment for insulin resistance; NAS, non-alcoholic fatty liver disease (NAFLD) activity score. 
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Discussion 
In a group of biopsy-proven NAFLD patients with obesity, we found lower adiponectin and higher 
chemerin serum levels as compared to healthy control subjects. Adiponectin, but not chemerin serum 
levels were also associated with disease severity and grade of steatosis. In contrast to the serum levels, 
chemerin VAT expression appeared inversely associated with NAFLD severity, as expression was 
significantly lower in patients with higher degrees of steatosis and overall NAS. This finding persisted 
after adjustment for age, BMI and HOMA-IR. Further, our results suggest that the well-established link 
between insulin resistance and NAFLD/NASH might in part be dependent on VAT expression of 
chemerin. 
NAFLD develops when surplus fat accumulates in the liver, which might be both resulting from and 
contributing to insulin resistance. Indeed, insulin resistance is known to result in an increased hepatic de 
novo lipogenesis, together with an increased delivery of lipids to the liver [17]. The prevalence and 
severity of NAFLD have been strongly related to BMI, waist circumference, hyperinsulinemia, 
hypertriglyceridemia, impaired glucose tolerance and type 2 diabetes, which are all metabolic 
parameters with the common underlying factor insulin resistance [18, 19]. Although NAFLD severity did 
not associate with BMI in this study, HOMA-IR was associated with steatosis, hepatocyte ballooning and 
lobular inflammation score and with overall NAS independent of sex, age and BMI  
Our study also showed an inverse association between serum adiponectin levels and grade of steatosis, 
lobular inflammation, hepatocyte ballooning, fibrosis and overall NAS, corroborating previous findings 
[20]. Adiponectin has an anti-steatotic effect on hepatocytes by increasing fatty acid oxidation and 
decreasing gluconeogenesis, fatty acid influx and de novo lipogenesis [21]. Additionally, anti-
inflammatory and anti-fibrotic effects of hepatic adiponectin have been reported [22]. Recently, a meta-
analysis confirmed lower adiponectin levels in NASH/NAFLD compared to controls [23]. The few 
prospective studies with paired liver biopsies however, reported conflicting results and could not always 
associate adiponectin with NAFLD progression [24, 25]. In our multivariate analysis, the association 
between NAS and adiponectin was lost when HOMA-IR was added to the model, suggesting that insulin 
resistance might mediate the relation between NAFLD and adiponectin. Since adiponectin is highly 
associated with insulin resistance, these findings suggest that low circulating levels of adiponectin may 
contribute to insulin resistance, which in turn may influence NAFLD.  
Chemerin has been described as a marker of insulin resistance, with both higher serum levels and 
adipose tissue expression in patients with impaired glucose tolerance or type 2 diabetes [26, 27]. 
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Chemerin has been reported to interfere with insulin signaling in skeletal muscle cells and to be 
implicated in the regulation of inflammation, suggesting a potential involvement in NAFLD [6, 7]. Indeed, 
several studies have reported elevated serum or hepatic expression levels of chemerin in NAFLD and/or 
NASH patients and found positive associations with NAS or hepatic inflammation [28, 29]. In this study, 
serum chemerin levels were higher in NAFLD patients with obesity compared to controls; however, they 
were similar among the three NAFLD groups and were not related to histopathological severity. In 
contrast, chemerin VAT expression had a tendency to be lower in patients with NAFLD versus controls 
and was lower in patients with higher grades of steatosis compared to lower steatosis grades. Chemerin 
expression was moderately negatively associated with NAS, independent of confounding factors. 
Moreover, the association between HOMA-IR and NAS lost significance after correcting for chemerin 
VAT expression, suggesting that chemerin may at least partly influence the link between HOMA-IR and 
NAFLD severity. Recently, Wolfs et al. similarly reported a negative association between chemerin VAT 
expression and histopathological parameters of NAFLD patients. In their study, chemerin expression was 
negatively associated with steatosis, lobular and portal inflammation, independent of obesity, HOMA-IR 
and type 2 diabetes [30]. Experimental studies have reported inconsistent results, indicating both pro- 
and anti-inflammatory properties of chemerin. It has been described as a chemoattractant of innate 
immune cells such as Kupffer cells, which in turn are believed to be key players in the pathophysiology 
of NAFLD [31]. However, while a mouse model with diminished chemerin action showed no effects on 
insulin resistance and NAFLD compared to wild type [32], the administration of recombinant chemerin 
attenuated the inflammatory response in another model [33]. Although the associations were 
moderate, the anti-inflammatory effects of chemerin and its negative association with NAS suggest that 
this lower VAT expression of chemerin in patients with obesity may be involved in the pathophysiology 
of NAFLD. Importantly, none of the adipokine serum levels were associated with their respective VAT 
expression. As the majority of blood flow (±80%) to the liver is delivered via the portal vein, which is 
closely connected to VAT, it is likely that systemic serum concentrations of adipokines do not accurately 
reflect hepatic delivery of adipokines. Furthermore, secretion of adipokines is different between 
subcutaneous adipose tissue (SAT) and VAT, of which SAT is suggested to contribute more to systemic 
levels. Indeed, Alfadda et al. recently highlighted the differential expression of chemerin between SAT 
and VAT in subjects with obesity, with higher expression in SAT [34]. 
Other adipokines neither associated with histological parameters nor with NAFLD severity in our cohort. 
VAT expression of omentin and SFRP4 were significantly higher in subjects with obesity versus controls, 
without differences in serum levels. This counteracts with the description of omentin in literature as an 
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anti-inflammatory and insulin-sensitizing adipokine, of which low serum levels have been reported in 
patients with obesity, insulin resistance and type 2 diabetes [35]. NAFLD and higher degree of 
hepatocyte ballooning in biopsy-proven NAFLD patients have previously been positively associated with 
serum omentin levels [36]. Higher levels of SFRP4 have been linked to type 2 diabetes and obesity [37] 
and could be related to NAFLD because a mouse model with the hepatocyte-specific knockout of the 
canonical Wnt pathway was more sensitive to develop NASH and fibrosis compared to wild type [38]. 
However, we investigated SFRP4 levels in human NAFLD for the first time and could not confirm this. 
Finally, although serum MCP-1 levels were lower in the small group of patients with obesity but without 
NAFLD, serum levels nor VAT expression were associated with histopathological severity. This contrasts 
with experimental studies suggesting involvement of MCP-1 in hepatic inflammation [10, 11] and 
reports of higher MCP-1 levels in NAFLD patients [39]. 
This study has some limitations. Firstly, the cross-sectional design does not allow to indicate a causative 
link or to address the mechanisms behind the observed associations. These results are thus merely 
suggestive and need further investigation in larger-scaled prospective studies. The use of paired biopsies 
could allow investigating changes of certain adipokines when NAFLD progresses or regresses over time. 
Next, the relatively small sample size among study groups limits the generalizability of our results and 
conclusions. Thirdly, patients with obesity, type 2 diabetes and NAFLD are closely linked because of the 
common causative factor insulin resistance, which makes it difficult to distinguish metabolic 
confounding factors. Furthermore, it is known that VAT, and not SAT, is strongly associated with NAFLD 
severity [40]. In this cohort, adipose tissue distribution was not assessed, which might potentially 
explain the lack of association between BMI and NAFLD. Finally, although liver biopsy is recognized to be 
the golden standard to diagnose NAFLD, the chance of sampling error remains inevitable. 
In summary, we found that in patients with obesity and NAFLD, disease severity and the degree of 
hepatic steatosis inversely associate with chemerin VAT expression independent of insulin resistance. 
These findings suggest a potential role of lowered chemerin VAT expression in the pathophysiology of 
hepatic steatosis. Moreover, chemerin VAT expression even appears to modulate the relation between 
NAFLD severity and insulin resistance. More knowledge on the determinants of chemerin VAT 
expression might help to elucidate the relation between both consequences of obesity.  
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4.1. Determinants of testosterone levels in human male obesity 
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Abstract 
Testosterone (T) levels are decreased in obese men, but the underlying causes are incompletely 
understood. Our objective was to explore the relation between low (free) T levels and male obesity, by 
evaluating metabolic parameters, subcutaneous adipose tissue (SAT) aromatase expression and 
parameters of the hypothalamic-pituitary-gonadal axis. We recruited 57 morbidly obese men (33 had 
type 2 diabetes (DM2)) and 25 normal-weight men undergoing abdominal surgery. Fourteen obese men 
also attended a follow-up, 2 years after gastric bypass surgery (GBS). Circulating T levels were quantified 
by LC-MS/MS, whereas free T levels were measured using serum equilibrium dialysis and SHBG, LH and 
FSH by immunoassay. SAT biopsies were used to determine adipocyte cell size and aromatase 
expression by real-time PCR. Total and free T levels were decreased in obese males vs. controls, with a 
further decrease in obese men with DM2 versus obese men without DM2. There were no differences in 
aromatase expression among the study groups and sex steroids did not correlate with aromatase 
expression. Pearson analysis revealed an inverse association between (free) T and SAT cell size, 
triglycerides and HOMA-IR. Multivariate analysis confirmed the inverse association between (free) T and 
SAT cell size (β=-0.321, P=0.037 and β=-0.441, P=0.011; respectively), independent of age, triglycerides, 
HOMA-IR, obesity or diabetes. T levels were normalized 2 years after GBS. These data suggest SAT cell 
size rather than SAT aromatase expression or parameters of the hypothalamic-pituitary-gonadal axis is 
related to low T in male obesity, which points to adipose cell size-related metabolic changes as a major 
trigger in decreased T levels. 
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Introduction 
The relationship between decreased testosterone (T) levels and male obesity is incompletely 
understood. In general, the synthesis of T by Leydig cells in the testis is stimulated by luteinizing 
hormone (LH) together with follicle-stimulating hormone (FSH). Estradiol (E2) is known to be an 
important down-regulator of serum T levels by inhibiting the release of these gonadotropins from the 
pituitary gland [1,2]. Some studies suggest that an increased activity of aromatase, the enzyme 
converting T into E2, in adipose tissue may contribute to elevated E2 levels in obese men [3,4]. However, 
data on E2 levels in obese men are inconsistent, as some studies reported increased E2 levels while 
others reported no changes or even lower levels [5-7]. Alternatively, abdominal obesity itself may 
contribute to the decline in circulating T levels [8,9]. Obesity leads to an expansion of fat (hypertrophy of 
adipocytes), which is associated with a deteriorated metabolic profile, including glucose intolerance, 
dyslipidemia, hypertension and inflammation [10,11]. Prospective studies have shown that both 
adiposity as well as presence of the metabolic syndrome are predictive of future low T levels and could 
accelerate the age-related decline of T [12,13]. Consistently, weight loss has led to increased T levels in 
obese men [14,15]. Although the underlying mechanisms are still unclear, these findings suggest that 
hypertrophy of the adipocytes and its related metabolic changes may associate with the decline in T 
levels in obese men.  
This cross-sectional study aimed to explore potential determinants of (free) T levels in a cohort of 
morbidly obese men with and without type 2 diabetes as well as men with normal body weight. 
Specifically, associations with adipose tissue aromatase expression levels, subcutaneous adipose tissue 
(SAT) cell size, insulin resistance and triglyceride (TG) levels (marker of adiposity), were examined. 
Furthermore, the effects of weight loss following gastric bypass surgery (GBS) on (free) T levels and 
potential determinants thereof were examined in morbidly obese men at a follow-up examination 2 
years after GBS.  
 
  
 
 
136 
 
Research design and methods 
Subjects 
The study cohort consisted of twenty-five normal-weight and fifty-seven morbidly obese men. Thirty-
three of the morbidly obese men had type 2 diabetes according to the American Diabetes Association 
(ADA) criteria [16]. All men were scheduled for abdominal surgery. The obese men underwent GBS, and 
normal-weight men had surgery for adhaesiolysis, rupture of the stomach, intestinal resection, stomach 
closing or Nissen fundoplication. Obesity was defined as BMI > 30 kg/m2. Although having abdominal 
surgery, the normal-weight men had an overall good health. Participants with primary hypogonadism, 
abnormal thyroid function, hepatitis or malignancies, serum total cholesterol > 300 mg/dl and/or serum 
TG > 450 mg/dl were excluded. None of the subjects used steroids, and oral glucose lowering-
medication were discontinued prior to surgery. A subgroup of thirty-six patients that underwent GBS 
was invited for a follow-up examination, when two years had passed since surgery. Fourteen of them 
were willing to participate (39 %). Subjects attending follow-up were not using sex steroids or other 
androgen-related drugs and three out of fourteen subjects were using metformin medication. The study 
was approved by the institutional ethics committee and participants gave their written informed 
consent, which was validated by the Ethical Review Board of Ghent University Hospital and conducted 
according to the principles of the Declaration of Helsinki (Registration no B67020084018). 
At baseline and during follow-up, clinical and anthropometric parameters were assessed as described 
previously [17].  The fat percentage of body weight (fat %) was estimated by bio-impedance (Bodystat 
1500, Bodystat, Ltd, Isle of Man, UK).  
Hormonal and biochemical assays 
Blood samples were collected from the patients after overnight fasting, prior to surgery. Serum samples 
were centrifuged, fractionated and stored at -80°C until analysis. Fasting TG, glucose and insulin levels 
were measured using standard laboratory assays (modular immunoassay, Roche Diagnostics, 
Mannheim, Germany). HOMA-IR was calculated with the following formula: (fasting glucose [mmol/L] x 
fasting insulin [µU/mL])/22.5] [18]. Total T and E2 were measured with liquid chromatography tandem 
mass spectrometry (LC-MS/MS). Serum T levels were analyzed using a Waters C-18 Acquity Ultra-
Performance Liquid Chromatography (UPLC) column (Waters Corporation, Milford, MA), with a limit of 
quantification (LOQ) of 0.087 nmol/L (CV<20%, n≥6). Intra- and inter-assay coefficients of variation (CV) 
were 9.1% at 0.48 nmol/L and 7.3% at 1.35 nmol/L, respectively. For determination of E2 levels, 2D-LC-
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MS/MS was performed on a AB Sciex 5500 triple-quadrupole mass spectrometer (AB Sciex, Toronto 
Canada) as described by Fiers T et al [19]. LOQ (CV<20%, n≥6) could be ascertained at 1.1 pmol/L for E2 
and intra- and inter-assay CV were 3.7% at 69.4 pmol/L and 4.0% at 77.4 pmol/L, respectively. Free T 
levels were measured using a validated equilibrium dialysis method, as described previously by 
Vermeulen et al. [20]. Free E2 levels were calculated from total E2, sex hormone-binding globulin (SHBG) 
and albumin concentrations as described elsewhere [21]. Commercial immunoassays were used to 
determine SHBG (Orion Diagnostica, Espoo, Finland), LH and FSH (Elecsys LH and FSH immunoassay; 
Roche Diagnostics).  
Adipose tissue processing  
SAT biopsies were obtained at the end of the surgical intervention and stored at -80°C until further 
analysis, or fixated in formol (buffered 4% paraformaldehyde solution; Klinipath, Belgium) at room 
temperature for microscopic analysis. Fixation, dehydration, cleaning and paraffin impregnation (Tissue 
Tek Vip, Sakura, USA) of these samples was performed, followed by embedding with a TBS 88 Paraffin 
Embedding System (Medite, USA). By means of a Tissue Tek Prisma (Sakura), Haematoxylin-eosin 
staining and film coverslipping of 3μm slides was completed. Digital photographs of the paraffin slides 
were taken with an AxioCam ERc 5s camera and Axioskop 20 light microscope (Zeiss, Jena, Germany) at 
20x magnification, with a total of 6 photographs per slide (Figure 1). The surface area of by average 143 
adipocytes per slide was then measured using the ZEN 2011 software (Zeiss) by indicating the margins of 
the cell membrane of all complete adipocytes. As adipocytes were assumed to be spheres, as many as 
possible complete imaged adipocytes were measured in order to calculate the median surface area as 
expressed in µm2 per study patient, followed by calculation of the median SAT cell size per study group. 
SAT cell size assessment was blinded to grouping and was determined in 50 subjects from the cross-
sectional study cohort. 
 Aromatase expression was determined in the frozen SAT samples of 36 subjects using real-time 
polymerase chain reaction (real-time PCR). First, RNA was isolated out of 100 mg of the frozen fat 
biopsies with the Tripure Isolation Reagent kit (Roche Diagnostics) according to the manufacturer’s 
instructions. Contaminating genomic DNA was removed with the RNase-Free DNase Set (Qiagen, Hilden, 
Germany), followed by a clean-up step with the RNeasy Mini Kit (Qiagen). cDNA synthesis was carried 
out using the SuperScript First-Strand Synthesis System for RT-PCR kit (Invitrogen, Ghent, Belgium) 
according to the manufacturer’s instructions. Aromatase expression levels were quantified by real-time 
PCR using a Quantitect CYP19A1 primer assay (Qiagen) and SYBR Green PCR Master Mix (Applied 
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Biosystems, Foster City, CA, USA) on a StepOne Plus system (Applied Biosystems). The obtained 
threshold cycle (Ct) values were normalized for the expression of the stable reference gene RPS18 
(Quantitect RPS18 primer assay; Qiagen) using the ΔCt-method. 
 
 
Figure 1 Digital photographs of the subcutaneous adipose tissue (SAT) paraffin slides from a control, obese without 
and obese subject with type 2 diabetes, respectively. Photographs were taken with an AxioCam ERc 5s camera 
placed on an Axioskop 20 light microscope at 20x magnification. Mean surface area of adipocytes was measured 
using the ZEN 2011 software by indicating margins of all complete adipocytes imaged on the slides, expressed in 
µm2. Presented images were randomly selected. Scale bar represents 100 µm.   
 
Statistical analysis 
The statistical analysis was performed using IBM SPSS Statistics (version 20.0). Data distribution was 
evaluated with the Kolmogorov-Smirnov test. Variables displaying a normal distribution were expressed 
as mean ± S.D, whereas non-Gaussian distributed variables were described as median (interquartile 
range). ANOVA and Tukey HSD post hoc test were used for the comparison of variables among non-
obese men, morbidly obese men and morbidly obese men with type 2 diabetes of the cross-sectional 
study. Non-Gaussian distributed variables were tested using Kruskal-Wallis and Mann-Whitney U test. 
Pearson correlation coefficients were calculated for the whole study samples as well as for the 
subgroups (normal-weight men, obese men with and obese men without type 2 diabetes), and were 
adjusted for age. If not normally distributed, the variables underwent a logarithmic transformation prior 
to analysis. Multivariate linear regression analysis was used to identify independent factors associated 
with T levels in men, using a model containing significant variables from univariate analysis. Regression 
analysis was corrected for grouping by adding obesity and type 2 diabetes as independent binary 
variables (yes/no) to the model. Prior to regression analysis, variables were standardized in order to 
retrieve standard error (SE) and 95 % confidence intervals (95 % CI) on β coefficients. Effects after 
bariatric surgery were analysed using a paired Student t test or Wilcoxon matched-pairs signed-ranks 
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test in case of non-parametric data distribution. P-values < 0.05 (two-tailed) were considered as 
statistically significant.  
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Results 
Subject characteristics 
Characteristics of the study participants are listed in Table 1. Briefly, obese men without type 2 diabetes 
were younger as compared to the normal-weight men and obese men with type 2 diabetes (41 [32-49] 
versus 49 [43-64] versus 54 [50-61] years, respectively; (median[Q1-Q3]) P = 0.001). Apart from a higher 
BMI, the obese men were insulin resistant and had an increased fasting glucose, fasting insulin and 
fasting TG levels versus normal-weight men. In obese men with type 2 diabetes, BMI, HOMA-IR, and 
fasting insulin as well as fasting glucose levels were even higher as compared to obese men without type 
2 diabetes. Finally, although SAT cell size was similar between obese men with or without type 2 
diabetes, it almost doubled versus normal-weight men (Table 1).  
Obese men with type 2 diabetes had lowest T levels versus obese men without type 2 diabetes and 
normal-weight men, respectively (7.17, 10.81 and 16.36 nmol/L, respectively; P < 0.001). Similarly, free T 
levels were lowest in obese men with type 2 diabetes versus obese men without type 2 diabetes and 
normal-weight men, respectively (164.1, 239.5 and 295.0 pmol/L, respectively; P < 0.001). There were 
no differences in circulating E2 and LH levels and SAT aromatase expression among the groups. Finally, 
levels of FSH and SHBG were 35% and 43% lower in obese men, irrespective of type 2 diabetes, whereas 
LH levels were similar among the groups (Table 1). 
Associations with testosterone levels 
To identify potential mechanisms underlying the decrease in circulating (free) T levels in obese men, we 
performed a univariate correlation analysis. SAT aromatase expression showed no associations with sex 
steroids or with metabolic parameters neither in the whole study sample nor when analysing subgroups 
(latter data not shown). In contrast, T was strongly negative associated with TG levels (r = -0.390, P < 
0.001), HOMA-IR (r = -0.444, P < 0.001) and SAT cell size (r = -0.619, P < 0.001), in the whole study 
cohort. Similarly, free T levels were also negatively associated with TG levels (r = -0.242, P = 0.033), 
HOMA-IR (r = -0.286, P = 0.013) and SAT cell size (r = -0.599, P < 0.001) (Table 2). All correlation analyses 
were adjusted for age. An additional BMI adjustment retained the inverse association between T levels 
and TG levels (r = -0.235, P = 0.041), as well as between free T levels and SAT cell size (r = -0.340, P = 
0.020). Furthermore, subgroup analyses revealed that the inverse correlation between total T levels and 
TG (r = -0.506, P = 0.016), as well as between free T levels and SAT cell size (r = -0.719, P = 0.019) (Fig. 2) 
remained significant in obese men without type 2 diabetes.  
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Table 1 Clinical and laboratory data of the study cohort, including control, obese and obese subjects with DM 2  
Parameter Controls (N=25) Obese (N=24) 
Obese + DM2 
(N=33) 
P 
Pcontrol vs 
obese 
Pcontrol vs 
obese+DM2 
Pobese vs 
obese+DM2 
Clinical and biochemical characteristics 
Age, years 49 [43-64] 41 [32-49] 54 [50-61] 0.001 0.015 0.350 <0.001 
BMI, kg/m² 24 ± 4 41 ± 6 44 ± 6 <0.001 <0.001 <0.001 0.051 
Glucose, mmol/L 4.72 [4.08-5.30] 5.33 [4.77-5.61] 6.99 [6.30-9.10] <0.001 0.014 <0.001 <0.001 
Insulin, pmol/L 
35.9 [22.3-64.6] 114.8 [61.8-179.4] 
197.9 [122.2-
278.0] 
<0.001 <0.001 <0.001 0.003 
Triglycerides, mmol/L 1.20 [0.81-2.27] 2.10 [1.30-3.18] 1.76 [1.34-2.66] 0.015 0.012 0.011 0.588 
HOMA-IR 0.64 [0.40-1.15] 1.99 [1.07-3.19] 4.02 [2.56-4.90] <0.001 <0.001 <0.001 0.001 
SAT cell size
a
, µm
2
 3346 ± 1494 6370 ± 1009 5765 ± 1192 <0.001 <0.001 <0.001 0.381 
Sex steroids        
SAT aromatase
b
, AU 94.0 [60.0-148.0] 137.0 [70.0-226.0] 92.5 [55.3-244.0] 0.546 0.237 0.702 0.547 
Testosterone, nmol/L 16.36 ± 6.74 10.81 ± 5.09 7.17 ± 2.90 <0.001 0.001 <0.001 0.024 
Estradiol, pmol/L 63.9 [45.1-88.6] 87.1 [57.8-103.1] 67.5 [52.5-96.0] 0.180 0.060 0.460 0.247 
Free testosterone, pmol/L 295.0 ± 138.7 239.5 ± 109.0 164.1 ± 69.9 <0.001 0.174 <0.001 0.029 
Free estradiol, pmol/L 1.17 [0.77-1.67] 1.61 [1.13-2.15] 1.32 [1.07-1.90] 0.076 0.024 0.165 0.310 
SHBG, nmol/L 41.0 [32.3-49.0] 22.4 [18.2-29.3] 24.0 [16.4-27.9] <0.001 <0.001 <0.001 0.771 
LH, IU/L 5.0 [3.6-8.0] 4.0 [3.0-5.1] 4.6 [2.8-6.8] 0.347 0.143 0.714 0.298 
FSH, IU/L 7.2 [4.3-17.3] 4.2 [2.9-5.6] 5.1 [3.6-10.5] 0.024 0.010 0.173 0.076 
BMI, SAT cell size, T and Free T were analysed by one-way anova and Tukey HSD post hoc test. Non-Gaussian distributed variables were tested using Kruskal 
Wallis test and Mann-Whitney U test. SAT subcutaneous adipose tissue; DM2 type 2 diabetes. 
a
 SAT cell size was determined in N = 16 controls; N = 12 obese men without DM2 and N = 22 obese men with DM2 
b
 SAT aromatase expression was determined in N = 11 controls; N = 11 obese men without DM2 and N = 14 obese men with DM2 
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Table 2 Associations between sex steroids, aromatase and metabolic parameters  
Parameter Testosterone P value 
Free 
testosterone 
P value 
Ratio T / E2 P value N 
SAT 
aromatase 
-0.095 0.600 0.027 0.879 -0.343 0.047 36 
LH 0.187 0.104 0.061 0.597 0.112 0.326 82 
FSH 0.216 0.064 0.088 0.452 0.173 0.136 82 
SHBG 0.694 < 0.001 0.383 0.001 0.604 < 0.001 82 
E2 0.211 0.064 0.214 0.056 -0.308 0.005 82 
Free E2 0.054 0.637 0.162 0.151 -0.463 < 0.001 82 
TG -0.390 < 0.001 -0.242 0.033 -0.388 < 0.001 82 
HOMA-IR -0.444 < 0.001 -0.286 0.013 -0.606 < 0.001 82 
SAT cell size -0.619 < 0.001 -0.599 < 0.001 -0.648 < 0.001 50 
Data are Pearson correlation coefficients (r) adjusted for age. In case of non-gaussian distribution, variables were 
log-transformed. LH luteinizing hormone; E2 estradiol; TG triglycerides; HOMA-IR homeostasis model of 
assessment for insulin resistance; SAT subcutaneous adipose tissue. 
 
 
Figure 2 The relationship between triglycerides and serum testosterone levels (n=23; A) as well as inverse 
associations between free testosterone and subcutaneous adipose tissue (SAT) cell size (n=11; B) in obese men 
without type 2 diabetes. 
 
Finally, when T to E2 ratio (ratio T / E2) was considered, similar results were found. Apart from the 
obvious relations to E2, Ratio T / E2 was negatively associated with TG (r = -0.388, P < 0.001), HOMA-IR 
(r = -0.606, P < 0.001) and SAT cell size (r = -0.648, P < 0.001).  Furthermore, there was a negative 
association with SAT aromatase, though this association was less strong (r = -0.343; P = 0.047) (Table 2). 
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To further substantiate the above findings, multivariate linear regression analysis was applied. 
Parameters showing statistical significance in univariate analysis were entered as variables of interest, 
after controlling for age and grouping (control vs. obesity/diabetes). Regression analysis confirmed 
associations between T levels and SAT cell size (β = -0.324, P = 0.040) in a model which contained age, 
grouping, TG levels and HOMA-IR. An identical model with free T levels and T / E2 ratio (the latter model 
contained also SAT aromatase considering its statistical significance in univariate analysis) dependent 
variable showed similar results (β = -0.446, P = 0.013 and β = -0.391, P = 0.051; respectively) (Table 3).  
 
Table 3 Multivariate linear regression model of variables significantly associated with total and free 
testosterone levels as well as testosterone to estradiol ratio (ratio T / E2) as dependent variables. All β 
coefficients were standardized. N = 50 
Variable β SE (β) 95 % CI P value 
Total testosterone    
Obesity -0.153 0.194 -0.546; 0.240 0.435 
DM 2 -0.617 0.220 -1.061; -0.173 0.008 
Age -0.171 0.118 -0.410; 0.068 0.157 
Triglycerides -0.054 0.106 -0.269; 0.160 0.610 
HOMA-IR -0.015 0.168 -0.354; 0.324 0.929 
SAT cell size -0.324 0.153 -0.633; -0.015 0.040 
Free testosterone    
Obesity 0.049 0.218 -0.391; 0.489 0.822 
DM 2 -0.239 0.246 -0.735; 0.258 0.337 
Age -0.472 0.132 -0.740; -0.205 0.001 
Triglycerides 0.043 0.119 -0.197; 0.282 0.722 
HOMA-IR -0.077 0.188 -0.457; 0.302 0.683 
SAT cell size -0.446 0.171 -0.791; -0.100 0.013 
Ratio T / E2     
Obesity -0.183 0.274 -0.772; 0.357 0.455 
DM 2 -0.519 0.323 -1.271; 0.061 0.073 
Age 0.089 0.211 -0.325; 0.543 0.610 
Triglycerides -0.158 0.143 -0.437; 0.153 0.330 
HOMA-IR 0.116 0.302 -0.493; 0.750 0.673 
SAT cell size -0.391 0.218 -0.897; 0.002 0.051 
SAT aromatase -0.167 0.184 -0.565; 0.192 0.319 
Obesity and DM 2 are binary variables (yes/no). DM 2 type 2 diabetes; HOMA-IR homeostasis model of assessment 
for insulin resistance; SAT subcutaneous adipose tissue; SE standard error; CI confidence interval 
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Characteristics and sex steroid levels of study participants after GBS 
Fourteen men agreed to undergo a follow-up investigation 2 years after GBS. Table 4 displays their 
characteristics and sex steroid levels at baseline and 2 years after GBS. Metabolic characteristics of 
subjects who participated in the prospective study changed with a significant improvement of BMI (45 
kg/m2 to 34 kg/m2), fat mass (45 to 36 %), TG (borderline; 1.55 to 1.09 mmol/L), glucose (6.47 to 5.35 
mmol/L) and insulin (122.0 to 61.1 pmol/L) concentrations and insulin sensitivity (HOMA-IR 3.3 to 1.1). 
Mean total T levels increased from 8.99 to 14.62 nmol/L (P = 0.004), SHBG levels increased from 27.9 to 
52.4 nmol/L (P < 0.001) and FSH levels increased from 5.7 to 7.4 IU/L (P < 0.001). No significant 
differences could be established for free T or E2 before and after bariatric surgery. There were no 
associations of ∆ (free) T levels with any of the improved parameters (latter data not shown).  
 
Table 4 Subject characteristics and sex steroid levels before and after bariatric surgery 
 Pre-bariatric surgery 
(N=14) 
Post-bariatric surgery (N=14) P value 
Clinical and biochemical 
characteristics 
   
Age, years 51 ± 12 53 ± 12 < 0.001 
BMI, kg/m² 45 ± 8 34 ± 8 < 0.001 
Fat, % 45 ± 9 36 ± 12 0.009 
Triglycerides, 
mmol/L 
1.55 ± 0.79 1.09 ± 0.46 0.067 
Glucose, mmol/L  6.47 ± 1.69 5.35 ± 0.74 0.051 
Insulin, pmol/L 122.0 [99.7-211.7] 61.1 [49.9-121.3] 0.001 
HOMA-IR 3.3 [2.1-4.2] 1.1 [0.9-2.3] 0.002 
Sex steroids    
Testosterone, 
nmol/L 
8.99 ± 4.70 14.62 ± 6.65 0.004 
Free testosterone, 
pmol/L 
189.6 ± 110.5 229.0 ± 116.8 0.157 
Estradiol, pmol/L 70.4 ± 32.1 68.8 ± 25.9 0.848 
Free estradiol, 
pmol/L 
1.33 ± 0.52 1.11 ± 0.44 0.117 
SHBG, nmol/L 27.9 [17.0-36.0] 52.4 [39.6-59.1] < 0.001 
LH, IU/L 5.2 [3.0-9.3] 5.8 [2.7-12.6] 0.832 
FSH, IU/L 5.7 [5.0-12.0] 7.4 [5.7-18.4] < 0.001 
Data are means ± SD or median (1
st
 -3
rd
 quartile) in case of non-Gaussian distribution. P values were determined 
using a paired Student t test. Non-Gaussian distributed variables were log-transformed.  
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Discussion 
The present study showed a link between enlarged SAT cell size and low T levels in male obesity, and 
could not establish a predominant role for adipose tissue aromatase expression and parameters of the 
hypothalamic-pituitary-gonadal (HPG) axis. SAT cell size was independent inversely associated with both 
total and free T levels after multivariate regression analysis corrected for age, grouping (control vs. 
obesity/diabetes), HOMA-IR and TG levels. Overall, the findings suggest that low T in male obesity might 
be related to enlargement of SAT cell size and its related metabolic changes.  
In response to an ongoing energy supply adipose tissue is known to expand, due to enlargement of 
adipocytes [22]. Previous hypotheses suggested that low T levels in obese men may result from an up-
regulated aromatase activity in the expanded adipose tissue, followed by elevated E2 levels which 
suppress the HPG axis [3,4]. Studies however, which examined the role of aromatase and/or elevated E2 
levels in obesity, reported conflicting results [23-25]. In males, this is one of the few studies evaluating 
aromatase expression in adipose tissue. Differences in SAT aromatase expression could not be 
established between obese men (with or without type 2 diabetes) versus normal-weight men. 
Furthermore, we could not determine significant results concerning visceral adipose tissue (VAT) 
aromatase expression (data not shown), though SAT aromatase expression only was used for remaining 
analysis considering the generally known higher expression of aromatase in subcutaneous versus 
visceral adipocytes [26]. It has previously been suggested that SAT aromatase expression was associated 
with generalized obesity as described by BMI, though Wake DJ et al. could not find any association 
between SAT aromatase and abdominal obesity with which obese men are mostly characterized with 
[24]. Some studies have reported data that counteracts with the increased aromatase activity-
hypothesis. Firstly, Dhindsa S et al. reported lower E2 levels, measured with LC-MS/MS, excluding down-
regulation by elevated E2 of the HPG axis as the main cause for low T levels in men with type 2 diabetes 
[7]. Similar findings have been reported by Tajar A et al., who used LC-MS/MS to determine E2 as well 
[27]. Finally, obese males have been described to have lower SHBG levels, which also counteracts with 
the increased aromatase activity-hypothesis resulting in elevated E2 levels since E2 is known to normally 
stimulate SHBG production [28].  
In the present study we found, apart from an inverse correlation between (free) T and SAT cell size in 
univariate analyses, an inverse association of (free) T levels with TG and insulin sensitivity (HOMA-IR). 
Inverse associations between T levels and TG are consistent with findings of previous studies [29,30]. 
Elevated circulating TG levels have been suggested to be an indicator of metabolic derangement, 
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associated with both glucose intolerance and increased amounts of VAT [31-33]. The inverse link 
between sex steroids and lipids has been described previously, suggesting a protective role of T and E2 
for the cardiovascular system [34]. Pitteloud et al. reported an inverse association between human 
chorionic gonadotropin (HCG)-induced T secretion by Leydig cells and insulin sensitivity (measured by 
hyperinsulinemic euglycemic clamp) among men with various degrees of glucose tolerance. Thus, Leydig 
cell function is suggested to be altered in insulin resistant men, resulting in decreased T secretion [35]. 
Another study reported a diminished T response to HCG in obese men, which correlated with baseline 
leptin levels [36]. Furthermore, Sertoli cell function was also suggested to be impaired in obese insulin 
resistant men, since two Sertoli cell markers inhibin B and anti-Müllerian hormone were found to be 
lower in obese vs. control men [37]. The inverse correlation between (free) T and adipocyte cell size, 
HOMA-IR as well as circulating TG in this study also supports the findings of Pitteloud et al. [35]. On 
multivariate regression analysis however, SAT cell size remained the only metabolic parameter that was 
independently related to (free) T. Adipocyte cell size has been recognized for many years as an 
important parameter in the pathogenesis of metabolic derangement. Enlarged subcutaneous adipocytes 
have been shown to predict DM 2 in a prospective cohort, independent from clamp-measured insulin 
sensitivity [38,39]. It has been shown that insulin-sensitive, though severely obese individuals had a 
smaller adipocyte size compared to an equally obese but insulin-resistant group matched for age, sex 
and body fat, suggesting mechanisms beyond obesity per se determine the pathological metabolic 
consequences in obesity [40]. Furthermore, adipocyte cell size has been associated with low grade 
systemic inflammation and macrophage accumulation in adipose tissue [41,22]. Our data emphasizes 
the importance of enlarged SAT cell size and related metabolic changes as a potential determinant of 
low T levels in obese men. However, these findings derive from a cross-sectional study, limiting 
conclusive statements on causality. 
Our results suggest a direct negative impact of adipocytes, but not IR, on free and total T levels in obese 
men. The influence of adipokines, which are regulatory products of adipose tissue, on reproductive 
hormones and function has been repeatedly reported [42-44]. For instance, high adiponectin levels 
(typical of normal weight) have recently been found to regulate Leydig cell steroidogenesis and T 
secretion, through the transcriptional regulation of steroidogenic genes [44]. Expanded adipose tissue is 
known to have a different secretion pattern of adipokines, leading to the release of more pro-
inflammatory and less anti-inflammatory adipokines in case of obesity. A potential explanation of low 
(free) T levels could thus be a pro-inflammatory status in testes secondary to a deregulated adipokine 
secretion pattern, as enlarged adipocytes have been related to a systemic inflammatory state [41,45]. 
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Some inflammatory mediators such as the adipokines TNF-α and leptin have been shown to negatively 
influence HCG-induced T secretion directly from Leydig cells as well as to disturb Sertoli cell function 
[35,42,43]. Especially leptin has been indicated as an important mediator in the development of reduced 
androgens in male obesity, as both influences on the HPG axis as well as direct testicular effects were 
reported by in vitro and in vivo studies [36,46-48]. A recent study reported the suppression of HCG-
induced T secretion in primary Leydig cells after addition of chemerin, a novel adipokine of which 
elevated levels have been associated with both obesity and diabetes in humans [49]. In addition, 
inflammatory mediators have also been shown to suppress the HPG axis [50,51]. The latter could explain 
the assumed disturbances in HPG axis, since primary testes injury normally is accompanied by an up-
regulated gonadotropin release which cannot be demonstrated in our study cohort. Vermeulen et al. as 
well as Giagulli et al. have indicated these alterations in feedback regulation of gonadotropins by 
determining LH pulse amplitudes in obese men [4,52].    
Finally, bariatric surgery normalized BMI, TG, HOMA-IR, T, SHBG and FSH values in the prospective part 
of our study. Our findings are consistent with previously reported data, which found improved BMI and 
T levels in men after bariatric surgery together with a restored sexual function and fertility. In 
accordance with previous studies, we found no changes in LH levels before and after surgery. Despite 
the use of the dialysis method, we found no changes in free T levels after GBS, in contrast to studies that 
used less precise methods such as calculated free T from total T [15,53,54]. This may suggest that a 
change in SHBG is mainly responsible for the increase in T, instead of recovery of the initial causative 
factors. Another explanation is the limited number of patients willing to participate in the follow-up part 
of the study, which could affect detection of small changes. Longitudinal studies on a larger scale are 
needed to confirm these results. Recently, when bariatric surgery in hypogonadal subjects was 
compared to eugonadal men however, increase in (free) T levels after surgery had only been observed in 
hypogonadal men in combination with a more pronounced reduction in waist circumference (a marker 
of abdominal adiposity of these men). Furthermore, this study showed lower E2 levels at baseline in 
hypogonadal vs. eugonadal obese men, also minimizing its role as a determinant of T levels in obese 
men [54].     
The present study has the benefit of LC-MS/MS methods to determine T levels compared to previous 
commercial radioimmunoassay kits, leading to more reliable results, though larger studies are needed to 
confirm the findings. Another limitation of this study is the lack of information on adipose tissue 
aromatase activity in addition to the expression analysis, because SAT samples were frozen or fixated.  
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In conclusion, low T levels in obese men inversely associate with SAT cell size, HOMA-IR and TG levels 
and not with adipose tissue aromatase expression, suggesting obesity-related metabolic disturbances to 
be more important for explaining the T levels in obese men. Further research should be directed at 
primary T secretion failure of the testis. 
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V. SUMMARY OF CONTRIBUTIONS AND GENERAL DISCUSSION 
A complex interplay exists between the increasing epidemics of obesity, IR, NAFLD and CVD. Adipose 
tissue dysfunction has been repeatedly put forward as the initial insult of metabolic disease, as set out in 
the introduction of this thesis. Unraveling the molecular mechanisms involved in the pathophysiology of 
dysfunctional adipose tissue and its related conditions, may lead to the development of effective 
therapeutic or even preventive strategies. Interestingly, a profound sexual dimorphism exists with 
regard to adipose tissue distribution and a disturbed sex steroid profile is common in obese subjects, 
suggesting a potential link between sex steroid metabolism and adiposity. The main aim of this thesis 
was to enhance knowledge on the potential role of dysfunctional adipose tissue of obese subjects in the 
development of NAFLD and the impaired sex steroid profile in men. To this end we investigated SAT and 
VAT biopsies derived from obese patients with or without biopsy-proven NAFLD, to determine adipocyte 
cell size and expression of adipokines and the aromatase enzyme.  
 
1. Main findings and general discussion 
1.1. NAFLD in obesity 
In chapter 3.2., we describe NAFLD prevalence and histological characteristics in two cohorts of obese 
patients that were scheduled for bariatric surgery, i.e. patients of the Hepobster and NASH study. In 
total, we recruited 90 obese patients, of whom a liver biopsy was obtained irrespective of a priori 
suspected liver disease. This is a major advantage compared to many other studies investigating biopsy-
proven NAFLD patients, in which patients are mostly highly selected because of a suspected presence of 
NAFLD (for instance because of elevated liver function parameters). Notwithstanding our study cohort 
was randomly composed, 81 out of 90 obese patients were diagnosed to have NAFLD according to NAS. 
This confirms the very high prevalence (80 - 90%) of NAFLD amongst the high-risk obese population as 
described in literature [1]. Firstly, we analyzed anthropometrics, metabolic and liver function 
parameters in this cohort.  
 In literature, both the prevalence and the severity of NAFLD have been strongly related to BMI, WC, 
hyperinsulinemia, hypertriglyceridemia, impaired glucose tolerance and type 2 diabetes, which are all 
metabolic parameters with the common underlying factor IR [2, 3]. NAFLD severity did not associate 
with BMI in our study population, but HOMA-IR was associated with grade of steatosis, hepatocyte 
ballooning and lobular inflammation and with overall NAS independent of age and BMI. Further 
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evidence of the link between obesity, its metabolic comorbidities and NAFLD derives from prospective 
studies, in which weight loss in obese patients has been associated with improvement of histological 
features of NAFLD or even resolution of NASH. Indeed after lifestyle intervention, the magnitude of 
weight loss was associated with changes in histological features of NAFLD. After bariatric surgery-
induced weight loss, up to 85 % of NAFLD patients achieved NASH resolution after one year [4]. These 
results suggest that the probability that NASH (and other comorbidities) resolves depends on the 
amount and extent of weight loss. For example, compared to lifestyle intervention gastric bypass 
surgery is known to result in a greater loss of VAT and more improvement of glucose metabolism and 
insulin sensitivity, whereas loss of SAT throughout the human body is comparable between both 
interventions [5]. This could explain at least partly our finding that although hepatic steatosis is clearly 
linked with obesity, once NAFLD is present its severity was predominantly associated with HOMA-IR 
instead of BMI. Indeed, BMI is not always a good representative measurement of obesity, as 
metabolically healthy obese patients (BMI > 30 kg/m2) have been described with higher insulin 
sensitivity and lower liver fat content [6]. 
In clinical practice, abnormal liver function tests, described as mildly raised transaminase (ALT > AST) 
and/or GGT levels, are often used as markers for evaluating liver disease and the severity of hepatic 
injury. However, ALT has often been wrongly assumed as a surrogate marker of significant liver disease, 
because ±80% of patients with liver disease still have normal ALT levels (< 40 IU/L in males and < 31 IU/L 
in females) [7]. Furthermore, ALT levels even may tend to decrease and AST levels increase as fibrosis 
progresses to cirrhosis and ALT was not found to correlate with histopathological disease severity in 
patients with NAFLD [8, 9]. We could confirm those findings for ALT in our study cohort. AST and GGT 
but not ALT levels were higher in obese NAFLD patients compared to healthy controls and obese 
patients without NAFLD. Both AST and GGT were also related to NAFLD severity, as levels were higher 
with higher grades of histopathological severity. Notwithstanding AST and GGT were related with liver 
histology in this study, conflicting results in literature suggest that the presence of NAFLD, NASH and/or 
fibrosis cannot be excluded in obese patients with liver function tests within the normal range [8, 10, 
11]. Moreover, patients with elevated liver function tests occasionally show normal liver histology 
without any evidence of progressive liver disease [12]. Taken together, these findings question the use 
of liver function tests as a screening tool for NAFLD in obese patients and highlight the need for new 
biomarkers that allow identifying subjects at risk.   
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1.2. Associations between adipokines and liver histology in NAFLD 
In general, NAFLD has been proposed to develop according a “multihit hypothesis”, with a dysregulated 
hepatic fatty acid metabolism and IR leading to SS as an initial insult (first hit). Consequently, 
hepatocytes would become more susceptible to secondary insults (second hit), like imbalances in 
adipokine exposure, inflammation and oxidative stress, which then can lead to the progression of NAFLD 
to NASH [13, 14]. Alterations in adipokine levels are suggested to be involved in this “multihit” process, 
and their imbalance may play an important role in both the development of NAFLD and further 
progression to NASH [14]. 
In chapter III, we investigated the associations between adipokines and histopathological severity in 
biopsy-proven NAFLD patients. Firstly, we performed a systematic review to recapitulate current 
knowledge on recently described adipokines and their relation with liver histology in NAFLD patients 
(chapter 3.1.). Thirty-one cross-sectional studies were included in this review, in which seven different 
adipokines were investigated, i.e. chemerin, resistin, RBP4, visfatin, AFABP, vaspin and apelin. Of these 
seven novel adipokines, our review pointed out that only three displayed a potentially relevant 
association with disease severity. Both chemerin and AFABP associated with hepatocyte ballooning 
degeneration, whereas the hepatic expression of chemerin was found to be associated with fibrosis, 
steatosis and inflammation. Although serum resistin had been most extensively studied during recent 
years, only half of the studies effectively reported significant associations with liver histology in NAFLD 
patients with grade of steatosis as the strongest associated parameter, followed by inflammation. 
Studies investigating visfatin, RBP4, vaspin and apelin were too divergent or reported no significant 
associations, lacking evidence of their potential involvement in NAFLD and excluding them from further 
analysis in this thesis. Based on experimental data, most of the NAFLD-associated adipokines are 
suggested to be involved in the inflammatory response that develops within the context of NAFLD, 
either at hepatic or at systemic level, and/or to contribute to hepatic IR [15]. For example, both 
chemerin and resistin are suggested to inhibit Akt phosphorylation and its downstream targets, thereby 
interfering with insulin signaling and increasing glucose levels [16, 17]. Resistin has been found to 
activate PGC1α, leading to the transcriptional activation of gluconeogenic target genes, and to promote 
glucose-6-phosphatase to hydrolyse glucose-6-phosphate into free glucose leading to an increased 
glucose output [18]. Furthermore, it has been reported that resistin induces de novo lipogenesis by 
activating SREBP-1, potentially promoting hepatic steatosis [19]. Omentin is the only adipokine who is 
suggested to perform insulin-sensitizing effects by stimulating Akt phosphorylation [20]. Chemerin, 
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resistin, AFABP and MCP-1 are generally proposed to induce an inflammatory response by activating the 
NFκB and JNK pathways [16, 21-23]. 
Altogether, data regarding the impact of recently described adipokines on disease progression is still 
scarce and often confined to small patient numbers. There is a high need for longitudinal studies on 
larger and homogenous patient groups compared with carefully matched healthy controls. Furthermore, 
a major heterogeneity was observed across study results. Most importantly, the usage of different ELISA 
assays resulted in wide ranging adipokine serum levels across different studies, which highlights the 
urgent need of standardized assays to determine adipokine levels in serum. 
At least in part because of the close anatomical proximity between VAT and the liver and the direct 
drainage of VAT through the portal vein, VAT has been proposed as a major contributor to NAFLD and 
IR, independent of overall BMI [24-27]. Adipokine expression analysis in VAT might therefore be an 
interesting tool to investigate potential contributing factors in the pathophysiology of NAFLD. In chapter 
3.2., we aimed to evaluate whether circulating levels and/or VAT expression of adiponectin, omentin, 
chemerin, MCP-1 and SFRP4 associate with the histopathological disease severity in obese patients with 
biopsy-proven NAFLD, independently from obesity and IR. Adiponectin serum levels were lower, 
whereas omentin and SFRP4 VAT expression were higher in NAFLD patients compared to controls. When 
NAFLD patients were subdivided into groups with SS, borderline NASH and NASH, adiponectin serum 
levels and omentin expression were lower in NASH patients versus patients with SS. However, only 
serum adiponectin was negatively associated with NAS, with lower levels in patients with higher grades 
of steatosis, hepatocyte ballooning, lobular inflammation and fibrosis. This is in line with previous 
findings [28, 29]. Adiponectin has an anti-steatotic effect on hepatocytes by increasing FA oxidation and 
decreasing gluconeogenesis, FFA influx and de novo lipogenesis [30]. Additionally, anti-inflammatory and 
anti-fibrotic effects of hepatic adiponectin have been reported [31]. Importantly, the association 
between NAS and adiponectin was lost when HOMA-IR was added to the multivariate regression model, 
suggesting that IR might mediate the relation between NAFLD and adiponectin. Since adiponectin is 
highly associated with IR, these findings suggest that low circulating levels of adiponectin may 
contribute to IR, which in turn may influence NAFLD. Other adipokines, except for chemerin (see further 
section 1.3.), neither associated with histological parameters nor with NAFLD severity in our cohort. 
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1.3. Potential role of chemerin in NAFLD 
Chemerin is an adipokine of which elevated levels in patients with metabolic dysfunction have been 
associated with BMI, serum glucose, TG, HDL cholesterol levels, and blood pressure [32]. As described 
previously (section 1.2.), chemerin is also known to be involved in chemotaxis and to induce IR in 
skeletal muscle cells [16, 33]. The relative contribution of tissues or cells to systemic levels of chemerin 
has not been definitively established, but evidence is supporting that adipose tissue and liver are the 
major, although potentially not exclusive, sites of chemerin production and secretion. Chemerin and its 
receptors are highly expressed in the liver, suggesting that the liver is an important target for chemerin 
signaling [34, 35]. 
In our cohort of biopsy-proven NAFLD patients (chapter 3.2.), serum chemerin levels were higher 
compared to healthy controls but were not different among the three groups of NAFLD patients and 
were not related to disease severity. Chemerin VAT expression in male NAFLD patients however, was 
reduced and inversely associated with overall NAS and hepatic steatosis independent of age, BMI and 
HOMA-IR. Moreover, the association between HOMA-IR and NAS lost significance after correcting for 
chemerin VAT expression, suggesting that chemerin may at least partly influence the link between 
HOMA-IR and NAFLD severity. Recently, Wolfs et al. similarly reported a negative association between 
chemerin VAT expression and histopathological parameters of biopsy-proven NAFLD patients. In their 
study, chemerin expression was negatively associated with steatosis, lobular and portal inflammation, 
independent of obesity, HOMA-IR and type 2 diabetes [36]. Experimental studies have reported more 
inconsistent results. While a mouse model with diminished chemerin function showed no differences in 
IR and NAFLD compared to wild type mice [37], anti-inflammatory effects of chemerin have been 
showed both in vivo and in vitro [38, 39]. In conjunction with the negative association between VAT 
chemerin expression and NAS, these results suggest that lower VAT expression of chemerin in obese 
patients may be involved in the pathophysiology of NAFLD progression. 
The contribution of hepatic chemerin expression to NAFLD has been investigated by other groups, 
yielding conflicting results. Deng et al. reported lower hepatic chemerin expression in three different 
mouse models of NAFLD and human liver samples of NAFLD patients compared with controls, which was 
independent of obesity and IR [40]. In contrast, Döcke et al. reported higher hepatic chemerin 
expression in patients with NASH versus borderline or no NASH. They found a positive association 
between hepatic chemerin expression and grade of steatosis, lobular inflammation, hepatocellular 
ballooning and even fibrosis, all were independent of sex, age, BMI, alcohol consumption and oral 
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antidiabetics [41]. We did not measure hepatic expression of adipokines in our study cohort, but it 
would be interesting in future studies to measure both hepatic and VAT expression of chemerin and 
compare the results with hepatic protein measurements to determine the contribution of both sites. 
This could be of importance for the development of specifically targeted therapeutic strategies, once 
more evidence has proven the exact role of chemerin in NAFLD pathophysiology. 
 
1.4. Low testosterone levels and adipose tissue dysfunction in obese men 
As discussed, the relationship between decreased T levels and male obesity is still incompletely 
understood. In chapter IV, we aimed to explore potential determinants of TT and FT levels in a cohort of 
morbidly obese men with and without type 2 diabetes as compared to men with normal body weight. 
More specifically, we evaluated the potential influence of adipose tissue dysfunction, metabolic 
parameters and SAT aromatase expression on parameters of the HPG axis. Differences in in situ 
aromatase expression, both in abdominal SAT and VAT, could not be found between obese men (with or 
without type 2 diabetes) and normal-weight men. This corroborates other findings rejecting the 
increased aromatase activity hypothesis to explain low T levels in obese men. For instance, lower E2 
levels have been reported repeatedly in obese men with or without type 2, arguing against 
downregulation of the HPG axis by elevated E2 as a main cause for low T levels in those men [42, 43]. 
Furthermore, a recent RCT with low-dose administration of aromatase inhibition compared to placebo 
in obese men, showed no beneficial effects on clinical endpoints such as body composition, glucose and 
lipid metabolism [44].  
In our study population however, abdominal SAT cell size was inversely associated with both TT and FT 
levels after multivariate regression analysis corrected for age, group (control versus obesity/diabetes), 
HOMA-IR, and TG levels. Adipocyte cell size has been recognized for many years as an important marker 
in the pathogenesis of metabolic derangement. Enlarged subcutaneous adipocytes have been shown to 
predict type 2 diabetes in a prospective cohort, independent from clamp-measured insulin sensitivity 
[45, 46]. It has been shown that severely obese though insulin-sensitive individuals had a smaller 
adipocyte size compared to an equally obese but insulin-resistant group matched for age, sex and body 
fat, again suggesting mechanisms beyond obesity per se determine the pathological metabolic 
consequences in obesity [47]. Furthermore, adipocyte cell size has been associated with low grade 
systemic inflammation and macrophage accumulation in adipose tissue [48, 49]. Our data emphasize the 
importance of enlarged SAT cell size and related metabolic changes as a potential determinant of low T 
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levels in obese men. Two years after bariatric surgery, we observed lower BMI, TG and HOMA-IR, and 
higher T, SHBG and FSH values in part of our study population. However, we found no changes in FT and 
LH levels, suggesting that mostly changes in SHBG are responsible for the increase in TT whereas the 
HPG axis has still not fully recovered. 
 
1.5. A potential role for adipokines in the disturbed sex steroids profile?  
As previously described (section 1.4.) our results suggest a direct negative impact of adipocyte cell size, 
but not IR, on TT and FT levels in obese men. This highlights the potential role of adipose tissue 
dysfunction in the disturbed sex steroid profile of obese men, for instance via an impaired adipokine 
secretion pattern. Indeed, the influence of adipokines on reproductive hormones and function has been 
repeatedly reported [50-52]. A potential explanation of low (free) T levels could thus be a pro-
inflammatory status in testes secondary to a deregulated adipokine secretion pattern, as enlarged 
adipocytes have been related to a systemic inflammatory state [48, 53]. Some inflammatory mediators 
such as the adipokines TNF-α and leptin have been shown to negatively influence HCG-induced T 
secretion from Leydig cells as well as to disturb Sertoli cell function [50, 51, 54]. Interestingly, a recent 
study reported the suppression of HCG-induced T secretion in primary Leydig cells after the addition of 
chemerin, suggesting a potential role for chemerin in regulation male reproduction [55]. Larger human 
studies are needed to confirm those findings, which may ultimately help in the production process of 
therapeutics that could combat against the high prevalence of obese subjects with impaired sex steroid 
levels and the associated discomforts.  
 
 
  
 
 
164 
 
2. Clinical relevance 
Presence of NAFLD is mostly asymptomatic and is often diagnosed by incident because of abnormal liver 
function tests or steatosis on imaging. As mentioned before, the assessment of NAFLD diagnosis by liver 
biopsy is the most reliable approach but is too invasive to implicate in clinical practice. Other currently 
available diagnosing measurements like liver function parameters (serum transferase levels) and 
imaging techniques (CT and MRI) do not reliably assess hepatic steatosis, steatohepatitis and fibrosis in 
NAFLD patients [7]. Therefore, there has been major interest in developing predictive non-invasive 
biomarkers for identifying NAFLD and NASH patients, although firstly a more thorough knowledge on 
the pathophysiology is needed.   
It is generally known that presence of NAFLD may exacerbate metabolic status. Indeed, metabolites of 
FA and TG such as DAG and ceramide accumulate in hepatic steatosis, which in turn may impair insulin 
signaling by inhibiting insulin signal transduction and increase hepatic glucose production [56]. 
Furthermore, FA can induce inflammatory pathways by activating NFκB, JNK and oxidative as well as ER 
stress [57, 58]. However, recent data has revealed that in certain conditions NAFLD is not accompanied 
by these adverse events and is characterized by a metabolically benign state, preventing progression of 
disease severity. One example potentially explaining this is an elevated hepatic TG synthesis, allowing 
storage of lipids in their least toxic form [59]. Mechanisms on how these compensatory events occur in 
certain subjects are of utmost importance to identify people at risk of developing disease progression to 
NASH (with or without fibrosis), cirrhosis or even HCC.  
Adipokines are known to be involved in the regulation of lipid metabolism, inflammation, glucose 
homeostasis and insulin signaling, which makes them interesting therapeutic targets for metabolic 
diseases including NAFLD [60, 61]. Some mouse models have already shown beneficial effects of 
administrated adipokines. For example, the administration of adiponectin to a mouse model of NAFLD 
and alcoholic fatty liver disease, attenuated hepatic steatosis and inflammation by enhancing hepatic FA 
oxidation and decreasing FA synthesis and cytokine production [62]. Although the specific modulation of 
adipokines has not yet been investigated in human clinical trials, evidence suggests that some 
commonly used therapeutic agents for obesity act at least in part via the activation or inhibition of 
adipokines. Pioglitazone for example, exerts its insulin-sensitizing effects partly through the up-
regulation of adiponectin [63]. In this thesis we found an inverse association between VAT expression of 
chemerin as well as serum adiponectin levels on one hand and NAFLD severity on the other hand. 
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However, further investigation, comprising both experimental and human trials on a larger scale, is 
needed to prove if therapies directed at chemerin would beneficiate in patients with NAFLD.  
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3. Limitations and perspectives 
The findings in this thesis have provided additional evidence on the high impact of adipose tissue 
dysfunction in obesity, suggesting a role in the development of NAFLD and the impaired sex steroid 
profile of obese men. However, the work presented in this thesis has some limitations. Firstly, we were 
unable to draw causative conclusions because of the cross-sectional design of our clinical trials. 
Secondly, it is important to recognize that beside adipose tissue-derived adipokines, other tissues such 
as skeletal muscle and liver can release similar proteins with direct effects on several targets such as 
insulin signaling and inflammation. As an example, it is suggested that a fatty liver may secrete higher 
levels of certain factors, called hepatokines. One example is fetuin-A, which has been shown to inhibit 
insulin signaling and to stimulate inflammatory cytokine expression in immune cells [64, 65]. As these 
products of skeletal muscle (named myokines) and liver cells are also secreted into systemic circulation, 
one must take into account that measuring adipokines in serum does not necessarily reflect the adipose 
tissue-derived adipokines. Furthermore, as the majority of blood flow (±80%) to the liver is delivered via 
the portal vein that drains VAT directly, it is likely that systemic serum concentrations of adipokines do 
not accurately reflect the hepatic delivery of adipokines. For instance, IL-6 concentrations in the portal 
vein of morbidly obese individuals were found to be 50% higher than their peripheral artery [66]. 
Furthermore, secretion of adipokines is suggested to be different between SAT and VAT, at least partly 
clarifying divergent results between serum levels and VAT expression as observed in our and other 
studies [27, 67].  
Both NAFLD and type 2 diabetes are multifactorial diseases, of which the etiology is complex and which 
are closely linked to each other. Although both conditions are clearly driven by obesity, not every obese 
subject develops NAFLD and/or type 2 diabetes and some of them even remain metabolically healthy 
[68]. Because of these complex multifactorial origins, many studies investigating the etiology of NAFLD 
and type 2 diabetes, including those within the scope of this thesis, are often restricted to studying 
specific aspects of the disease [69]. This allows us to identify the potential contribution of single factors 
and give insight into specific mechanisms involved, but interpreting those results should keep in mind 
the whole context of the complex disease that may involve the interplay of several mechanisms. 
Although our study population did not allow us to explore this, it is generally known that gender is 
associated with the prevalence of NAFLD. While at first it was believed that NAFLD was more common in 
women, evidence from population-based studies now shows that male gender is associated with a 
higher prevalence of NAFLD [70]. Further, several cross-sectional population-based studies showed a 
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direct relationship between low TT levels and NAFLD independent of confounding factors such as BMI, 
VAT insulin resistance and dyslipidemia [71, 72]. In contrast, others reported inverse associations 
between SHBG but not TT or FT levels and NAFLD severity in patients with type 2 diabetes [73, 74]. 
Monosaccharide-induced de novo lipogenesis inhibited hepatic SHBG expression both in vitro and in vivo 
in human hepatocytes, potentially explaining the link between low SHBG and TT levels and NAFLD [75]. 
However, Seo et al. reported after a median follow-up of four years that serum TT levels did not 
independently associate with the development or regression of NAFLD, whereas obesity and metabolic 
parameters (i.e. BMI, WC, glucose, HDL cholesterol, TG, systolic blood pressure) did [76]. Furthermore, 
E2 levels were suggested to be lower in men with NAFLD versus no NAFLD, which may promote oxidative 
stress and lipid peroxidation in the liver [77]. It is important to notice that the above mentioned studies 
measured TT levels using radioimmunoassays, whereas presence of liver fat content and NAFLD was 
determined by imaging. The LC-MS/MS method is currently the state of the art technique for measuring 
T and E2 and should be encouraged in future research to overcome the lack of both specificity and 
sensitivity of the still widely used radioimmunoassays. The potential link between sex steroids and 
NAFLD should be further investigated in larger-scaled studies using LC-MS/MS methods in patients with 
biopsy-proven NAFLD diagnosis. To this end, we plan to expand the Hepobster study by measuring sex 
steroid levels in serum samples of biopsy-proven NAFLD patients using LC-MS/MS, both at the time of 
bariatric surgery as well as during a follow-up period.     
Up till now, we and others were not able to identify any adipokine of which circulating levels are clearly 
linked with NAFLD severity and that could be a potential biomarker. Therefore, larger-scaled studies are 
needed to examine adipokines prospectively, evaluating them when NAFLD progresses or resolves via 
paired liver biopsies. Furthermore, as a defined “normal range” for adipokine serum concentrations has 
not yet been established and the range of measurement assays used across different studies is very 
divergent, their potential usage as a disease biomarker is still questionable. However, once it has been 
clearly elucidated that adipokines are key players in the pathogenesis and progression of NAFLD as well 
as in the impaired sex steroid profile of obese subjects, the pharmacologic manipulation of adipokines 
could be a feasible option in future therapeutics of obesity and the use of adipokines as part of a 
noninvasive diagnostic tool for NAFLD could be of interest. 
In order to further elucidate the potential role of adipokines in the pathophysiology of NAFLD, the 
inclusion of patients in the Hepobster study cohort will be continued to maximize statistical power on 
additional analyses. Furthermore, a follow-up study is currently being set-up in collaboration with the 
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department of Gastroenterology and Hepatology and the department of Pathology, both at Ghent 
University Hospital. While the baseline study protocol will be similar to the Hepobster study, patients 
will additionally be investigated at several timepoints after bariatric surgery. This allows to examine the 
progression of NAFLD on liver biopsy and the progression of adipose tissue (dys)function and metabolic 
parameters simultaneously. Adipokine levels will be measured in serum and their expression will be 
assessed in VAT, SAT and liver.  
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